

A Decade of Excellence

THE 10TH ANNUAL

Bio[®] Investor Forum

Company Profiles

13therapeutics.....	2	Ikaria, Inc.	69
A&G Pharmaceutical, Inc.....	4	Immune Targeting Systems	70
Aciont Inc.....	5	ImmunoCellular Therapeutics, Ltd.	72
Advaxis, Inc.	7	ImmunoGenes AG	74
ADVENTRX Pharmaceuticals, Inc.....	9	ImmusanT Inc.	75
Affimed Therapeutics AG	11	Indel Therapeutics, Inc.	76
Afraxis, Inc.....	12	Inimex Pharmaceuticals, Inc.....	77
Allon Therapeutics Inc.....	13	Intra-Cellular Therapies, Inc.....	78
Anchor Therapeutics, Inc.	15	InVasc Therapeutics, Inc.	79
AnGes MG, Inc.	16	Jennerex Biotherapeutics, Inc.....	81
Aquinox Pharmaceuticals, Inc.	18	Kareus Therapeutics, LLC.....	82
Aradigm Corporation.....	19	LigoCyte Pharmaceuticals, Inc.....	83
Arbovax, Inc.....	21	Lipocine, Inc.	84
Axikin Pharmaceuticals, Inc.....	22	MabVax Therapeutics, Inc.....	85
BCO Pharma Ltd.....	23	MannKind Corporation	87
Bio-Path Holdings, Inc.....	24	Maruho Co., Ltd.	89
BioSante Pharmaceuticals, Inc.....	26	Mersana Therapeutics, Inc.....	90
BIOTECCanada	28	Metasignal Therapeutics Inc.....	91
BMO Capital Markets - Banking	29	Mirna Therapeutics, Inc.	92
Campbell Alliance	30	Mithridion, Inc.	93
Catabasis Pharmaceuticals, Inc.	31	Molecular Templates, Inc.	95
Catalyst Pharmaceutical Partners, Inc.	32	Muscular Dystrophy Association	96
CoLucid Pharmaceuticals, Inc.....	34	MyeloRx LLC	97
Constellation Pharmaceuticals, Inc.....	35	Nanocarrier Co., Ltd.	98
CureFAKtor Pharmaceuticals, LLC	36	NeurogesX, Inc.	100
Curis, Inc.....	37	OncoMed Pharmaceuticals, Inc.....	102
Cyclacel Pharmaceuticals, Inc.	39	PharmaNeuroBoost NV.....	103
Dicerna Pharmaceuticals, Inc.....	41	Plx Pharma, Inc.	105
DLVR Therapeutics Inc.	42	ProNAi Therapeutics, Inc.	106
DNA Therapeutics SA	43	Psyadon Pharmaceuticals, Inc.	107
EBD Group	45	Rediens, Inc.	108
EluSys Therapeutics, Inc.....	46	Relypsa, Inc.	109
Emisphere Technologies, Inc.	47	Rib-X Pharmaceuticals, Inc.	110
Envoy Therapeutics, Inc.....	49	Rodman & Renshaw, LLC	111
Epiomed Therapeutics, Inc.....	51	Savara Inc.	112
Epizyme, Inc.	52	Sirius Genomics, Inc.....	113
Esperion Therapeutics, Inc.	53	Sorbent Therapeutics, Inc.	114
FasterCures	54	Spinifex Pharmaceuticals Pty. Ltd.	115
Flexion Therapeutics, Inc.	55	STATegics, Inc.	116
FluGen, Inc.....	56	Susavion Biosciences, Inc.	117
FreeMind Group, LLC.....	57	Syndax Pharmaceuticals, Inc.	119
Gamma Therapeutics, Inc.	58	SynTara LLC	120
Genocea Biosciences, Inc.....	59	Syntaxin Limited	121
Genprex, Inc.	60	TeraDiscoveries, Inc.....	122
GenVec, Inc.....	62	The Salter Group	123
GlobImmune, Inc.	64	Theraclone Sciences, Inc.	124
Glycoregimmune, Inc.....	66	Tranzyme, Inc.	125
HemaQuest Pharmaceuticals, Inc.....	67	Trevena, Inc.....	127
Heptares Therapeutics Limited	68	Trius Therapeutics, Inc.....	128
		Zymeworks Inc.....	130

13therapeutics

BIO Member, Presenting Company

Clinical Foci: Drug Discovery, AutoImmune, Biopharmaceuticals

Thomas Bruggere

Chief Executive Officer

2611 SW 3rd Avenue, Suite 200
Portland, OR 97201
USA

www.13therapeutics.com

1-503-525-4885

Incorporated: 2009

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Completed FDA Pre-IND meeting for P13 in Hearing Disorders. Ready to begin IND-Toxicity trials.
Received 3 year SBIR Phase III grant for P7 in sepsis.

Upcoming

Complete Series A financing, grants, and/or partnership. Start IND-Tox testing in P13.
Receive Army grant for Noise Induced HL.

CORPORATE MISSION

13therapeutics, Inc. is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for isolating novel peptides from immunoregulatory proteins, produced by pathogens, which impact the immune system. 13therapeutics spun out of the Oregon Health and Science University (OHSU) in Portland, Oregon.

The company's peptides have application in treating multiple inflammatory diseases, especially those diseases characterized by over-production of inflammatory cytokines and mediators (e.g., diseases characterized by a "cytokine storm"). These peptides are postulated to have several competitive advantages over current anti-inflammatory therapeutics, including a unique targeting mechanism (inhibition of intracellular TLR signaling), greater efficacy, enhanced safety (based on initial studies), oral and topical bioavailability, ease of manufacturing, and low COGS. Moreover, because testing to date has shown them to be effective inhibitors of multiple inflammatory mediators, greater efficacy may be seen when compared to single mediator inhibitors.

The company is focusing its lead peptide, P13, as a TOPICAL (ear drops) treatment/prevention for hearing disorders: Noise Induced HL, Age Related HL, and Otitis Media. These are multi-billion dollar markets with no effective therapeutics.

The company is self-funded, having received over USD \$7 million from NIH peer reviewed grants, including multiple Phase II and a Phase III SBIR grant. The company's stock is privately held by employees and OHSU. The company is considering a Series A financing or partnership to advance our lead therapeutics through IND Tox testing and clinical trials. 13therapeutics has an experienced management and scientific team capable of developing the company, and a commercialization team that has help bring compounds such as Enbrel and Epogen to market.

PROPRIETARY TECHNOLOGY

The company has a platform for isolating peptides which impact the immune system with application in treating multiple inflammatory diseases, especially those characterized by over-production of inflammatory cytokines. This platform has resulted in a portfolio of over 20 unique peptides which inhibit intracellular TLR signaling, have greater efficacy, enhanced safety, oral & topical bioavailability, ease of manufacturing, and low COGS. They are effective inhibitors of multiple inflammatory mediators so greater efficacy may be seen when compared to single mediator inhibitors. The company is focusing its lead peptide, P13, as a TOPICAL (ear drop treatment) for Noise Induced HL, Age Related HL, Otitis Media, and other hearing disorders.

CORPORATE ALLIANCES

The company has a close alliance with the Oregon Health and Science University (OHSU) where its animal experiments are performed. It also has an experienced commercialization team which has helped to market therapeutics like Epogen, Nepogen and Enbrel.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
P13	Noise Induced Hearing Loss	Lead Series	Shown pre-clinical TOPICAL efficacy for prevention/treatment. P13 has completed an FDA pre-IND meeting.
P13	Age Related Hearing Loss	Preclinical	Shown Pre-clinical efficacy in delaying onset.
P13	Acute Otitis Media	Preclinical	Shown pre-clinical TOPICAL efficacy in reducing fluid buildup and improving hearing.
P13	Otitis Media with Effusion	Preclinical	Shown pre-clinical TOPICAL efficacy in reducing fluid and improving hearing.
P7	Age Related Hearing Loss	Preclinical	Shown pre-clinical TOPICAL efficacy in animal testing.
P7	Sepsis	Preclinical	Shown increased survivability in extreme animal models.
P13	Rheumatoid Arthritis	Preclinical	Oral efficacy in initial animal testing.

SENIOR MANAGEMENT	
Thomas Bruggere, Chief Executive Officer • Steven Hefeneider, Chief Scientific Officer • Sharon McCoy, Vice President	
BOARD OF DIRECTORS	
Thomas Bruggere, 13therapeutics, Inc. • Steven Hefeneider, PhD, 13therapeutics, Inc. • Sharon McCoy, 13therapeutics, Inc.	
SCIENTIFIC ADVISORY BOARD	
Dennis R. Trune, PhD, MBA, Professor, Oregon Health and Science University • Jeffrey A. Gold, MD, Associate Professor of Medicine, Oregon Health and Science University • Carol J. MacArthur, MD, Pediatric Ear, Nose and Throat, Oregon Health and Science University	
FINANCING HISTORY	
Investors:	Employees (76%) • OHSU (10%) • Consultants, etc (4%) • Option pool (10%)

A&G Pharmaceutical, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Autoimmune, Diagnostics

Ginette Serrero, PhD Chief Executive Officer

9130 Red Branch Road
Columbia, MD 21045
USA

www.agpharma.com

1-410-884-4100

Incorporated: 2000

Ownership: Private

HIGHLIGHTS

Recent

A&G finished a 600 breast cancer patient clinical study trial for a new tissue called ONCOSTAIN 88™. GP88 correlates with a HIGH likelihood of breast cancer recurrence. The test is being run on all newly diagnosed breast patients at U. of Maryland.

The ONCO 88™ BLOOD TEST received a major endorsement. The Avon Foundation Breast Cancer Prevention Research Initiative has awarded A&G a three year grant to conduct multicenter monitoring clinical study focused on the measurement of GP88 in blood.

Precision Antibody was selected by SAIC to make "gold-standard" antibodies for NCI's CPTC, which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

Upcoming

Expecting distribution deal with large diagnostic multi-national company in 4Q11.

CORPORATE MISSION

A&G Pharmaceutical is based in Columbia, MD and is focused on developing cancer-specific targets that have therapeutic and diagnostic applications. A&G has a biomarker target called GP88/Progranulin which is expressed in breast, lung, and other cancers. A&G has developed neutralizing therapeutic antibody to GP88 that has been validated in animal studies and is entering toxicology study. GP88 has two near-term diagnostic- tissue & blood products- that will improve early detection, diagnosis and treatment of breast cancer and other diseases. A&G is open to partnership for both the therapeutic and diagnostic technologies.

PROPRIETARY TECHNOLOGY

A&G has a PRECISION ANTIBODY technology (www.precisionantibody.com) that rapidly develops customized, high-affinity monoclonal antibodies in as little as 30 to 45 days. This accelerated generation of monoclonal antibodies has been used to conduct thousands of monoclonal projects for large and small biotech and pharmaceutical partners as well as NIH and academic labs. For example, Precision Antibody has been selected as an antibody developer for the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research. We have also developed and produced numerous custom antibodies for NIAID's Malaria (MR4) program.

CORPORATE ALLIANCES

A&G has an anti-GP88 therapeutic antibody candidate for the treatment of breast & lung cancer. Celltrion, based in South Korea, is performing bioprocess development, scale-up, and cGMP manufacturing to provide material for toxicology studies as well as Phase I and Phase II US clinical studies. We are currently looking for a therapeutic partners for this program.

PRODUCTS

Name	Indication	Phase	Milestone
OncoStain 88	Prognostic for identification of recurrence risk in newly diagnosed cancer patients	Diagnostics	Licensing Opportunity
ONCO 88 Blood Test	Blood Test that Monitors Breast Cancer Recurrence	Diagnostics	Large Clinical Trial Funded by Avon Foundation
GP88 Therapeutic Program	Neutralizing Antibody for Cancer	Preclinical	Ready for Toxicity Trial
RA Compounds	Rheumatoid Arthritis	Optimized Lead	Currently optimizing 3 lead compounds

SENIOR MANAGEMENT

Ginette Serrero, PhD, Chief Executive Officer • **Michael Keefe**, Chief Operating Officer • **Jun Hayashi, PhD**, Senior Vice President • **David Hicks**, Director • **Bing Miller**, Director • **Joe Corvera**, Director

BOARD OF DIRECTORS

Gordon Sato, PhD, Co-Founder, A&G Pharmaceutical • **Tom Hancock**, Nexus Medical Partners • **Lars Hanan**, Broad Oak Capital • **Jennie Mather, PhD**, MacroGenics • **SeungSuh Hong, PhD**, Celltrion • **Ginette Serrero, PhD**, Co-Founder & CEO, A&G Pharmaceutical, Inc.

SCIENTIFIC ADVISORY BOARD

Gordon Sato, PhD, Co-Founder, A&G Pharmaceutical • **Seung-il Shin, PhD**, Founder, Celltrion • **Jennie Mather, PhD**, Senior Vice President, Stem Cell Research, MacroGenics • **Ginette Serrero, PhD**, CEO, A&G Pharmaceutical, Inc.

FINANCING HISTORY

Investors: Maryland Venture Fund (0%) • Olympus (0%) • Emerge Capital (0%) • Celltrion (0%) • Crocker Capital (0%)

Aciont Inc.

BIO Member, Presenting Company

Clinical Foci: Ophthalmic, Drug Delivery, Specialty Pharmaceutical

John Higuchi, MBA, MSIS

President & CEO

350 West 800 North
Salt Lake City, UT 84103
USA

www.aciont.com

1-801-359-3461

Incorporated: 2000

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

We have met with the FDA on the uveitis project and they have in principle agreed with our proposed development plans. This project is funded by the NEI/NIH through a phase II SBIR.

We have demonstrated the delivery of therapeutically relevant levels of a 150KD macromolecule to the posterior section of the eye in rabbit which also showed no discernable adverse effects during and following treatment.

In the past year we have had a couple issued patents; we also have numerous pending and recently filed patents relating to the projects discussed above.

Upcoming

Complete GLP Toxicological Study, File IND and begin phase I clinical trials on first product.

Secure additional commercialization funding for the AMD project which was initially funded by the NEI/NIH.

CORPORATE MISSION

Aciont Inc is an early stage, specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont endeavors to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance.

There are no current commercialized products that have a non-invasive system that can deliver drugs to the back of the eye. Moreover, our technologies comprise the basis for a platform of high-demand product options that are not limited to only one market opportunity. The back of the eye drug delivery market is driven by an aging population, new research on drugs in the field, and increased understanding of the causes of various eye diseases.

Our own products will focus on innovative therapeutics based on our technologies and off-patent or new commercially available drugs. Combining our technology with the off-patent drugs can help expedite FDA approval because of the known safety profile of an existing commercialized pharmacological agent. Further, Aciont plans to partner with leading pharmaceutical companies involved with ocular therapeutics who may need our technology to deliver their drugs, or who may want to help us market our own products currently in development.

PROPRIETARY TECHNOLOGY

Our two main projects include the topical or non-invasive delivery of small molecules to both the anterior and posterior sections of the eye; and the non-invasive delivery of anti-VEGF macromolecules to the posterior section of the eye for the treatment of age related macular degeneration. We employ a scleral lens shaped eye applicator to deliver passively (during a 5-10 minute treatment) therapeutically relevant levels of small molecules (both water soluble and poorly soluble agents) to the posterior section of the eye. We also have a similar eye applicator employing a novel electroosmotic technology using a mild electrical current to facilitate the transport of macromolecules to the posterior section of the eye during a 10-20 minute treatment.

CORPORATE ALLIANCES

We intend to partner with investors and biopharmaceutical companies in ophthalmology in order to move our projects from a successful preclinical phase to a clinical proof of concept phase. Through SBIR funding, the National Eye Institute has funded both projects and we continue to seek additional development funding through such partnerships. For our uveitis project, we have secured alliances for the GMP manufacturing of our drug and device. Aciont seeks a Series A investment partner (USD \$2-4 million) to help us fund our phase I and II clinical trials. Also, Aciont seeks collaborations with biopharmaceutical companies investigating the development of small molecules or biologics in the ophthalmic industry.

PRODUCTS

Name	Indication	Phase	Milestone
DSP Visulex	Severe Uveitis	Preclinical	FDA agreed in principle to study plans
Anti-VEGF Visulex	Wet Age Related Macular Degeneration	Preclinical	Completed preclinical proof of concept studies
Transient Analgesia Visulex	Ocular Surface Pain	Preclinical	Preliminary preclinical proof of concept studies completed

SENIOR MANAGEMENT

John Higuchi, MBA, MSIS, President & CEO • Balbir Brar, DVM, PhD, Vice President • Kongnara Papangkorn, PhD, Manager • William Higuchi, PhD, Chief Scientific Officer

BOARD OF DIRECTORS

William Higuchi, PhD, Founder, Aciont, Inc. • **John Higuchi, MBA, MSIS**, President & CEO, Aciont, Inc.

SCIENTIFIC ADVISORY BOARD

Gary Novack, Regulatory Consultant • **Paul Laskar**, Drug CMC Consultant • **Paul Bernstein**, AMD Medical Consultant • **Albert Vitale**, Intraocular Inflammation Medical Consultant • **Nick Mamalis**, Eye Surface/Ocular Pathologist Medical Consultant • **Kevin Li**, Pharmaceutical Sciences Consultant

FINANCING HISTORY

Round Date (Amount, US\$) 09/01/2005 (4.00 million)

Investors: William Higuchi (95%)

Advaxis, Inc.

BIO Member, Presenting Company

Clinical Foci: Immunology, Oncology, Infectious Disease

Thomas Moore

Chief Executive Officer

305 College Road East
Princeton, NJ 08540
USA

www.advaxis.com

1-609-452-9814

OTC BB: ADXS

Incorporated: 2002

Employees: 12

Ownership: Public

HIGHLIGHTS

Recent

Advaxis Completes Pre-IND Meeting for ADXS-PSA
Advaxis Completes Enrollment of Low Dose Cohort in CIN Study
UPenn Initiates Canine Osteosarcoma Study with Advaxis HER2

Upcoming

Results from Phase 2 Cervical Cancer Study 1H12.

CORPORATE MISSION

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.

PROPRIETARY TECHNOLOGY

Advaxis immunotherapies are based upon a novel platform technology that utilizes live attenuated *Listeria monocytogenes* (Lm) bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Lm-LLO consists of a truncated fragment of the Lm protein listeriolysin (LLO), fused to target antigens of interest. Lm-LLO stimulates a powerful immune response not only to Lm which is inherent in humans, but redirects this same response to the target antigen(s). Lm-LLO based immunotherapy generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, and changes the tumor microenvironment by increasing tumor infiltrating killer T-cells and decreasing Tregs/MDSCs.

CORPORATE ALLIANCES

Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>
ADXS-HPV	Cervical Cancer	Phase II, IIa, IIb
ADXS-HPV	CIN	Phase II, IIa, IIb
ADXS-HPV	Head & Neck Cancer	Phase II, IIa, IIb
ADXS-HER2	Canine Osteosarcoma	Phase I
ADXS-PSA	Prostate Cancer	Preclinical
ADXS-HER2	Breast Cancer	Preclinical

SENIOR MANAGEMENT

Thomas Moore, Chief Executive Officer • **Mark Rosenblum**, Chief Financial Officer • **John Rothman**, Chief Operating Officer • **Robert Petit**, Other • **Chris French**, Director • **Diana Moore**, Investor Relations

BOARD OF DIRECTORS

Thomas Moore, Chairman • **Dr. James Patton**, Director • **Roni A. Appel**, Director • **Dr. Thomas McKearn**, Director • **Richard Berman**, Director



Market Data

Current Price	0.13
Currency	US Dollar
Net Change	-0.76
Volume	200,067
YTD % Change	0.05
52Wk Range	0.10-0.25
Avg. Daily Volume (thousands)	588,338

First Call Data

Market Cap (MM)	31.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.03
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	127.63

Shareholders

<i>Institution</i>	<i>Holding %</i>
SFMG LLC	0.1%
Pacific West Financial Consultants, Inc.	0.0%

Mutual Fund

	<i>Holding %</i>
SFMG LLC	0.1%
Pacific West Financial Consultants, Inc.	0.0%

Source: Thomson Reuters

ADVENTRX Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Hematology, Specialty Pharmaceutical

Brian M. Culley, MA, MBA Chief Executive Officer

12390 El Camino Real, Suite 150
San Diego, CA 92130
USA

www.adventrx.com

1-858-552-0866

NYSE Amex: ANX

Incorporated: 1997

Employees: 12

Ownership: Public

HIGHLIGHTS

Recent

ADVENTRX to Meet with FDA to Discuss Development Plans for Exelbine™, ANX-514 and ANX-188.

ADVENTRX Receives Complete Response Letter for Exelbine NDA.

ADVENTRX Reports Second Quarter 2011 Financial Results (USD \$42 million In Cash as of June 30, 2011).

Upcoming

Provide Update on Exelbine NDA & Development Plans After meeting with FDA to discuss the Agency's Complete Response Letter.

Provide Development Update on ANX-514 & Anticipated Phase 3 Safety Study After meeting with FDA.

Provide Development Update on ANX-188 & Anticipated Phase 3 Pediatric Study After meeting with FDA.

CORPORATE MISSION

ADVENTRX Pharmaceuticals, Inc. is an oncology and hematology-focused specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates.

The company's lead product candidates are Exelbine™, or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®); ANX-514, a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel (Taxotere®); and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. The company is based in San Diego, California.

PROPRIETARY TECHNOLOGY

Two of the Company's lead product candidates, Exelbine™ (vinorelbine injectable emulsion), or ANX-530, and ANX-514 (docetaxel emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs. The Company's other lead product candidate, ANX-188 (purified poloxamer 188), is a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
ANX-188 (purified poloxamer 188)	Sickle cell disease	Phase III	Pediatric Phase 3 study planned to begin in 2012
ANX-514 (docetaxel emulsion)	Breast, non-small cell lung, prostate, gastric and head and neck cancers	Phase III	Phase 3 study planned to begin in 2012
Exelbine	Non-small cell lung cancer	NDA/BLA filed, or in process	

SENIOR MANAGEMENT

Brian M. Culley, MA, MBA, Chief Executive Officer • **Patrick L. Keran, JD**, Chief Operating Officer • **Martin R. Emanuele, PhD**, Senior Vice President • **Gregory D. Gorgas**, Senior Vice President • **Brandi L. Roberts, MBA**, Vice President

BOARD OF DIRECTORS

Jack Lief, Arena Pharmaceuticals • **David A. Ramsay**, Halozyme Therapeutics, Inc. • **Lewis J. Shuster**, Shuster Capital



Market Data

Current Price	0.84
Currency	US Dollar
Net Change	-2.33
Volume	273,572
YTD % Change	-0.68
52Wk Range	0.81-4.21
Avg. Daily Volume (thousands).....	751,734

First Call Data

Market Cap (MM)	22.2
Short Interest Shares	1,784,834
Short Interest Ratio	1.03
PE (Trailing 12 Months)	-0.46
EPS (Last Fiscal Year)	-0.75
Consensus Estimate (Y)	-0.46
Consensus Recommend	--
Price/Sales	45.46

Shareholders

<i>Institution</i>	<i>Holding %</i>
RA Capital Management LLC.....	8.9%
Tang Capital Management LLC	8.4%
BlackRock Advisors LLC.....	7.5%
Fidelity Management & Research Co.	4.9%
Barclays Capital, Inc.	3.4%
<i>Mutual Fund</i>	<i>Holding %</i>
RA Capital Management LLC.....	8.9%
Tang Capital Management LLC	8.4%
BlackRock Advisors LLC.....	7.5%
Fidelity Management & Research Co.	4.9%
Barclays Capital, Inc.	3.4%

Source: Thomson Reuters

Affimed Therapeutics AG

Clinical Foci: Oncology, AutoImmune, Immunology

Dr. Rolf Günther Chief Operating Officer

Technologiepark Im Neuenheimer Feld 582
69120 Heidelberg
Germany

www.affimed.com
49-6221-6530710

Incorporated: 2000
Employees: 29
Ownership: Private

HIGHLIGHTS

Recent

AFM13: Filed CTA and IND in 2010; Initiated phase 1/2a in EU and US; In the initial dose the product appeared to be safe and well tolerated.

AFM11: Initiated GMP production and pre-clinical development.

AbCheck, a subsidiary of Affimed, signed partnership with Eli Lilly on human antibody screening and optimization.

Upcoming

AFM13: Report clinical safety and activity data in 2011/12.

AFM11: Finalize IND-Tox studies in 2012.

AFM13: Prepare pivotal trial in HL.

CORPORATE MISSION

Affimed is a clinical stage company developing bispecific RECRUIT-TandAb antibodies in oncology. The lead product AFM13 is currently investigated in Phase I/IIa trials in Hodgkin's lymphoma patients. The product appears to be safe and well tolerated and showed initial activity in patients. AFM13 has potential to be filed in 2014 for 3rd line and in 2016 for 1st line therapy. The market size is well above USD \$1 billion and no immunotherapy is licensed or in development.

A second program, AFM11, is developed for the treatment of NHL, a market with high need and huge potential.

TandAbs possess drug-like properties with excellent product stability. A robust manufacturing process has been established. These antibodies possess increased therapeutic potential compared to monoclonal antibodies or other antibody fragments.

Affimed is backed by a peer group of investors including Orbimed, Aeris, LSP, BioMed Invest and Novo Nordisk A/S.

PROPRIETARY TECHNOLOGY

TandAbs® are bispecific, tetravalent human antibody formats that have two binding sites for each antigen and bind the targets with the same avidity as an IgG. In oncology, the RECRUIT-TandAb platform provides an enhanced effector function by directly engaging immune effector cells (T- or NK-cells and macrophages) to induce specific tumor cell killing. Therefore, RECRUIT-TandAbs possess higher activity than Fc-optimised monoclonal antibodies. In addition, RECRUIT-TandAbs evenly address the patient population by overcoming a genetic polymorphism that is responsible for a variable response of monoclonal antibodies.

CORPORATE ALLIANCES

AbCheck, a subsidiary of Affimed, entered partnership with Eli Lilly on human antibody generation.

Affimed is preparing to enter strategic alliances around its proprietary product candidates and its TandAb® technology platform.

PRODUCTS

Name	Indication	Phase	Milestone
AFM13	Hodgkin's Lymphoma	Phase I	Safety, tolerability, PK and efficacy
AFM11	Non-Hodgkin's Lymphoma	Preclinical	in vitro and in vivo data

SENIOR MANAGEMENT

Dr. Rolf Günther, Chief Operating Officer • **Dr. Adi Hoess**, Chief Executive Officer • **Prof. Dr. Melvyn Little**, Chief Scientific Officer • **Dr. Florian Fischer**, Chief Financial Officer • **Dr. Miroslav Ravic**, Chief Medical Officer

BOARD OF DIRECTORS

Dr. Thomas Hecht, Hecht Healthcare Consulting • **Dr. Frank Mühlenbeck**, General Partner, aeris CAPITAL • **Dr. Jörg Neermann**, General Partner, Life Sciences Partners • **Dr. Gerhard Ries**, General Partner, BioMedInvest AG • **Dr. Michael Sheffery**, General Partner, OrbiMed • **Dr. Richard B. Stead**, BIOPHARMA Consulting Services LLC

FINANCING HISTORY

Round Date (Amount, US\$) 09/14/2000 (8.00 million) • 03/15/2007 (30.00 million) • 04/15/2010 (20.00 million)

Afraxis, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, CNS

Jay Lichter, PhD

Chief Executive Officer

11099 North Torrey Pines Road, Suite 290
San Diego, CA 92037
USA

www.afraxis.com

1-858-750-4707

Incorporated: 2007

Employees: 6

Ownership: Private

CORPORATE MISSION

Afraxis is discovering and developing drugs to treat rare and neglected diseases through the modulation of p21-activated kinase (PAK). Afraxis' initial indication of interest is Fragile X syndrome with future expansion into other diseases of the central nervous system, including schizophrenia and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Dendritic spines constitute the receptive side of a neural synapse and their dysfunction degrades synaptic function leading to deficits in learning, cognition and behavior. The company's lead program targets PAK, a protein that regulates the development and activity of dendritic spines, creating therapies that actually modify the disease rather than just treat symptoms. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients.

In addition to its impact on dendritic spine biology, PAK is also implicated in a number of different oncological settings. Therefore, Afraxis is exploring the potential of PAK inhibitors for the treatment of cancers such as neurofibromatosis, glioblastoma, tamoxifen-resistant breast cancer and lung cancer. Recent work published in PNAS by Genentech illustrates the potential of PAK inhibitors in breast cancer and squamous NSCLC.

Afraxis has developed a high content technology platform to evaluate dendritic spine and synapse function that provides detailed insight into the pharmacological activity of novel treatments. Afraxis is using this platform to optimize the biological activity of its compounds and build a portfolio of its own drug programs. In addition, Afraxis will seek to leverage its dendritic spine analysis platform to help advance external programs in collaboration with partners.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
PAK inhibitor	Fragile X Syndrome	Preclinical
PAK inhibitor	Neurofibromatosis	Preclinical
PAK inhibitor	Glioma	Preclinical
PAK inhibitor	Breast Cancer	Preclinical

SENIOR MANAGEMENT

Jay Lichter, PhD, Chief Executive Officer • **David Campbell, PhD**, Chief Scientific Officer • **Carmine Stengone**, Vice President

BOARD OF DIRECTORS

Jay Lichter, PhD, Avalon Ventures • **Brady Bohrman**, Avalon Ventures • **Steve Heineman, PhD**, The Salk Institute

SCIENTIFIC ADVISORY BOARD

Susumu Tonegawa, PhD, MIT • **Gary Lynch, PhD**, UC-Irvine • **Steve Heinemann, PhD**, The Salk Institute • **Dennis Selkoe, PhD**, Harvard Medical School • **Akira Sawa, PhD**, Johns Hopkins University

Allon Therapeutics Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: CNS

Gordon C. McCauley President & CEO

506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Canada

www.allontherapeutics.com

1-604-736-0634

Toronto: NPC

Incorporated: 2001

Employees: 18

Ownership: Public

HIGHLIGHTS

Recent

Allon has enrolled 75% in pivotal progressive supranuclear palsy (PSP) study.
Allon wins National Biotech Award as Early Stage Company of the Year (Health) from BIOTECANADA.
Allon enrolling patients in a pivotal davunetide Phase 2/3 clinical trial in progressive supranuclear palsy.

Upcoming

Complete enrollment in pivotal progressive supranuclear palsy (PSP) study.

CORPORATE MISSION

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's lead drug davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP). This advanced trial is the subject of a Special Protocol Assessment (SPA) with the US FDA and is based upon statistically significant human efficacy demonstrated in amnesic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. The company is listed on the Toronto Stock Exchange (TSX:NPC) and based in Vancouver.

PROPRIETARY TECHNOLOGY

Allon's two neuroprotective technology platforms are based on two naturally occurring proteins secreted by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF). Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drug davunetide is derived from ADNP, while preclinical stage drug AL-309 is derived from ADNF.

CORPORATE ALLIANCES

Allon's corporate alliances include The National Institute of Aging, The National Institutes of Health, The Michael J. Fox Foundation, Alzheimer's Drug Discovery Foundation, Tel Aviv University, and TURNS (Treatment Units for Research on Neurocognition and Schizophrenia).

PRODUCTS

Name	Indication	Phase	Milestone
Davunetide	Alzheimer's disease, PSP, and cognitive impairment associated with schizophrenia.	Phase II, Ila, I Ib	Allon is currently enrolling patients in a pivotal phase 2/3 clinical trial in PSP. Davunetide has demonstrated human efficacy in aMCI, a precursor to Alzheimer's disease, and cognitive impairment associated schizophrenia.
AL-309	Neuropathy	Preclinical	Announced that data demonstrate potential for peripheral neuropathy.
AL 408	Neuroprotection	Preclinical	Positive data in pre-clinical models of neuroprotection.
AL 508	Neuroprotection	Preclinical	Positive data in pre-clinical models of neuroprotection.

SENIOR MANAGEMENT


Gordon C. McCauley, President & CEO • **Matthew J. Carlyle, CFA**, Chief Financial Officer • **Bruce H. Morimoto, PhD**, Vice President • **Alistair J Stewart, PhD**, Vice President • **Michael Gold, MS, MD**, Chief Medical Officer

BOARD OF DIRECTORS

James J. Miller, PhD, Managing Partner, NDI Capital Inc. • **Gordon C. McCauley**, President & CEO, Allon Therapeutics Inc. • **Prof. Illana Gozes, PhD**, Co-Founder, Allon Therapeutics Inc. • **Anthony Phillips, PhD**, Professor, Department of Psychiatry, UBC • **Frank Holler**, CEO, Lions Capital Corp. • **Martin Barkin, MD, BSc, MA, FRCSC**, Former President, Draxis Health • **Michael Aldridge, BSc (Hons), MAppFin**, Executive Director, Xenome Inc.

SCIENTIFIC ADVISORY BOARD

Anthony Phillips, PhD, Prof, Department of Psychiatry, UBC • **Esther Shohami, PhD**, Prof, Department of Psychiatry, UBC • **Howard Fillit, MD**, Alzheimer's Drug Discovery Foundation • **Prof. Illana Gozes, PhD**, Allon Therapeutics Inc. • **Keith Black, MD**, Director at Irvine Medical Center • **Mati Fridkin, PhD**, Weizman Institute • **Michael Charness, MD**, Professor, Harvard University • **Michael Moskowitz, MD**, Professor, Harvard Medical School



Market Data

Current Price	0.22
Currency	Canadian Dollar
Net Change	4.88
Volume	127,700
YTD % Change	-0.43
52Wk Range	0.20-0.53
Avg. Daily Volume (thousands)	65,855

First Call Data

Market Cap (MM)	16.9
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.22
EPS (Last Fiscal Year)	-0.22
Consensus Estimate (Y)	-0.22
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
AGF Investments, Inc.	5.6%
Mackenzie Financial Corp.	0.2%
<i>Mutual Fund</i>	<i>Holding %</i>
AGF Investments, Inc.	5.6%
Mackenzie Financial Corp.	0.2%

Source: Thomson Reuters

Anchor Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Drug Discovery, Metabolic Disease

Frederick (Rick) Jones, MD

President & CEO

67 Rogers Street
Cambridge, MA 02142
USA

www.ascentrx.com

1-617-715-1904

Incorporated: 2006

Employees: 18

Ownership: Private

CORPORATE MISSION

Anchor Therapeutics, Inc. is developing therapeutics for metabolic and cardiovascular diseases using a well-validated platform to identify peptide allosteric G protein-coupled receptor (GPCR) modulators. The company has examples of negative and positive modulators as well as pure agonists. Working on proprietary and partnered projects, Anchor is moving toward identifying first-in-class development candidates targeted at several GPCRs that have been difficult to address with standard technologies.

PROPRIETARY TECHNOLOGY

Anchor has exclusive rights to technology that allows design of lipidated peptides based on the amino acid sequence of the target GPCR. These molecules equilibrate into cell membranes where they interact with their target via an allosteric site. This interaction affects the target GPCR conformation, leading to enhancement or damping of receptor signaling. The mechanism of this interaction has been described in recent PNAS and JCAS publications.

CORPORATE ALLIANCES

Novartis: Anchor entered into an option agreement covering a small set of GPCR targets in 2007.

Ortho-Macneil-Janssen (J&J): Anchor entered into a research collaboration focused on specific metabolic and oncology GPCR targets in 2010.

PRODUCTS

Name	Indication	Phase	Milestone
TGR5 positive modulators and agonists	Metabolic disease	Lead Series	In vivo data 4Q2011
APJ agonists	Cardiovascular and metabolic disease	Lead Series	In vivo data 3Q2011
CXCR4 agonists	Regenerative medicine	Optimized Lead	Outlicense
GLP-1 modulator	Diabetes	Research	Lead optimization 4Q2011
gpr120 modulator	Metabolic disease	Research	Lead optimization 4Q2011
gpr40 modulator	Metabolic disease	Research	
gpr43 modulator	Metabolic disease	Research	

SENIOR MANAGEMENT

Frederick (Rick) Jones, MD, President & CEO • Steve Hunt, PhD, Chief Scientific Officer • Ken Carlson, PhD, Vice President • Tom McMurry, PhD, Vice President

BOARD OF DIRECTORS

Christopher Mirabelli, PhD, HealthCare Ventures • Lauren Silverman, PhD, Novartis Option Fund • Jens Eckstein, PhD, TVM • Mike Webb, Allegro Diagnostics • Robert Kamen, PhD, Biotech Consultant; Past President, Abbott Bioresearch Center, Abbott • Frederick Jones, MD, President & CEO, Anchor Therapeutics, Inc.

SCIENTIFIC ADVISORY BOARD

Graeme Milligan, University of Glasgow • Thomas Sakmar, Rockefeller University • Tom Muir, Princeton • Thue Schwartz, University of Copenhagen • Steve Kunkel, University of Michigan • Athan Kuliopulos, Tufts University • Lidija Covic, Tufts University

FINANCING HISTORY

Investors: HealthCare Ventures (0%) • Novartis Option Fund (0%) • TVM (0%)

AnGes MG, Inc.

Clinical Foci: Biopharmaceuticals, Gene/Cell Therapy, Oncology

Ei Yamada, PhD President & CEO

5-20-14 Shiba
Tokyo 108-0014
Japan

www.anges-mg.com

81-3573-02489

TOKYO: 4563

Incorporated: 1999

Ownership: Public

HIGHLIGHTS

Recent

AnGes and Shionogi executed an exclusive global co-development and licensing agreement for NFkB Decoy in the dermatological field. An equity investment by Shionogi was completed in conjunction with this licensing deal.

AnGes and Midikit executed a Term Sheet for co-development and marketing NFkB Decoy for restenosis, in Japan. Clinical trials a planned to start shortly.

AnGes executed a license agreement with MEDRx Co. Ltd. for a transdermal formulation technology, being developed by MEDRx.

Upcoming

Initiation of Phase 3 of HGF Plasmid in PAD (CLI) as well as partnering of this program.

Advance Development of NFkB Decoy for Atopic Dermatitis.

Phase 3 Results of Allovectin-7 for Metastatic Melanoma.

CORPORATE MISSION

AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on an innovative discovery by researchers of Osaka University. We specialize in development and commercialization of genetic medicine. At present, we are engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and NFkB decoy which controls various inflammations.

We are also making every effort to develop the HVJ Envelope Vector (a new delivery technology for medicines) through our subsidiary, GenomIdea Inc. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL).

We are as determined as ever to continue our efforts to satisfy the expectations of patients and families who await new drugs, as well as those of shareholders, investors, and society as a whole.

PROPRIETARY TECHNOLOGY

Essentially our business has two axes: horizontal (genetic medicine) and vertical (lifestyle-related diseases/chronic conditions). The representative agent is the HGF (Hepatocyte Growth Factor) genetic medicine. Applying the HGF's vascularization effects shall provide for better treatment of arteriosclerosis obliterans, which clogs the arteries in the legs, as well as ischemic heart disease (IHD), deteriorating blood circulation in the heart. Unlike cancers, often untraceable due to different gene re-combinations involved, the two disorders listed above can be treated with a method of physics - vascularization. Therefore, among all the genetic medication types, treatment of these diseases represents the field that is nearest to practical applications.

CORPORATE ALLIANCES

- 1) Daiichi Sankyo Co., has been cooperating with us in development of HGF Plasmid in the fields of peripheral arterial disease (PAD) and Ischemic heart disease (IHD). They own marketing rights in Japan.
- 2) Shionogi obtained global marketing rights of NFkB Decoy for skin diseases. Co-development has started by selecting Atopic Dermatitis as the first target indication.
- 3) Vical, Inc. and AnGes executed a collaborative R&D agreement for Allovectin-7 for advanced metastatic melanoma. In addition, AnGes MG obtained development and marketing rights of Allovectin-7 in Asia.
- 4) BioMarin Pharmaceutical Inc. provided AnGes MG with exclusive rights to market and distribute Naglazyme for Mucopolysaccharidosis VI in Japan.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Collatogene	PAD, CLI, Lymphedema	Phase III	Partnering ex-Japan
Allovectin-7(DNA Vaccine)	Metastatic Melanoma	Phase III	Partnering
Naglazyme	Mucopolysaccharidosis VI	On Market	Sales
Functional Peptides	Wound	Optimized Lead	
HGF Plasmid	Lymphedema	Phase I	Partnering
NFkB Decoy	Atopic Dermatitis	Phase II, IIa, IIb	Partnered with Shionogi

SENIOR MANAGEMENT


Ei Yamada, PhD, President & CEO • **Masanori Muryama**, Executive Vice President • **Shunsuke Sami, PhD**, Executive Vice President

BOARD OF DIRECTORS

Shirow Enoki, Former President & Chairman, Seikagaku Corporation

TRADING STATUS AS OF OCTOBER 5, 2011

TOKYO: 4563



Market Data

Current Price	62900.00
Currency	Japanese Yen
Net Change	-3.68
Volume	87
YTD % Change	-0.45
52Wk Range	58,100.00–131000.00
Avg. Daily Volume (thousands).....	273

First Call Data

Market Cap (MM)	7,694.8
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-13206.14
EPS (Last Fiscal Year)	-15925.16
Consensus Estimate (Y)	-13206.14
Consensus Recommend	--
Price/Sales	26.07

Shareholders

Institution

Holding %

Siemens Kapitalanlagegesellschaft mbH	0.0%
Washington State Investment Board.....	0.0%
KBC Fund Management Ltd.	0.0%
--	--
--	--

Mutual Fund

Holding %

Siemens Kapitalanlagegesellschaft mbH	0.0%
Washington State Investment Board.....	0.0%
KBC Fund Management Ltd.	0.0%
--	--
--	--

Source: Thomson Reuters

Aquinox Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Pulmonary, Immunology, Drug Development

David J. Main

President & CEO

Suite 430 - 5600 Parkwood Way
Richmond, BC V6V 2M2
Canada

www.aqxpharma.com

1-604-629-9223

Incorporated: 2006

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

June 2010: Aquinox completed a USD \$25 million Series B including new investor Pfizer Venture Investments along with all other existing investors: Johnson & Johnson Development Corporation, Baker Brothers Investments and BC Advantage Funds (VCC).

September 2010: Renowned Pharmacologist, Csaba Szabó, MD, PhD, was appointed Vice President, Research and Chief Scientific Officer of Aquinox to lead its world-leading research and development efforts.

Upcoming

January 2012: Aquinox anticipates announcing interim results of its first Phase IIa clinical study of its lead clinical candidate, AQX-1125.

CORPORATE MISSION

Aquinox Pharmaceuticals Inc. is a private, venture-backed biopharmaceutical company committed to the discovery and development of novel and targeted small molecule therapeutics for the treatment of inflammatory disease. The company is focused on developing drugs that act as activators of the enzyme SH2-containing inositol 5'-phosphatase (SHIP1). SHIP1 has been shown to counter-regulate the PI3K pathway in hematopoietic cells and compounds that activate it, such as those being developed by Aquinox, have potential applications in a broad range of inflammatory indications including Asthma, COPD, Arthritis, IBD, and Atopic Dermatitis. Aquinox is currently completing a Phase I clinical study in 52 healthy volunteers for its lead SHIP1 activator, AQX-1125, and anticipates initiating Phase IIa clinical studies in Q4 2011. AQX-1125 can be dosed once-a-day orally.

PROPRIETARY TECHNOLOGY

Aquinox's scientific founders discovered a unique biochemical enzyme called SH2-containing inositol 5'-phosphatase (SHIP1) and have shown that it regulates the critical PI3K pathway in blood cells. They have also demonstrated that small molecule drugs can regulate SHIP1. SHIP1 is unique in that it exclusively regulates blood cells and can be harnessed in the treatment of disorders such as multiple myeloma, leukemia, lymphoma, inflammation, allergy and autoimmune diseases while having no, or minimal, effect on non-blood tissues. SHIP1 is an ideal drug target allowing for the development of a number of potential drug candidates that interact with it. From this discovery, the company has created two research and development programs: the SHIP1 activator program and the SHIP1 inhibitor program

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
AQX-1125	Inflammation	Phase II, IIa, IIb
AQX-1000 Series	Inflammation	Lead Series
AQX-200 Series	Inflammation	Lead Series
AQX-300 Series	Inflammation, Oncology	Lead Series
SHIP1 Activators	Ocular Inflammation	Preclinical

SENIOR MANAGEMENT

David J. Main, President & CEO • **Thomas B. MacRury, PhD**, Chief Operating Officer • **David Chernoff, MD**, Chief Medical Officer • **Csaba Szabo, MD, PhD**, Chief Scientific Officer • **Lloyd Mackenzie**, Director • **Mr. Kamran Alam**, Chief Financial Officer • **Patrick Tam, PhD**, Director • **Jason Robertson**, Business Development

BOARD OF DIRECTORS

David J. Main, President & CEO, Aquinox Pharmaceuticals Inc. • **Kenneth Galbraith**, General Partner, Ventures West Capital • **Daniel Levitt, MD, PhD**, Chief Medical Officer, CytRx Corporation • **Asish Xavier, PhD**, Vice President, Johnson & Johnson Development Corporation • **Elaine Jones, PhD**, Executive Director, Pfizer Venture Investments • **Frank Holler**, President & CEO, Lion's Capital Corp.

FINANCING HISTORY

Round Date (Amount, US\$) 06/12/2007 (14.50 million) • 06/17/2010 (25.00 million)

Aradigm Corporation

BIO Member, Presenting Company

Clinical Foci: Pulmonary, Specialty Pharmaceutical, Drug Delivery

Igor Gonda

President & CEO

3929 Point Eden Way
Hayward, CA 94545
USA

www.aradigm.com

1-510-265-9000

OTC BB: ARDM

Incorporated: 1992

Employees: 13

Ownership: Public

HIGHLIGHTS

Recent

Positive safety and efficacy data from two Phase 2b clinical trials with once daily inhaled ciprofloxacin in patients with non-cystic fibrosis bronchiectasis.

Positive safety and efficacy data from a Phase 2a clinical trial with once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis.

Proof of principle human study in smokers, showing profound reduction of craving for cigarettes following single breath administration of inhaled nicotine by Aradigm's proprietary palm-size inhaler.

Upcoming

Partnerships on inhaled Ciprofloxacin and on inhaled Nicotine.

CORPORATE MISSION

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases by pulmonologists. Current activities include development programs addressing the treatments of bronchiectasis, cystic fibrosis, inhaled bioterrorism infections and smoking cessation. In selecting our proprietary development programs, we primarily seek drugs approved by the United States Food and Drug Administration that can be reformulated for both existing and new indications in respiratory diseases. Our intent is to use our pulmonary delivery methods and formulations to improve their safety, efficacy and convenience of administration to patients.

PROPRIETARY TECHNOLOGY

1) AERx Inhalation Technology Platform that can deliver a great variety of drugs and biologics in the form of water solutions and nanodispersions efficiently and precisely into the lung typically in 1-2 breaths. 2) Liposomal nanoencapsulation to provide the convenience of once a day dosing, with potential benefits of improved drug efficacy, safety and tolerability.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Dual release Ciprofloxacin for inhalation	Bronchiectasis	Phase II, IIa, IIb	Partner program prior to Phase 3
Ciprofloxacin for inhalation	Cystic Fibrosis	Phase II, IIa, IIb	
Ciprofloxacin for inhalation	Prevention and treatment of inhaled bioterrorism infections	Phase II, IIa, IIb	Obtain non-dilutive funding for confirmatory non-human primate studies
Inhaled nicotine	Tobacco smoking cessation	Phase II, IIa, IIb	Obtain non-dilutive financing for Phase 2b study or partner
Sumavel (asset sold to Zogenix)	Migraine	On Market	Ongoing receipt of royalties on net sales

SENIOR MANAGEMENT


Igor Gonda, President & CEO • **Nancy Pecota**, Chief Financial Officer

BOARD OF DIRECTORS

Virgil D. Thompson (Chairman), Aradigm, Savient, Questcor • **Frank H. Barker**, Former company group chairman, Johnson & Johnson • **John M. Siebert**, Former Chairman & CEO, Cydex; former President & CEO, CIMA • **Igor Gonda**, CEO & President, Aradigm • **Tamar Howson**, Former Sr. VP, Bristol-Myers Squibb

SCIENTIFIC ADVISORY BOARD

Peter R. Byron, Medical College of Virginia • **Peter S. Creticos**, The Johns Hopkins University School of Medicine • **Stephen J. Farr**, Zogenix • **Michael Konstan**, Rainbow Babies and Children's Hospital • **Babatunde Otulana**, Aerovance • **Adam Wanner**, University of Miami • **Martin Wasserman**, Formerly Roche and AtheroGenics



Market Data

Current Price	0.16
Currency	US Dollar
Net Change	6.67
Volume	47,947
YTD % Change	-0.05
52Wk Range	0.12–0.29
Avg. Daily Volume (thousands).....	299,840

First Call Data

Market Cap (MM)	31.7
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.06
EPS (Last Fiscal Year)	-0.03
Consensus Estimate (Y)	-0.06
Consensus Recommend	--
Price/Sales	36.98

Shareholders

<i>Institution</i>	<i>Holding %</i>
First Eagle Investment Management LLC	36.0%
Conus Partners, Inc.	5.6%
Fidelity Management & Research Co.	0.3%
Nomura Securities Co., Ltd. (Private Banking).....	0.2%
Gutmann Kapitalanlage AG.....	0.1%
<i>Mutual Fund</i>	<i>Holding %</i>
First Eagle Investment Management LLC	36.0%
Conus Partners, Inc.	5.6%
Fidelity Management & Research Co.	0.3%
Nomura Securities Co., Ltd. (Private Banking).....	0.2%
Gutmann Kapitalanlage AG.....	0.1%

Source: Thomson Reuters

Arbovax, Inc.

Presenting Company

Clinical Foci: Vaccines, Veterinary

Malcolm Thomas

President & CEO

617 Hutton Street
Raleigh, NC 27606
USA

www.arbovax.com

1-919-655-0412

Incorporated: 2005

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Completed successful primate trials on Dengue 2 candidate.

Upcoming

Complete animal trials on Chikungunya vaccine.
complete tetravalent Dengue vaccine trials in primates.
GMP Production and Human Phase 1 clinical trials.

CORPORATE MISSION

ARBOVAX™, Inc. has a unique and innovative, proprietary technology that modifies insect-borne viruses (Arboviruses) preventing them from replicating in mammalian cells. ARBOVAX will leverage this technology through partnerships with pharmaceutical companies to facilitate the development of a portfolio of improved human and animal vaccines against the worldwide threat of arthropod-borne diseases.

PROPRIETARY TECHNOLOGY

The technology is based on a modification of the transmembrane portion of the virus which allows it to replicate normally in insect cells while inhibiting its ability to reproduce in mammalian cells. The resulting virus produces immunity in the absence of disease.

CORPORATE ALLIANCES

CRADA US army

PRODUCTS

Name	Indication	Phase	Milestone
Dengue Fever vaccine	Dengue Fever	Preclinical	Tetravalent vaccine testing in primates
Chikungunya vaccine	Chikungunya fever	Preclinical	Testing in mouse model

SENIOR MANAGEMENT

Malcolm Thomas, President & CEO • Raquel Hernandez, PhD, Chief Scientific Officer

BOARD OF DIRECTORS

Christopher English, Former President, Biometric Imaging, • Jonathan Lawrie, PhD, NCBC • Charlton Owensby, MD, JD, MBA, PAN • Jeremy Mario, MFP • Leslie Alexandre, DrPH, Consultant; Adjunct Professor, Dept. of Management, Innovation and Entrepreneurship, North Carolina State University • Troy Knauss, Partner, Guardant Partners • Malcolm Thomas, President & CEO, Arbovax

FINANCING HISTORY

Round Date (Amount, US\$) 07/01/2008 (1.50 million) • 01/01/2010 (1.70 million)

Investors: Piedmont Angel Network (17%) • Mario Family Partners (11%) • Research Development Foundation (17%) • Wilmington Investor Network (3%) • Emergent Growth Fund (4%)

Axikin Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Pulmonary, Drug Development, Immunology

Kevin Bacon, PhD Chief Scientific Officer

10835 Road to the Cure
San Diego, CA 92121
USA

www.axikin.com

1-858-458-1890

Incorporated: 2008

Employees: 7

Ownership: Private

HIGHLIGHTS

Recent

Axikin's GPCR inhibitors have proven efficacious in preclinical non-human primate models of allergic asthma.

Axikin's COPD target may have a significant role to play in fibrosis - a common pathology associated with COPD.

Axikin's GPCR inhibitors have shown efficacy in vitro, in models relevant to ocular inflammation, and age-related macular degeneration.

Upcoming

Axikin is on track to file an IND by 4Q11 for AXP1275 in asthma and rhinitis, beginning clinical trials in 1Q12.

Axikin anticipates positive results for the in vivo efficacy of GPCR inhibitors in a non-human primate model of AMD (age-related macular degeneration).

Axikin anticipates positive results for the in vivo efficacy of kinase-specific siRNA in a murine (hu-SCID) model of fibrosis.

CORPORATE MISSION

Axikin Pharmaceuticals, Inc. is focused on small molecule drug discovery and development for respiratory diseases and inflammation. Specifically targeting asthma, rhinitis, and eosinophilic esophagitis, Axikin's targets may also have strong implications in oncology, ophthalmology and neuroinflammation.

PROPRIETARY TECHNOLOGY

Small molecule inhibitors of GPCR and kinase targets.

Novel kinase gene upregulated in COPD.

SENIOR MANAGEMENT

Kevin Bacon, PhD, Chief Scientific Officer • **Peter McWilliams, PhD**, Venture Capitalist • **Kevin B. Bacon, PhD**, President

BOARD OF DIRECTORS

Peter McWilliams, PhD, Principal, Sanderling Ventures • **Kevin Bacon, PhD**, President, Axikin Pharmaceuticals, inc • **Fred Middleton**, Principal, Sanderling Ventures • **Walter Olesiak**, Mitsui Ventures

SCIENTIFIC ADVISORY BOARD

Gary Hardiman, UCSD • **Gerard Manning**, Salk Inst.

FINANCING HISTORY

Round Date (Amount, US\$) 07/11/2011 (3.50 million)

BCO Pharma Ltd.

Clinical Foci: Drug Delivery, Infectious Disease, Cardiovascular Disease

Seamus O'Loan
Chief Executive Officer

Unit 1, Fota Business Park
Carrigtwohill, Cork
Ireland

www.bcopharma.com

1-484-919-8089

Incorporated: 2009

Ownership: Private

CORPORATE MISSION

BCO Pharma focuses on pediatric care and is located in Philadelphia, PA and Cork, Ireland. The company has two products in development. One is a simple way to treat otitis media topically in patients that do not have tympanostomy tubes ("grommets"). This form of drug delivery—which is currently not practical absent an appropriate delivery mechanism—allows for a several hundred-fold increase in the concentration of drug in the middle ear compared to what can be achieved by dosing either orally or by injection. The product is ideal for the one third of patients whose otitis media is severe or recurring.

The other product—a novel presentation of a anti-hypotensive agent for babies and children—is expected to enter a phase III in the fall of this year. Approximately 200,000 children in Europe, disproportionately newborns, will be treated for hypotension each year using drugs not studied in pediatric populations. The trial is being funded in part by the European Union and we expect to be granted a 10-year regulatory exclusivity in the EU by way of a Pediatric Marketing Use Authorizing (PUMA). We believe the product will also qualify as an orphan drug in Europe, the US and Japan.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
BCO 1	Neonatal Hypotension	Phase III	To begin dosing in November 2011
BCO 2	Otitis Media	Other	To initiate phase III trial in mid 2012

SENIOR MANAGEMENT

Seamus O'Loan, Chief Executive Officer

SCIENTIFIC ADVISORY BOARD

Joseph E. Dohar, MD, MS, FAAP, FACS, University of Pittsburgh/Children's Hospital, Pittsburgh • **Eugene Dempsey, MB, BCh, BAO, MD, MSc, FRCPI**, Cork University Maternity Hospital • **Michael Harney, MB, BCh, BAO, FRCSI, MD, FRCS (ORL)**, Bon Secours Hospital, Cork

Bio-Path Holdings, Inc.

Presenting Company

Clinical Foci: Drug Delivery, Oncology

Peter Nielsen

Chief Executive Officer

2626 South Loop
Houston, TX 77054
USA

www.biopathholdings.com

1-832-971-6616

OTC BB: BPTH

Incorporated: 2000

Ownership: Public

HIGHLIGHTS

Recent

First cohort of Phase I trial with lead compound Grb-2 completed. Compound was well tolerated and activity seen at low starting dose. Second cohort currently enrolling.

Dr. Ana M. Tari joins company as Director, Preclinical Operations and Research.

Completed private placement, raising USD \$1.8 million and received \$244,000 government grant.

Upcoming

Completion of Phase I second cohort.

Potential presentation at American Society of Hematology (ASH) Annual Meeting in December.

CORPORATE MISSION

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors, and its third candidate is a liposomal siRNA cancer drug that is in the final pre-clinical development stage. These product candidates and the delivery technology have been licensed from The University of Texas MD Anderson Cancer Center.

PROPRIETARY TECHNOLOGY

Neutral liposomal delivery technology for nucleic acid drugs.

CORPORATE ALLIANCES

M.D. Anderson Cancer Center

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Liposomal Grb-2	blood cancers	Phase I	First Cohort of study completed; drug well tolerated and activity already seen even at low-starting dose
BP-100-1.02	Lymphoma and solid tumors	Preclinical	Compound is IND ready
BP-101.2.01	Ovarian, colon, thyroid and head & neck cancers	Preclinical	

SENIOR MANAGEMENT


Peter Nielsen, Chief Executive Officer • **Doug Morris**, Business Development • **Ana Maria Tari, PhD, MBA**, Chief Scientific Officer

BOARD OF DIRECTORS

Peter Nielsen, Bio-Path Holdings, Inc. • **Douglas Morris**, Celtic Investment Inc. • **Gillian C. Ivers-Read**, Clovis Oncology • **Thomas Garrison, MD**, Practicing physician

SCIENTIFIC ADVISORY BOARD

Gabriel Lopez-Berestein, MD, MD Anderson Cancer Center • **Anil Sood, MD**, MD Anderson Cancer Center



Market Data

Current Price	0.34
Currency	US Dollar
Net Change	-2.30
Volume	--
YTD % Change	-0.03
52Wk Range	0.25-0.85
Avg. Daily Volume (thousands)	18,964

First Call Data

Market Cap (MM)	19.1
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.04
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	--

Source: Thomson Reuters

BioSante Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Hormone Therapy, Reproductive, Oncology

Stephen M. Simes Chief Executive Officer

111 Barclay Boulevard
Lincolnshire, IL 60069
USA

www.biosantepharma.com

1-847-478-0500

NYSE: BPAX

Incorporated: 1996

Employees: 58

Ownership: Public

HIGHLIGHTS

Recent

Three Phase III clinical studies of LibiGel® in treatment of female sexual dysfunction ongoing; LibiGel® increased the number of satisfying sexual events by 238% in Phase II study. Three SPAs received. All three studies have completed enrollment.

One LibiGel® Phase III study is a cardiovascular and breast cancer safety study; 3,656 women enrolled. The study's DMC has reviewed all unblinded data six times and has advised BioSante to continue per protocol with no modifications.

Closed USD \$48 million underwritten financing; As of August 2, 2011, approximately \$79 million in cash.

Upcoming

Complete all three LibiGel® Phase III clinical studies.

LibiGel® efficacy data in 4Q11; safety data in 3Q12.

Submit LibiGel® NDA in 2012.

CORPORATE MISSION

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a US Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the US by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.

PROPRIETARY TECHNOLOGY

BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a US Food and Drug Administration (FDA) Special Protocol Assessment. BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the US by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals,

CORPORATE ALLIANCES

AZUR Pharma for marketing rights in the US to Elestrin™ (estradiol gel) for the treatment of hot flashes in menopausal women.

Teva is responsible for regulatory and marketing issues for Bio-T-Gel for hypogonadism.

Pantarhei Biosciences for the development and commercialization of The Pill Plus, triple component contraceptive.

Aduro Biotech for the development of BioSante's pancreatic cancer vaccine in combination with Aduro's platform listeria vaccine.

The Hussman Foundation for development of BioSante's melanoma vaccine.

PRODUCTS

Name	Indication	Phase	Milestone
LibiGel	Female Sexual Dysfunction (FSD)	Phase III	Complete Phase III Studies; submit NDA in 2012.
Bio-T-Gel	Male hypogonadism	NDA/BLA filed, or in process	FDA PDUFA date 11/14/11.
Elestrin	Hot Flashes	Cleared for US Marketing	Increase sales.
The Pill Plus	Contraception	Phase II, IIa, IIb	Additional Phase II data.
BioSante Cancer Vaccines	Therapeutic cancer vaccines in pancreatic, breast and prostate cancer, among other cancer types	Phase II, IIa, IIb	Phase II data in various cancer types.

SENIOR MANAGEMENT


Stephen M. Simes, Chief Executive Officer • **Phillip Donenberg**, Chief Financial Officer • **Bill Milling**, Chief Operating Officer • **Michael Snabes, MD, PhD**, Chief Medical Officer • **Joanne Zborowski**, Vice President • **Jeffrey Winkelman, PhD, JD**, Vice President • **Sandy Croak-Brossman, PhD**, Vice President • **Patty Adams**, Vice President

BOARD OF DIRECTORS

Louis W. Sullivan, MD, Morehouse School of Medicine • **Fred Holubow**, William Harris Investors • **Ross Mangano, JO & Co.** • **Edward Rosenow, III, MD**, Mayo Clinic • **Stephen Sherwin, MD**, Chairman BIO • **John Potts, MD**, Mass General

TRADING STATUS AS OF OCTOBER 5, 2011

NYSE: BPAX



Market Data

Current Price	55.56
Currency	US Dollar
Net Change	3.18
Volume	1,233,188
YTD % Change	-0.04
52Wk Range	51.83–66.64
Avg. Daily Volume (thousands).....	1,042,945

First Call Data

Market Cap (MM)	35,692.5
Short Interest Shares	4,823,476
Short Interest Ratio	4.53
PE (Trailing 12 Months)	5.63
EPS (Last Fiscal Year)	5.21
Consensus Estimate (Y)	5.63
Consensus Recommend	5.64
Price/Sales	1.67

Shareholders

<i>Institution</i>	<i>Holding %</i>
TD Asset Management, Inc.	6.7%
RBC Global Asset Management, Inc.	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.	2.2%
<i>Mutual Fund</i>	<i>Holding %</i>
TD Asset Management, Inc.	6.7%
RBC Global Asset Management, Inc.	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.	2.2%

Source: Thomson Reuters

BIOTECanada

BIO Member

Peter Brenders

President & CEO

600 - 1 rue Nicholas St
Ottawa, ON K1N 7B7
Canada

www.biotech.ca

1-613-230-5585

Incorporated: 1987

Employees: 11

Ownership: Private

CORPORATE MISSION

BIOTECanada is dedicated to the sustainable commercial development of biotechnology innovation in Canada. It is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations.

SENIOR MANAGEMENT

Peter Brenders, President & CEO • **Lynn Buchanan**, Vice President • **Cate McCreedy**, Vice President • **Graeme Fraser**, Director • **Mejda Lortie**, Director • **Kira Pejemsky**, Director

BMO Capital Markets - Banking

Sponsor

Thomas V. Milroy
Chief Executive Officer
 3 Times Square, 29th Floor
 New York, NY 10036
 USA

www.bmocm.com
 1-212-702-1160

Toronto: BMO
Incorporated: 2006
Employees: 2000
Ownership: Public

CORPORATE MISSION


BMO Capital Markets is the investment banking arm of the Bank of Montreal. We are part of BMO Financial Group, one of the largest diversified financial service providers in North America with a market capitalization of approximately USD \$35 billion. Our investment banking business provides full services to mid-cap and emerging growth companies. Our healthcare investment banking team is comprised of approximately 30 bankers, many with substantial experience.

SENIOR MANAGEMENT

Thomas V. Milroy, Chief Executive Officer • **Eric C. Tripp**, President • **Perry Hoffmeister**, Other • **Bill Butt**, Managing Director • **Annette Grimaldi**, Managing Director

TRADING STATUS AS OF OCTOBER 5, 2011

TORONTO: TSE:BMO



Market Data

Current Price	57.66
Currency	Canadian Dollar
Net Change	1.28
Volume	1,807,871
YTD % Change	0.00
52Wk Range	55.02–63.94
Avg. Daily Volume (thousands)	1,876,203

First Call Data

Market Cap (MM)	36,738.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	5.62
EPS (Last Fiscal Year)	5.18
Consensus Estimate (Y)	5.62
Consensus Recommend	5.62
Price/Sales	1.74

Shareholders

<i>Institution</i>	<i> Holding %</i>
TD Asset Management, Inc.	6.7%
RBC Global Asset Management, Inc.	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.	2.2%
<i>Mutual Fund</i>	<i> Holding %</i>
TD Asset Management, Inc.	6.7%
RBC Global Asset Management, Inc.	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.	2.2%

Source: Thomson Reuters

Campbell Alliance

Sponsor

Nader Naeymi-Rad

Chief Executive Officer

8045 Arco Corporate Drive
Raleigh, NC 27617
USA

www.campbellalliance.com

1-919-844-7100

Incorporated: 1997

Employees: 325

Ownership: Private

CORPORATE MISSION

Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC; Parsippany, NJ; Los Angeles; San Francisco; Chicago; Boston; Philadelphia; New York City; Atlanta; and Zug, Switzerland the firm serves clients throughout North America, Europe, and Japan. For more information please visit www.campbellalliance.com.

SENIOR MANAGEMENT

Nader Naeymi-Rad, Chief Executive Officer • **Darius Naigamwalla**, Managing Director • **Michael Fleming**, Vice President

Catabasis Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Metabolic Disease, Drug Discovery, Drug Development

Jill Milne, PhD

Chief Executive Officer

One Kendall Square, Suite B14202
Cambridge, MA 02139
USA

www.catabasispharma.com

1-617-349-1971

Incorporated: 2008

Employees: 21

Ownership: Private

HIGHLIGHTS

Recent

09.08.11: Catabasis Pharmaceuticals Appoints Joanne M. Donovan, MD, PhD, as Chief Medical Officer.

08.01.11: PharmaVOICE: Michael Jirousek, PhD, Catabasis co-founder and CSO, recognized as one of "the 100 Most Inspiring People" in 2011.

06.14.11: Catabasis Pharmaceuticals Expands Leadership Team and Appoints Leading Experts to Clinical Advisory Board.

CORPORATE MISSION

Catabasis is a private, venture-backed biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company's scientific approach harnesses the beneficial effects of the essential omega-3 fatty acids DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid), which have clinical benefits as treatments for a wide range of diseases, including dyslipidemia, atherosclerosis and inflammatory diseases.

Effectively treating complex human disease requires targeting key biological pathways that are dysregulated. Preclinical studies have demonstrated that the company's compounds, which are new chemical entities, specifically modulate key nodes that converge upon a biological axis or disease state pathway, providing amplified efficacy and improved safety.

The company has a rich pipeline of omega-3 conjugated compounds that have the potential to treat a range of metabolic and inflammatory diseases. Its lead compound is in development to treat type 2 diabetes.

Catabasis was founded in 2008 by Chief Executive Officer Jill Milne, PhD; Chief Scientific Officer Mike Jirousek, PhD; Steven Shoelson, MD, PhD; Harvard Medical School and Joslin Diabetes Center on an approach that focuses on targeting inflammation to treat complex human diseases.

In 2010, Catabasis closed a USD \$39.6 million Series A financing. The company is backed by top-tier investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

PROPRIETARY TECHNOLOGY

Catabasis' proprietary chemistry platform produces NCEs that are conjugates of an omega-3 fatty acid and another clinically proven entity. The company's SMART linker technology provides an algorithm that enables Catabasis to move rapidly from concept to clinical candidate. This novel approach produces NCEs with superior efficacy and safety. The NCEs superior efficacy is due to targeting two opposing nodes in a disease pathway to produce a synergistic outcome. Superior safety is achieved by utilizing entities with proven clinical safety profiles and creating NCEs that are inactive until hydrolyzed in target tissues.

SENIOR MANAGEMENT

Jill Milne, PhD, Chief Executive Officer • **Joanne Donovan, MD, PhD**, Chief Medical Officer • **Chris Thomajan**, Chief Financial Officer • **Michael Curtis, PhD**, Vice President • **Lucienne Ronco, PhD**, Vice President • **Michael Jirousek, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Michael Ross, PhD, SV Life Sciences • **Jean George**, Advanced Technology Ventures • **Ron Laufer, MD**, MedImmune Ventures, Inc. • **Jeffrey Leiden, MD, PhD**, Clarus Ventures

SCIENTIFIC ADVISORY BOARD

Steve Shoelson, MD, PhD, Harvard Medical School and Joslin Diabetes Center • **Benjamin Cravatt, PhD**, Scripps Research Institute • **Diane Mathis, PhD**, Harvard Medical Center and National Academy of Sciences • **Ruslan Medzhitov, PhD**, Howard Hughes Medical Institute and Yale University • **Jerrold Olefsky, MD**, University of California, San Diego

FINANCING HISTORY

Round Date (Amount, US\$) 04/21/2010 (39.60 million) • 12/08/2010 (14.50 million)

Catalyst Pharmaceutical Partners, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS, Biopharmaceuticals, Drug Development

Patrick J. McEnany
Chief Executive Officer

355 Alhambra Circle
Coral Gables, FL 33134
USA

www.catalystpharma.com

1-305-529-2522

NASDAQ: CPRX

Incorporated: 2002

Employees: 7

Ownership: Public

HIGHLIGHTS

Recent

Enrolling patients in CPP-109 Phase II(b) trial.
Completed CPP-115 non-clinical studies necessary for IND filing.
Reported positive results of CPP-115 non-clinical Infantile Spasms study at Albert Einstein College of Medicine.

Upcoming

1Q12 - Results of CPP-115 US Phase I(a) study.
2Q12 - Complete enrollment of CPP-109 US Phase II(b) cocaine trial and
initiate CPP-115 US Phase I(b) study.
4Q12 - Top-line results for CPP-109 US Phase II(b) cocaine trial.

CORPORATE MISSION

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the US Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and for other selected central nervous disease indications. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA.

PROPRIETARY TECHNOLOGY

CPP-109 & its analog, CPP-115, increase GABA levels by inhibiting GABA-aminotransferase (GABA-AT). In epilepsy, increased GABA decreases overall excitability by raising the action potential threshold of many neurons. In addition, increased GABA dampens the perception of pleasure and reward associated with increased levels of dopamine from drugs of abuse, most notably by stimulants like cocaine & methamphetamine. Diseases like addiction and epilepsy that result from excessive neuronal activity are treatable by enhancing endogenous GABA in the brain through the blockade of GABA-AT. CPP-109 & CPP-115 have no addictive liability and are not receptor active; consequently, they do not appear to affect baseline levels of dopamine, nor variations in dopamine levels caused by normal stimuli.

CORPORATE ALLIANCES

Catalyst and the National Institute On Drug Abuse (NIDA) are jointly conducting a 200 subject, 11 site, US Phase II(b), double-blind, placebo-controlled clinical trial evaluating CPP-109 for the treatment of cocaine addiction. The Trial is designed to confirm the safety and efficacy of CPP-109 for the treatment of cocaine addiction and, if successful, Catalyst believes it will qualify as one of the adequate and well controlled trials required to support approval of an NDA for CPP-109. Catalyst expects to have top-line data from the Trial in the fourth quarter of 2012. NIDA, under their agreement with the Veterans Administration Cooperative Studies Program, has agreed to provide approximately 70% of the resources necessary to complete the Trial.

PRODUCTS

Name	Indication	Phase	Milestone
CPP-109	Cocaine & Methamphetamine Addiction	Phase II, IIa, IIb	Top-line Phase II(b) cocaine data in 4Q12.
CPP-115	Addiction and Epilepsy (Infantile Spasms)	Preclinical	Phase I(a) safety data in 1Q12.

SENIOR MANAGEMENT

Patrick J. McEnany, Chief Executive Officer • **Steven R. Miller, PhD**, Chief Operating Officer • **Jack Weinstein**, Chief Financial Officer • **Douglas Winship**, Vice President • **Charles Gorodetzky, MD, PhD**, Chief Medical Officer

BOARD OF DIRECTORS


Patrick J. McEnany, President, CEO & Co-Founder, Catalyst Pharmaceutical Partners, Inc. • **Philip H. Coelho**, President & CEO, Synergenesis Inc. • **Hubert E. Huckel, MD**, Co-Founder, Catalyst Pharmaceutical Partners, Inc. • **Charles B. O'Keeffe**, Professor, Virginia Commonwealth University • **David S. Tierney, MD**, President, COO and Director, Oceana Therapeutics • **Milton J. Wallace**, BOD Chairman, Renal Care Partners, Inc.

SCIENTIFIC ADVISORY BOARD

Stephen L. Dewey, PhD (SAB Chairman), Center for Behavioral & Molecular Imaging, Feinstein Institute, North Shore LIJ • **Jonathan Brodie, PhD, MD**, Marvin Stern Professor of Psychiatry, New York University School of Medicine • **Robert D. Fechtner, MD**, Professor of Ophthalmology, UMDNJ–New Jersey Medical School • **Thomas Kosten, MD**, Waggoner Professor of Psychiatry & Neuroscience at Baylor College of Medicine • **Eugene Laska, PhD**, Professor, Department of Psychiatry at New York University • **Richard A. Rawson, PhD**, Professor-in-residence, University of California, Los Angeles (UCLA) Department of Psychiatry • **Richard B. Silverman, PhD**, John Evans Professor of Chemistry, Northwestern University

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: CPRX



Market Data

Current Price	1.37
Currency	US Dollar
Net Change	3.79
Volume	18,260
YTD % Change	0.38
52Wk Range	0.89–2.25
Avg. Daily Volume (thousands).....	63,068

First Call Data

Market Cap (MM)	29.7
Short Interest Shares	126,928
Short Interest Ratio	1.21
PE (Trailing 12 Months)	-0.27
EPS (Last Fiscal Year)	-0.23
Consensus Estimate (Y)	-0.27
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
Federated Investment Management Co.	9.5%
Fidelity Management & Research Co.	7.2%
Federated Global Investment Management Corp.	5.3%
Hudson Bay Capital Management LP.....	3.2%
The Vanguard Group, Inc.	0.4%
<i>Mutual Fund</i>	<i>Holding %</i>
Federated Investment Management Co.	9.5%
Fidelity Management & Research Co.	7.2%
Federated Global Investment Management Corp.	5.3%
Hudson Bay Capital Management LP.....	3.2%
The Vanguard Group, Inc.	0.4%

Source: Thomson Reuters

Colucid Pharmaceuticals, Inc.

BIO Member, BIO Board Member

Clinical Foci: CNS, Neurology

Thomas P. Mathers

Chief Executive Officer

2530 Meridian Parkway, Suite 300
Durham, NC 27713
USA

www.colucid.com

1-919-806-4304

Incorporated: 2005

Employees: 7

Ownership: Private

HIGHLIGHTS

Recent

August 30, 2011 — Colucid raised USD \$7.5 million of planned \$9.5 million.
August 18, 2011 — Colucid received clearance for IND Application for Lasmiditan for the treatment of Acute Migraine.

Upcoming

Colucid conducts End of Phase 2 meeting with FDA confirming Phase 3 development plan.
Colucid doses first patient in Phase 3 study.

CORPORATE MISSION

Colucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmimine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders.

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies. Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT_{1F} receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor 5-HT_{1B/1D} receptors activated by triptans.

Five clinical studies have been successfully completed outside of the US, including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing ($p < 0.0001$) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia. Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, Colucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

PROPRIETARY TECHNOLOGY

Conjugated Stigmimine Platform — Concept:

Conjugate pharmaceutically active entities to stigmimine acetylcholinesterase inhibitors to allow delivery of 2 active agents to the CNS.

- Stigmimines are carbamate based cholinesterase inhibitors
- Enzyme inhibition occurs when carbamate binds to active site of enzyme.
- The bound carbamate enzyme is hydrolyzed, releasing carbonic acid that disassociates, releasing an inactive amine.
- Replacing the inactive amine with a therapeutically active amine can be accomplished by conjugating the stigmimine.
- Results in two active drugs being released in the CNS.
- Also results in an NCE, providing commercial exclusivity.

PRODUCTS

Name	Indication	Phase	Milestone
Lasmiditan (COL-144)	acute migraine	Phase III	Initiation of Phase III registration trials
COL-204	wake promotion	Optimized Lead	

SENIOR MANAGEMENT

Jim White, PhD, Other • Thomas P Mathers, Chief Executive Officer • Nadia Rupniak, PhD, Vice President • Alison Pilgrim, BM, BCh, DPhil, Chief Medical Officer • Linda C Hogan, Business Development • Barry Dussault, Director • Tim Gupton, CPA, Chief Financial Officer • Dan Boeglin, General Counsel

BOARD OF DIRECTORS

Art Pappas, Pappas Ventures • Jesse Treu, PhD, Domain Partners • Richard Markham, Care Capital

SCIENTIFIC ADVISORY BOARD

Peter Goadsby, UCSF • Richard Lipton, Albert Einstein • David Dodick, Mayo • Stephen Silberstein, University of Pennsylvania

FINANCING HISTORY

Round Date (Amount, US\$) 12/01/2005 (16.50 million) • 08/30/2011 (32.50 million)

Investors: Domain Associates (100%) • Pappas Ventures (100%) • Care Capital (100%)

Constellation Pharmaceuticals, Inc.

Presenting Company

Mark A. Goldsmith, MD, PhD

President & CEO

215 First Street, Suite 200
Cambridge, MA 02142
USA

www.constellationpharma.com

1-617-714-0555

Incorporated: 2008

Employees: 60

Ownership: Private

CORPORATE MISSION

Constellation's scientific founders represent the core thought leaders in the field of Epigenetics, responsible for key advances, insights and discoveries in the burgeoning field. Their deep scientific insights and those of our strong internal scientific team drive the company's mission and success in developing a robust pipeline of drug products aiming to treat a wide array of important diseases, including cancer and autoimmune diseases. Constellation has built a sophisticated technology platform to explore multiple targets broadly in multiple therapeutic areas. Constellation leverages this platform to build a diversified product pipeline of small molecules designed to modulate key epigenetic players – including chromatin writers, erasers and readers -- responsible for human disease. Its lead programs are progressing toward the clinic.

SENIOR MANAGEMENT

Mark A. Goldsmith, MD, PhD, President & CEO • **Garen Bohlin**, Chief Financial Officer • **James Audia, PhD**, Chief Scientific Officer • **Michael Cooper, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Mark Levin, Third Rock Ventures • **Bob Tepper, MD**, Third Rock Ventures • **Anthony Evnin, PhD**, Venrock • **Dave Goeddel, PhD**, The Column Group • **Tom Maniatis, PhD**, Columbia University • **Steven M. Paul, MD, PhD**, Weill Cornell Medical College • **Mark A. Goldsmith, MD, PhD**, Constellation Pharmaceuticals, Inc.

SCIENTIFIC ADVISORY BOARD

Danny Reinberg, PhD, NYUSOM / SMILOW Research Center • **Arnold Levine, PhD**, Institute for Advanced Studies • **David Livingston, MD**, Dana Farber Cancer Institute • **Thomas Jenuwein, PhD**, Max-Planck Institute • **Scott Lowe, PhD**, Cold Spring Harbor Laboratory • **Rick Klausner, MD**, The Column Group • **Stephen Baylin, MD**, Johns Hopkins University • **Arul M. Chinnaiyan, MD, PhD**, University of Michigan Health System • **Steve Gamblin, PhD**, MRC National Institute for Medical Research

FINANCING HISTORY

Round Date (Amount, US\$) 04/29/2008 (32.00 million) • 06/30/2010 (22.00 million) • 06/30/2011 (15.00 million)

Investors: Third Rock Ventures (0%) • The Column Group (0%) • Venrock (0%) • Altitude (0%) • SROne (0%)

CureFAKtor Pharmaceuticals, LLC

Presenting Company

Clinical Foci: Drug Development, Oncology

H. Shepardson Wild

President & CEO

14 Rock Dove Lane
Buffalo, NY 14127
USA

www.curefaktor.com

1-716-445-4918

Incorporated: 2008

Employees: 9

Ownership: Private

HIGHLIGHTS

Recent

The company's technology developments have been the subject of more than 115 peer-reviewed publications. Dr. William Cance and CureFAKtor have been featured on the CBS Radio Network and WCBS-AM.com. Podcasts available on our Web site.

CureFAKtor has been featured in the following publications (linked on our Web site): Life Science Leader Magazine, Buffalo Business First, Oncology Times, Pharmaceutical Business Review, and OnLive TechSector Q&A.

Key members of the CureFAKtor Staff have been selected to present at National Conferences including University of Florida Technology Showcase, The ASCO Gastrointestinal Cancers Symposium and Bright Buffalo

CORPORATE MISSION

CureFAKtor Pharmaceuticals, LLC has unlocked one of the basic molecular mechanisms which drive cancer and found ways to disrupt it.

CureFAKtor Pharmaceuticals has developed technology which the company believes will lead to significant advances in the therapy for all solid tumors. Preclinical results are dramatic with startling efficacy in even the most deadly and difficult indications, such as pancreatic cancer and melanoma, and the company's compounds are showing similar remarkable results against every type of tumor addressed.

The company's ground breaking research has been continuously funded by a total of over \$15 million in National Institute of Health peer reviewed grants for more than 15 years, recently again reviewed and continuing until 2015.

CureFAKtor Pharmaceuticals has an exclusive worldwide license to all of the technology and is engaged in its commercialization. The company is preparing for its first human trials for pancreatic cancer scheduled to begin in early 2012. The company's objective is to address the USD \$1.4 billion franchise for treating pancreatic cancer established by Lilly, whose chemotherapy Gemzar (Gemcitabine) goes off patent in 2011, with a CureFAKtor patented combination that has proven to be much more effective in pre-clinical models.

The company is also advancing extremely promising compounds for melanoma, breast, lung, colorectal and brain cancer which are expected to be the next indications addressed in human trials.

CureFAKtor's work has been and continues to be supported by more than USD \$15 million in NIH and other grants. As it enters human trials, the company seeks additional investments by private placement of its securities, adding to the funds already raised from high net worth individuals, families and trusts and from the Roswell Park Cancer Institute.

PROPRIETARY TECHNOLOGY

The company's Senior Scientist, Dr. William Cance and his team discovered that a protein, focal adhesion kinase (FAK) plays a central role in the growth and spread of cancer and that at the same time protects the tumors from chemotherapy, radiation and the body's natural defenses.

The company has developed a unique way of disabling the activity of FAK binding sites where the protein communicates with tumors, finding small molecules that disrupt the signaling.

CureFAKtor has found 13 such sites that interact with cancer in different ways and has a pipeline of 40 efficacious compounds that disrupt the activity of each of them, for example disrupting the growth of tumor blood vessels, retarding metastasis and allowing the body's natural death mechanisms to reach and destroy the tumors.

CORPORATE ALLIANCES

The company's scientific operations are located at the Roswell Park Cancer Institute in Buffalo, NY, which holds the National Cancer Institute designation of "comprehensive cancer center."

Roswell Park is a CureFAKtor Pharmaceuticals investor.

The University of Florida Research Foundation has provided grants to CureFAKtor.

The company's research has been continuously funded by a total of over USD \$15 million in National Institutes of Health peer reviewed grants for more than 15 years, recently again reviewed and continuing until 2015.

CureFAKtor has also been supported by grants from the Susan Komen for the Cure Foundation.

SENIOR MANAGEMENT

H. Shepardson Wild, President & CEO • **William Cance, MD**, Chief Scientific Officer

BOARD OF DIRECTORS

William G. Cance, MD, Roswell Park Cancer Institute • **H. Shepardson Wild**, President & CEO, CureFAKtor Pharmaceuticals, LLC • **David Keiser**, Alexion Pharmaceuticals, Former President and Founder • **George Potter**, Quality Systems International • **Daniel Kleiner, MD**, Instructor, University of Virginia, Board Certified Surgeon

Curis, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology

Daniel R. Passeri President & CEO

4 Maguire Road
Lexington, MA 02421
USA

www.curis.com

1-617-503-6500

NASDAQ: CRIS

Incorporated: 2000

Employees: 40

Ownership: Public

HIGHLIGHTS

Recent

September 2011: Curis collaborator Genentech submitted an NDA to the FDA seeking approval for vismodegib (GDC-0449, RG3616) to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC.

August 2011: Curis treated the first patient in a Phase I clinical trial of CUDC-101 in combination with cisplatin and radiation in head and neck cancer patients. Curis plans conduct a Phase II trial in head and neck cancer following this study.

January 2011: Curis selected CUDC-907 as a proprietary PI3K/HDAC inhibitor from our pipeline of targeted cancer drug candidates to advance into formal development.

Upcoming

Genentech's EU regulatory submission with EMA for vismodegib in advanced basal cell carcinoma and potential approval of US and EU submissions in this indication. Results from Genentech's ongoing Phase II study of vismodegib in operable BCC.

Progress CUDC-101: complete Phase Ib study in 2011 and progress through dose escalation of a Phase I HNC study with CUDC-101 in combination with cisplatin and radiation in head and neck cancer patients. Launch Phase I study of oral form of CUDC-101.

Complete IND-enabling work and initiate Phase I study with CUDC-907 in 1H12.

CORPORATE MISSION

Curis, Inc. is a biotechnology company focused on the development of targeted small molecules in oncology. These programs include vismodegib (GDC-0449; RG3616), a Hedgehog pathway inhibitor that is under collaboration with Genentech. Genentech reported positive results from a pivotal Phase II clinical trial in advanced basal cell carcinoma patients earlier in 2011 and filed an NDA in the US in September 2011 based on these results. Vismodegib is also being tested by Genentech in a Phase II clinical trial in operable basal cell carcinoma as well as in several NCI- and investigator-sponsored Phase I and Phase II clinical trials in other indications.

Curis' other targeted cancer programs include CUDC-101, an EGFR, Her2 and HDAC inhibitor in Phase Ib clinical testing in several cancers as well as in a Phase I study in locally advanced head and neck cancer in combination with cisplatin and radiation; Debio 0932 (formerly CUDC-305), a Phase Ib Hsp90 inhibitor under collaboration with Debiopharm; and CUDC-907, a PI3K/HDAC inhibitor that is in preclinical development. We also expect to select additional development candidates from a broad pipeline of preclinical programs in the future. For more information, please visit www.curis.com

PROPRIETARY TECHNOLOGY

Curis internal research and development efforts are focused on the development of targeted small molecule drugs for cancer applications. Curis' approach is to develop novel small molecules that seek to disrupt cancer resistance networks, which could lead to a more durable response for the cancer patient. We believe that this approach represents a potential breakthrough in cancer therapy and differentiates Curis from other cancer-focused companies.

CORPORATE ALLIANCES

Hedgehog Pathway Inhibitor (June 2003): Genentech and Roche are responsible for the clinical development and commercialization of vismodegib (GDC-0449, RG3616). Curis is eligible to receive cash payments upon the achievement of specified objectives and royalties on product sales of vismodegib by Genentech and its sublicensees.

Heat Shock Protein (HSP) 90 (August 2009): Debiopharm is responsible for all development and commercialization of Debio 0932. Curis is eligible to receive additional cash payments upon the achievement of specified objectives and royalties on product sales by Debiopharm or its sublicensees.

PRODUCTS

Name	Indication	Phase	Milestone
GDC-0449 (Hedgehog Pathway Inhibitor)	Advanced basal cell carcinoma	NDA/BLA filed, or in process	US NDA submitted Sept. 2011; future EU submission expected.
GDC-0449 (Hedgehog Pathway Inhibitor)	Operable basal cell carcinoma	Phase II, IIa, IIb	Phase II data.
GDC-0449 (Hedgehog Pathway Inhibitor)	Various-multiple NCI studies through NCI-Genentech collaboration	Phase II, IIa, IIb	Data from NCI studies.
CUDC-101 (HDAC, EGFR, Her2 Inhibitor)	Gastric, NSCLC, head and neck, liver and breast cancers	Phase I	Phase Ib enrollment completed 1H11.
CUDC-101 (HDAC, EGFR, Her2 Inhibitor)	Head and neck cancer	Phase I	Continue enrollment in combination with radiation and cisplatin (complete study in 2012).

PRODUCTS			
Name	Indication	Phase	Milestone
CUDC-101 (oral formulation)	cancers	Preclinical	Initiate Phase I dose escalation study with oral formulation in 1H12.
CUDC-907 (HDAC, PI3K inhibitor)	cancers	Preclinical	Initiate Phase I dose escalation study in 1H12.
Various network-targeted cancer programs	cancers	Research	Select additional development compounds.

SENIOR MANAGEMENT
Daniel R. Passeri, President & CEO • **Michael P. Gray**, Chief Operating Officer • **Mark Noel**, Vice President • **Changgeng Qian, PhD**, Senior Vice President

BOARD OF DIRECTORS
James R. McNab, Jr., Chairman & CEO, Palmetto Pharmaceuticals, Executive Chairman, FirstString Research • **Susan Bayh**, Director; Dyax, Dendreon, Wellpoint, Emmis Communications • **Martyn D. Greenacre**, Director; Acusphere, former Director; Cephalon • **Kenneth I. Kaitin, PhD**, Director of Tufts Center for the Study of Drug Development • **Robert E. Martell, MD, PhD**, Tufts Medical Center Cancer Center, Director Neely Cancer for Clinical Cancer, former positions at BMS, Bayer, Methylgene • **Daniel R. Passeri**, President & CEO, Curis • **Marc Rubin, MD**, Titan Pharmaceuticals, Executive Chairman, Board of Directors • **James R. Tobin**, Former President & CEO, Boston Scientific Corporation

SCIENTIFIC ADVISORY BOARD
Kenneth J. Pienta, MD, CAB/SAB Chairman; Director, Translational Medicine Committee, South West Oncology Group • **Stuart A. Aaronson, MD**, Chairman, Dept. of Oncological Sciences, Mount Sinai Medical Center, NY • **James D. Griffin, MD**, Dana Farber Cancer Institute • **Philip A. Philip, MD, PhD, FRCP**, Clinical Professor, Oncology, Barbara Ann Karmanos Cancer Institute • **Samir E. Witt, MD, PhD**, Rocky Mountain Cancer Care Center

TRADING STATUS AS OF OCTOBER 5, 2011	NASDAQ: CRIS	
	Market Data Current Price 3.26 Currency US Dollar Net Change 2.19 Volume 338,677 YTD % Change 0.65 52Wk Range 1.28–4.42 Avg. Daily Volume (thousands) 567,452	First Call Data Market Cap (MM) 249.5 Short Interest Shares 6,214,568 Short Interest Ratio 17.44 PE (Trailing 12 Months) -0.04 EPS (Last Fiscal Year) -0.24 Consensus Estimate (Y) -0.04 Consensus Recommend 0.04 Price/Sales 64.44
	Shareholders Institution First Eagle Investment Management LLC 22.9% BlackRock Fund Advisors 5.7% Baillie Gifford & Co. 4.4% The Vanguard Group, Inc. 2.4% State Street Global Advisors 1.7% Mutual Fund First Eagle Investment Management LLC 22.9% BlackRock Fund Advisors 5.7% Baillie Gifford & Co. 4.4% The Vanguard Group, Inc. 2.4% State Street Global Advisors 1.7%	<i>Source: Thomson Reuters</i>

Cyclacel Pharmaceuticals, Inc.

Bio Member, Presenting Company

Clinical Foci: Hematology, Oncology, AutoImmune

Spiro Rombotis

President & CEO

200 Connell Drive Suite 1500
Berkeley Heights, NJ 07922
USA

www.cyclacel.com

1-908-517-7330

NASDAQ: CYCC

Incorporated: 1996

Employees: 22

Ownership: Public

HIGHLIGHTS

Recent

Initiation of the pivotal Phase 3 SEAMLESS randomized trial of oral sapacitabine as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed AML who are not candidates for intensive induction chemotherapy.

Reported interim results from an ongoing, multicenter, Phase 1/2 clinical trial examining the safety and effectiveness of sapacitabine administered sequentially with decitabine.

Initiation of a Phase 2 trial of sapacitabine in patients with CLL or SLL hematological malignancies and 11q22-23 deletion

Upcoming

Interim recommendation by DSMB of SEAMLESS pivotal randomized Phase 3 study of sapacitabine in AML.

Interim data from Phase 2 study of sapacitabine in patients with NSCLC.

Patient biomarker analysis from the APPRAISE Phase 2b randomized discontinuation study of seliciclib in patients with NSCLC.

CORPORATE MISSION

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), an oral cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia. Seliciclib (CYC202 or R-roscovitine), an oral CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the US Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

PROPRIETARY TECHNOLOGY

Cyclacel is a leader in cell cycle biology including the use of biomarker analysis to help evaluate whether drug candidates are having their intended effect on their assumed mechanisms. Cyclacel relies on proprietary genomic technology to identify gene targets, which are then advanced to the discovery stage by means of structure-based design techniques. Cyclacel scientists have discovered nine (9) new chemical entity classes to date.

CORPORATE ALLIANCES

2007, ALIGN Pharmaceuticals, LLC: asset acquisition (Xclair® Cream, Numoisyn® Liquid and Lozenges);

2005, Altana Pharma AG: research collaboration applying Cyclacel's expertise in mitosis to identify the molecular targets of certain Altana Pharma compounds.;

2004, Corgentech: Out license Penetratin drug delivery technology for transcription factor decoy drugs;

2003, Sankyo Co., Ltd: In-license CYC682 (nucleoside analog prodrug).

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Sapacitabine (CYC682)	AML	Phase III	SEAMLESS Phase 3 trial initiated in AML under SPA.
Sapacitabine (CYC682)	MDS	Phase II, IIa, IIb	Phase 2 MDS extended survival data.
Sapacitabine (CYC682)	NSCLC	Phase II, IIa, IIb	NSCLC Phase 2 interim data.
Sapacitabine (CYC682)	CLL	Phase II, IIa, IIb	
Seliciclib (CYC202)	NSCLC	Phase II, IIa, IIb	APPRAISE Phase 2b biopsy analysis data.
Seliciclib (CYC202)	NPC nasopharyngeal cancer	Phase II, IIa, IIb	Phase 2 lead-in completed.
CYC116 Aurora & VEGFR2 inhibitor	Cancer	Phase I	
CYC065 CDK Inhibitor	Cancer	Preclinical	
PLK-1 inhibitor	Cancer	Preclinical	
GSK-3 inhibitor	Diabetes Type 2	Preclinical	

SENIOR MANAGEMENT

Spiro Rombotis, President & CEO • **Paul McBarron**, Chief Operating Officer • **Judy Chiao, MD**, Chief Medical Officer • **Robert Sosnowski**, Vice President

BOARD OF DIRECTORS


David U'Prichard, PhD, Druid Consulting LLC; 3-D Therapeutics, SmithKlineBeecham, Zeneca • **Nicholas Bacopoulos, PhD**, Mersana Therapeutics, Aton Pharma; OSI Pharmaceuticals; Pfizer • **Sir John Banham**, Spacelabs; Johnson Matthey; Amvescap • **Christopher S. Henney, PhD, DSc**, Co-Founder, Dendreon; ICOS; Immunex • **Gregory T. Hradsky**, Sielox; Avenue Capital Group; Bellport Capital; UBS Securities, T. Rowe Price • **Paul McBarron**, Cyclacel; Shire; SmithKlineBeecham; Sterling Drug • **Spiro Rombotis**, Cyclacel; Liposome; Bristol-Myers Squibb; Centocor; Novartis • **Lloyd Sems**, Sems Capital, LLC; Selectica, Inc.; Sport-Haley, Inc • **Daniel K. Spiegelman**, CV Therapeutics; Genentech

SCIENTIFIC ADVISORY BOARD

Professor Kenneth Harrap, PhD, Institute of Cancer Research, Sutton, Surrey & London • **Professor Stanley Kay, MD**, Institute of Cancer Research, The Royal Marsden Hospital • **Professor Michel Marty, MD**, University of Paris VII; Institut Gustave Roussy • **Professor Enrico Mihich, MD**, Roswell Park Cancer Institute, Buffalo • **Professor Karol Sikora, MD**, Brunel-Buckingham University Medical School, AstraZeneca, Imperial College School of Medicine; Hammersmith Hospital, London

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: CYCC



Market Data

Current Price	0.44
Currency	US Dollar
Net Change	10.00
Volume	1,828,017
YTD % Change	-0.70
52Wk Range	0.36–1.95
Avg. Daily Volume (thousands)	617,545

First Call Data

Market Cap (MM)	23.9
Short Interest Shares	258,160
Short Interest Ratio	1.13
PE (Trailing 12 Months)	-0.34
EPS (Last Fiscal Year)	-0.36
Consensus Estimate (Y)	-0.34
Consensus Recommend	--
Price/Sales	31.25

Shareholders

<i>Institution</i>	<i>Holding %</i>
AWM Investment Co., Inc.	5.2%
Manatuck Hill Partners LLC	2.8%
Redmile Group LLC	1.1%
Millennium Management LLC	0.9%
The Vanguard Group, Inc.	0.9%
<i>Mutual Fund</i>	<i>Holding %</i>
AWM Investment Co., Inc.	5.2%
Manatuck Hill Partners LLC	2.8%
Redmile Group LLC	1.1%
Millennium Management LLC	0.9%
The Vanguard Group, Inc.	0.9%

Source: Thomson Reuters

Dicerna Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Oncology, Drug Discovery

Douglas Fambrough, PhD

Chief Executive Officer

480 Arsenal Street
Watertown, MA 02472
USA

www.dicerna.com

1-617-612-6222

Incorporated: 2007

Employees: 30

Ownership: Private

HIGHLIGHTS

Recent

Dicerna's alliance with KHK has been highly successful to date and has been expanded from oncology to include immunology and inflammation, including an exercised optioned right, and has also been expanded to include additional delivery technologies.

Dicerna's DsiRNA and delivery technologies are achieving efficacy in multiple tumor models using clinically relevant delivery directed at classically undruggable targets.

CORPORATE MISSION

Dicerna is an oncology-focused next generation RNA interference company developing therapies based on Dicer Substrate siRNA (DsiRNA) molecules and proprietary RNAi drug delivery systems. Dicerna's Dicer Substrate Technology™ utilizes 25bp and longer RNA duplexes which are the natural substrate for Dicer, the entry point to the RNAi pathway. This structure provides enhanced activity, facilitates delivery formulation, defines a distinct IP estate, and positions Dicerna to realize the promise of RNAi therapeutics. Dicerna's programs are focused on high value otherwise undruggable targets in oncology, for diseases such as hepatocellular carcinoma and pancreatic adenocarcinoma. Dicerna's delivery system achieves RNAi delivery to these solid tumors and others, enabling RNAi to be broadly used within oncology. In addition, Dicerna has programs focused on the therapeutic areas of endocrinology, immunology and inflammation with its pharmaceutical partners Kyowa Hakko Kirin and Ipsen.

PROPRIETARY TECHNOLOGY

Dicerna's DsiRNA Technology offers significant advantages over earlier RNAi technologies, in terms of potency and longevity of gene silencing, achieved in in vitro and in vivo experiments to date, and in its enhanced delivery potential. Dicerna delivers these DsiRNAs to solid tumors via a proprietary targetable lipid nanoparticle technology that has been tuned to accumulate in tumors, bind and internalize into tumor cells, and escape from endosomes into the cytoplasm. This technology has proven effective in solid tumors of both liver and non-liver origin, and we continue to expand the breadth of applicability of this technology.

CORPORATE ALLIANCES

Dicerna has a major alliance in oncology with Kyowa Hakko Kirin, which has been expanded to include immunology and inflammation. Dicerna also has an alliance with Ipsen involving both oncology and endocrinology.

SENIOR MANAGEMENT

Douglas Fambrough, PhD, Chief Executive Officer • **Bob Brown, PhD**, Senior Vice President

BOARD OF DIRECTORS

David Madden, Narrow River Management • **Jonathan MacQuitty, PhD**, Partner, Abingworth Management • **Steve Hoffman, MD, PhD**, Managing Director, Skyline Ventures • **Brian Halak, PhD**, Partner, Domain Associates • **Jonathan Fleming**, Oxford Bioscience Partners • **Dennis Langer, MD, JD**, Professor, Dept. of Psychiatry, Georgetown University School of Medicine; Former Senior VP, R&D, GlaxoSmithKline • **Jim Jenson, PhD**, Dicerna Co-Founder • **Douglas Fambrough, PhD**, CEO, Dicerna Pharmaceuticals, Inc.

SCIENTIFIC ADVISORY BOARD

Frank McCormick, PhD, FRS, DSc (Hon), UCSF • **Thomas Roberts, PhD**, Dana-Farber Cancer Institute • **John Rossi, PhD**, City of Hope • **Mark Behlke, MD, PhD**, Integrated DNA Technologies • **Ronald Kahn, MD**, Joslin Diabetes Center • **Joseph Bonventre**, Harvard Medical School • **Carlo Croce, MD**, Ohio State University

FINANCING HISTORY

Round Date (Amount, US\$) 05/01/2008 (21.40 million) • 08/01/2010 (29.00 million)

Investors: Domain Associates (18%) • Skyline Ventures (18%) • Oxford Bioscience Partners (18%) • Abingworth Management (13%) • SR One (6%)

DLVR Therapeutics Inc.

Presenting Company

Clinical Foci: Oncology, Drug Delivery

Frank Gleeson

Chief Executive Officer

MaRS Centre, South Tower, 101 College St.,
Suite 800
Toronto, ON M5G 0A3
Canada

www.dlvtherapeutics.ca

1-647-237-3691

Incorporated: 2011

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

Company co-founded by University Health Network, MaRS Innovation and Ontario Institute for Cancer Research in 2011. Initial seed funding of CAD \$1 million secured.

Execution of initial corporate collaboration with a major pharmaceutical company to evaluate HPPS technology for siRNA delivery.

Upcoming

Selection of initial clinical candidate in 2012.

Completion of proof of concept evaluation and initiation for first co-development collaboration in 2012.

Securing of Series A equity financing in 2H12.

CORPORATE MISSION

DLVR Therapeutics Inc. is a privately held biotechnology company based in Toronto. Founded in 2011, the company is focused on developing a novel, HDL-mimicking nanoparticle delivery system suitable for a variety of different payloads: in particular small molecule lipophilic therapeutics and siRNA, initially for oncology indications. The company has two principal programs: the first is focused on improving the therapeutic index of chemotherapeutic drugs and advancing them into clinical development; the other is focused on the targeted delivery of siRNA in collaboration with biopharmaceutical partners. The company will be seeking Series A financing in H2, 2012.

PROPRIETARY TECHNOLOGY

DLVR's innovative technology is based on the synthesis and use of an HDL-mimetic phospholipid-based nanoparticle called HPPS (HDL-like Peptide-Phospholipid Scaffold). Exploiting the property of HDL to create a hydrophobic channel in the cell membrane, HPPS delivers its payload directly into the cytosol of its target cells. It further mimics the natural targeting of HDL to the scavenger receptor class B type I (SR-BI) which is upregulated in several cancers including breast, prostate and colon. HPPS exhibits similar pharmacokinetics as plasma-derived HDL with a long stable circulating time and favourable biodistribution. HPPS nanoparticles are ultra-small (10-25 nm), nontoxic, nonimmunogenic, biocompatible, easy to synthesize and customizable.

CORPORATE ALLIANCES

The company has entered into its first relationship with a major pharmaceutical corporation to undertake a proof of concept evaluation of the HPPS technology in siRNA delivery.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Chemotherapeutic development	Oncology	Lead Series	Advance HPPS - Gemcitabine into clinical candidate
Chemotherapeutic development	Oncology	Lead Series	Advance HPPS - Bendamustine into preclinical development
Chemotherapeutic development	Oncology	Research	Advance HPPS - SN-38 into preclinical development

SENIOR MANAGEMENT

Frank Gleeson, Chief Executive Officer • **Dr. Bev Incedon**, Vice President • **Dr. Malik Slassi**, Consultant • **Dr. Gang Zheng**, Chief Scientific Officer

BOARD OF DIRECTORS

Dr. Brian Barber • **Dr. Eric Rowinsky** • **Dr. Jeff Edelson**

FINANCING HISTORY

Round Date (Amount, US\$) 09/10/2011 (1.00 million)

DNA Therapeutics SA

Presenting Company

Clinical Foci: Oncology

Jian-Sheng Sun Chief Executive Officer

4 rue Pierre Fontaine
91058 Evry
France

www.dna-therapeutics.com

33-6-2475 3239

Incorporated: 2006

Employees: 10

Ownership: Private

HIGHLIGHTS

Recent

Initiating DRIIM trial to evaluate the safety, PK, preliminary anti-tumor activity and PD (using biomarkers) of locally administered DT01 in combination with radiotherapy in patients suffering metastatic melanoma with relapsed cutaneous tumors.

August 22, 2011, French Health Authority (AFSSAPS) issued its Clinical Trial Authorization for DNA Therapeutics' First-in-Human trial, without any question on the safety, quality of the investigational medicinal product - DT01, and trial protocol.

April 4, 2011, Japanese Patent Office notified its decision to grant the 1st Dbait patent in Japan. So far, the princeps patent of Dbait has been already granted in the major pharmaceutical territories, such as USA, Europe, Japan and Australia.

Upcoming

2H12 - clinical safety, PK/PD & preliminary efficacy of DT01.

1H13 - clinical Proof of Concept of Dbait to achieve validation of siDNA concept & technology.

1H15 - preliminary efficacy of DT01 in 2 major cancer indications in order to trigger a strategic partnership

CORPORATE MISSION

DNA Therapeutics is an emerging clinical stage biopharmaceutical company. It develops a paradigm-shift concept named signal interfering DNA (siDNA) and siDNA-based first-in-class small molecular drugs to address unmet needs in oncology. It primarily focuses on the treatment-related resistance of cancer. Anticancer therapies, such as radiotherapy and chemotherapy, often are inefficient in the treatment of relapsed cancer, due to tumor cells' enhanced capacity to repair DNA lesions caused by DNA damaging treatments.

DNA Therapeutics is a spin-off of 4 renowned French research institutions (Institut Curie, CNRS, INSERM, MNHN). It acts as an integrator of life science technologies and a business-driven drug developer, through its strong interactions with renowned research institutions for translational research, and biotech companies, and worldwide outsourcing to top tier CRO/CMO for drug development.

DNA Therapeutics has been successfully organized as a Virtually Integrated Pharmaceutical Company (VIPCo). This minimizes burning rate, keeps flexibility and optimizes value creation. Its management relies on the expertise of professionals from pharmaceutical and biotechnology industries, and on top notch consultants in chemistry-manufacture-control (CMC), early stage drug development and regulatory affairs, as well as Key Opinion Leaders in oncology.

The lead investigational medicinal product DT01 has a high therapeutic index as MTD was not reached, nor CNS & CVS disorder were observed in the ICH9 compliant 4-week animal toxicology studies with 2-week recovery in rat and in monkey. This provides high safety margin for 1st-in-human dosing.

The 1st trial of DT01 (combined with radiotherapy) in melanoma-in-transit is starting in France. It was specially designed to establish not only the safety and tolerance, but also the clinical proof of concept of DT01 with limited patients at early stage of clinical development. "THINK DIFFERENT" is also its credo!

PROPRIETARY TECHNOLOGY

The originality of siDNA is to use a short DNA fragment mimicking DNA damage. It acts by jamming DNA damage sensing and signaling, ultimately inhibiting DNA repair during its treatment. Therefore siDNA-based drugs sensitize anticancer therapies. This is a technology platform capable of generating multiple products – Dbait is its 1st family which interferes with the repair pathways of double strand break (DSB), a major DNA damage.

Dbait is not classical inhibitor, but a novel class of target therapy drugs which acts on a cascade of proteins involved in DSB repairs, the 1st example of SUPRA-MOLECULAR therapy. Only Dbait can block all DSB repair pathways without toxicity to normal cells. This prevents tumor cells from escaping the inhibition of targeted pathway through an alternative pathway.

CORPORATE ALLIANCES

DNA Therapeutics aims at bridging the gap between translational research and late stage drug development. After having achieved the clinical proof of concept of its products, it will look for strategic partner(s) in oncology field for late stage drug development, market approval and commercialization. It is also looking for the partners for regional, emerging, or veterinary markets through early stage licensing-out/co-development.

PRODUCTS

Name	Indication	Phase	Milestone
DT01	Oncology	Phase I	Safety, anticancer activity, clinical proof of concept
Pbait	Oncology	Lead Series	Lead optimization

SENIOR MANAGEMENT

Jian-Sheng Sun, Chief Executive Officer • **Marie Dutreix**, Chief Scientific Officer • **Alan Irvine**, Chief Medical Officer • **Bruno Cervera**, Chief Financial Officer • **Denis Ravel**, Consultant • **Brian Sproat**, Consultant • **Sidonie Hill**, General Counsel • **Valérie Gallois**, Attorney

BOARD OF DIRECTORS

Jian-Sheng Sun, CEO, DNA Therapeutics • **Béatrice Denys**, Partner, SGAM SEFTI • **Bernard Majoie**, BA; Former CEO, Fournier Pharma (now Abbott) • **Michel Raoult**, Chandra Capital; Formerly with Paul Capital, Crédit Lyonnais, Innolion • **Eric Viaud**, CEO, Gene Signal

SCIENTIFIC ADVISORY BOARD

Michel Marty, Saint Louis Hospital, Paris • **Alban Denys**, CHUV, Lausanne

FINANCING HISTORY

Round Date (Amount, US\$) 06/05/2006 (1.10 million) • 01/29/2009 (3.00 million) • 05/17/2011 (2.70 million)

Investors: SGAM SEFTI (VC) (55%) • Genopole 1er Jour Ile-de-France (Institutional seed) (5%) • Inserm-Transfert Initiative (Institutional seed) (3%) • Business angels (Belgian, Chinese, French) (20%) • Founders and management (17%)

EBD Group

BIO Member

Carola Schropp

President

2032 Corte del Nogal
Carlsbad, CA 92009
USA

www.ebdgroup.com

1-760-930-0500

Incorporated: 1993

Employees: 45

Ownership: Private

HIGHLIGHTS

Recent

BIO-Europe Spring® 2011: 1,803 attendees from 1,123 companies participated in 9,202 one-to-one meetings and 120 company presentations on products and technologies.

The next BIO-Europe Spring® will be, March 19–21, 2012 in Amsterdam, The Netherlands

ChinaBio® Partnering Forum 2011: 658 attendees participated in 807 one-to-one meetings, 38 biotech company presentations and 29 "Innovation Showcase" presentations.

Next year's ChinaBio® Partnering Forum will be in Suzhou, China; May 23–24, 2012

EuroMedtech™ 2011

261 attendees from more than 205 companies participated in 741 one-to-one meetings and 45 company presentations on products and technologies.

Save the date for EuroMedtech 2012 in Grenoble, France : May 31–June 1, 2012

Upcoming

BioPharm America™, Boston, USA

September 7–9, 2011 is where biotech industry partnerships get started.

<http://www.ebdgroup.com/bpa/index.php>

BIO-Europe® is Europe's largest partnering conference, serving the global biotechnology industry.

Will be held in Duesseldorf, Germany on October 31–November 02, 2011

<http://www.ebdgroup.com/bioeurope/index.php>

Biotech Showcase™: private and public life science companies present to an audience of investors and business development executives during the course of the world's largest annual healthcare investor conference.

<http://www.ebdgroup.com/bts/index.php>

CORPORATE MISSION

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

- BIO-Europe® and BIO-Europe Spring®, the world's largest stand-alone life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- EuroMedtech™, EBD Group's partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China.
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world. Outside of the conference format, EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com

PROPRIETARY TECHNOLOGY

EBD Group's partnering software, bundled into its partneringONE® services, is available to event organizers around the world, helping your delegates connect. Move your event to the next level by adding professional partnering services.

For a list of upcoming and past client events please visit: <http://www.ebdgroup.com/ebd/partneringone/events.htm>

EBD Group's Business Development consultants are experienced in a wide variety of partnering deals including out-licensing, in-licensing and R&D collaborations. Their services encompass identification of potential partners, initial introductions, location of in-licensing opportunities, identification of clients for CRO/CMO and support of deal negotiations.

CORPORATE ALLIANCES

In addition to EBD Group's own events, partneringONE services are used at numerous third-party events worldwide.

For a list of upcoming and past client events please visit <http://www.ebdgroup.com/ebd/partneringone/events.htm>

SENIOR MANAGEMENT

Constantine Theodoropoulos, Corporate Communications • **Carola Schropp**, President • **Philip Ledger**, Vice President • **Katharina Schropp**, Director • **Florian Schönhammer**, Director • **Karin Dierkes**, Director

EluSys Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease, Biodefense

Elizabeth Posillico, PhD

Chief Executive Officer

25 Riverside Drive
Pinebrook, NJ 07058
USA

www.elusys.com

1-973-808-0222

Incorporated: 1999

Employees: 25

Ownership: Private

HIGHLIGHTS

Recent

Awarded USD \$69 million, five (5) year, government advanced development contract for pre- and post-exposure indication of Anthim, anthrax anti-toxin to supplement previous \$143 million contract.

Initiated dose escalating human safety study.

CORPORATE MISSION

EluSys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. Anthim has consistently demonstrated significant efficacy in multiple non-clinical animal studies and has been successfully evaluated in two clinical safety trials.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Anthim monoclonal anthrax anti toxin	prophylaxis and treatment of anthrax infection	Phase II, IIa, IIb

SENIOR MANAGEMENT

Elizabeth Posillico, PhD, Chief Executive Officer • **Robert Love, MBA**, Chief Financial Officer • **Greg Torre, PhD**, Vice President • **Leslie Casey, PhD**, Vice President • **Jeremy Middleton**, Vice President • **James Porter**, Vice President • **Debra Duffy**, Director

BOARD OF DIRECTORS

Ron Eastman, Essex Woodlands Healthcare Ventures • **Johnson Evans**, Invesco • **Clinton Musil**, Essex Woodlands Healthcare Ventures • **Tyrell Rivers, PhD**, Medimmune • **Jeffrey Wolf**, Heat Biologics • **Frank Young, MD, PhD**, Essex Woodlands Health Ventures

Emisphere Technologies, Inc.

Clinical Foci: Drug Delivery

Michael R. Garone
Interim Chief Executive Officer &
Chief Financial Officer

240 Cedar Knolls Road
Cedar Knolls, NJ 07927
USA

www.emisphere.com

1-973-532-8000

OTC BB: EMIS

Incorporated: 1986

Ownership: Public

HIGHLIGHTS

Recent

Novartis Pharma AG is conducting Phase III trials of oral salmon calcitonin using Eligen® for the treatment of osteoporosis and osteoarthritis. Data from both trials is expected 2011. Novartis plans to file for regulatory approval of OP in 2012.

Novo Nordisk A/S is conducting clinical Phase I testing of an oral formulation of their GLP-1 receptor agonist and preclinical testing of oral formulations of their proprietary insulins using Eligen® Technology for Type 2 diabetes.

Emisphere completed a successful clinical trial that demonstrated its oral formulation of B12 using the Eligen® Technology was comparable in efficacy to the IM injection which is the current standard of care.

Upcoming

Emisphere's Eligen® Technology is a leading contender to be the first technology to successfully deliver a therapeutic peptide molecule orally in a commercial product.

Eligen® Technology facilitates and improves absorption of molecules which are otherwise poorly absorbed. We have demonstrated improved delivery and Tmax reduction for several pre-clinical candidates in pain, migraine and other therapeutic areas.

Emisphere can launch a B12 medical food product right now and is currently evaluating the feasibility of continuing development of a drug product.

CORPORATE MISSION

Emisphere Technologies Inc. is a biopharmaceutical company that focuses on improving the delivery of active pharmaceutical ingredients, medical foods and dietary supplements using its proprietary Eligen® Technology. The company's core focus is on oral delivery of molecules which are currently administered by injection. Emisphere's Eligen® Technology overcomes several major obstacles to effective oral delivery including degradation of the active and poor absorption. The major advantages of the technology include broad applicability, stand alone delivery approach – eliminating the need for penetration enhancing excipients, versatility of formulation design, ease of scale up and manufacture and cold chain elimination. In addition to enhancing the bioavailability of compounds, a key feature of the technology is an advantageous pharmacokinetic profile. This feature can be extremely valuable in certain therapeutic areas like pain, migraine, etc. Oral delivery has been shown with Eligen® in clinical trials of solid dosage forms of Unfractionated Heparin, two low molecular weight heparins, Salmon Calcitonin, Insulin, Parathyroid Hormone fragment 1-34, recombinant growth hormone, Cromolyn, Acyclovir and a bisphosphonate. Emisphere has also demonstrated oral delivery of over 60 other compounds in pre-clinical studies. Emisphere recently conducted a clinical trial that demonstrated complete repletion of cyanocobalamin - a vitamin that is poorly absorbed upon oral administration. To date, the Eligen® Technology has been evaluated in more than 140,000 human dosings in different clinical studies ranging in duration from a single dose up to 3 months of daily doses with no adverse events attributed to the technology. Eligen® Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, nasal, ophthalmic, otic, intra vaginal or transdermal.

PROPRIETARY TECHNOLOGY

Eligen® Technology is based upon proprietary, synthetic chemical compounds known as carriers or delivery agents that facilitate the transport of therapeutic macromolecules and other compounds across biological membranes. The Eligen® Technology only changes the physical nature of the molecule without chemically altering the molecule being delivered. We have designed and synthesized a library of over 2000 delivery agents and continue to evaluate these agents for their ability to facilitate the delivery of drugs without altering their ability to exert their pharmacological effect. In addition to improving the absorption of various therapeutic molecules, the technology has been shown to significantly reduce the time to maximum concentration when compared to the marketed formulations.

CORPORATE ALLIANCES

Novo Nordisk has licensed Eligen® Technology for use in combination with its proprietary GLP-1 and insulin analogs. This partnership with Novo Nordisk has the potential to offer new and significant solutions to millions of people with diabetes worldwide. Novartis Pharma AG has licensed Eligen® Technology for use in an oral Calcitonin formulation to treat osteoporosis and osteoarthritis. For osteoarthritis, Novartis completed on Phase III trial and a second Phase III clinical study is ongoing. Novartis is planning a regulatory submission for oral Calcitonin for the treatment of osteoporosis during 2012. These programs serve to validate Eligen® Technology in addition to providing oral delivery as an option for drugs that would otherwise require an invasive route of administration.

PRODUCTS

Name	Indication	Phase
Salmon Calcitonin	Osteoporosis and Osteoarthritis	Phase III
Oral GLP-1 Analogues	Type 2 Diabetes	Phase I
Oral Insulin	Type 1 and Type 2 Diabetes	Preclinical
Oral Eligen B12	repletion of B12 levels in deficient patients	Other

SENIOR MANAGEMENT


Michael R. Garone (CFO), Interim Chief Executive Officer • **M. Gary I. Riley, DVM, PhD**, Vice President • **Ron Zesch**, Vice President • **David Gschneidner**, Director • **Karen Brazzillo**, Director

BOARD OF DIRECTORS

Mark Rachesky, MHR Fund Management • **Michael Weiser**, Actin Biomed • **John Harkey**, Consolidated Restaurant Operations • **Tim Rothwell**

TRADING STATUS AS OF OCTOBER 5, 2011

OTC BB: EMIS



Market Data

Current Price	1.72
Currency	U.S. Dollar
Net Change	-3.91
Volume	45,784
YTD % Change	-0.29
52Wk Range	0.75–2.68
Avg. Daily Volume (thousands).....	100,430

First Call Data

Market Cap (MM)	104.4
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.33
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	1828.00

Shareholders

Institution

Holding %

MHR Fund Management LLC	30.5%
Dimensional Fund Advisors, Inc.....	0.7%
Jamison, Eaton & Wood, Inc.....	0.0%
Mellon Capital Management Corp.	0.0%
Manulife Asset Management Ltd.....	0.0%

Mutual Fund

Holding %

MHR Fund Management LLC	30.5%
Dimensional Fund Advisors, Inc.....	0.7%
Jamison, Eaton & Wood, Inc.....	0.0%
Mellon Capital Management Corp.	0.0%
Manulife Asset Management Ltd.....	0.0%

Source: Thomson Reuters

Envoy Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Drug Discovery, CNS, Metabolic Disease

Brad Margus Chief Executive Officer

555 Heritage Drive
Jupiter, FL 33458
USA

www.envoytherapeutics.com

1-561-210-7705

Incorporated: 2009

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

August, 2011 – Awarded "Mega Market" Newcomer award from State of Florida, citing the company's "outstanding contributions toward improving and diversifying Florida's economy plus distinctive community investment efforts".

July, 2011 – Awarded grant from The Michael J. Fox Foundation to develop compounds targeting a motor circuit compromised in Parkinson's disease via modulation of a receptor recently identified by Envoy.

May, 2011 – Harvard Medical School pain expert, Clifford Woolf, MD, PhD, joins Envoy's scientific advisory board. Dr. Woolf is a professor of neurology and neurobiology focusing on the development of somatosensory circuits, pain and regeneration.

CORPORATE MISSION

Envoy was founded in 2009 to apply a powerful new technology that greatly improves target identification and drug discovery. The technology allows us to measure, in vivo, the expression of each protein within any given cell type and to identify targets selectively expressed in cell populations important to diseases. With highly selective targets in-hand, we believe we can advance novel compounds through preclinical and clinical activities with lower rates of attrition.

In October 2009, we raised \$8 million from 5AM Ventures, Takeda and Roche. We subsequently formed research collaborations with Merck, focused on diabetes and obesity, and with Takeda focused on schizophrenia. These collaboration agreements provide up-front payments and non-dilutive, cash-flow positive research funding and potential milestone payments and royalties. We have also obtained non-dilutive funding from the US government for programs focused on Parkinson's disease and schizophrenia, and from the Michael J. Fox Foundation.

In the year ahead, as we advance compounds from our internal pipeline into lead optimization, we expect to complete a Series B financing. Our goal at the BIO Investor Forum is to introduce the company to investors and potential collaborators.

Our business model has three pillars: using our technology to profile cell types and identify specifically expressed drug targets, discovering new compounds that act on a number of those targets, and forming cash-flow-positive research collaborations with a handful of global pharmaceutical companies.

As our internal drug discovery programs achieve pre-clinical proof of concept in animal models, we expect our business model to gain a fourth pillar as we partner a subset of our compounds to pharmaceutical companies for further development and commercialization.

PROPRIETARY TECHNOLOGY

The pharmaceutical industry's pipeline for innovative therapies to treat neurological and psychiatric diseases is sparse. Envoy's technology holds the promise of bringing forth new, more effective medicines. Our patented bacTRAP translational profiling technology enables us to analyze in vivo all the proteins expressed in specific cell types that play critical roles in complex disease circuits, enabling us to identify novel, cell-type-specific drug targets that are less likely to cause off-mechanism side effects. The platform also enables us to identify the molecular adaptations that occur in specific cell types as a result of disease and drug treatment.

CORPORATE ALLIANCES

In December 2009, less than three months after closing our initial financing, Envoy formed a multi-year research alliance with Merck & Company to discover novel diabetes and obesity drug targets and advance new compounds that modulate them. Merck has thus far paid Envoy an upfront fee, research funding and a milestone payment; additional success-based milestones and royalties may be earned.

In October 2010, Envoy signed an additional collaboration agreement with Takeda to identify proteins selectively expressed in specific cell types known to be involved in schizophrenia. Takeda made a USD \$3 million upfront payment and is providing \$2.25 million per year to Envoy in research funding and fees. Envoy may earn additional success-based milestones and royalties.

PRODUCTS

Name	Indication	Phase
D130	Cognition	Preclinical
D110	Parkinson's disease	Preclinical
D150	Schizophrenia	Preclinical
D180	Parkinson's disease	Preclinical
D170	Addiction & Pain	Preclinical

SENIOR MANAGEMENT

Brad Margus, Chief Executive Officer • **Robert Middlebrook**, Chief Financial Officer • **Stephen Hitchcock, PhD**, Senior Vice President • **Matt Britz**, Business Development

BOARD OF DIRECTORS

John Diekman, PhD, 5AM Ventures • **Fmr. Senator William Bradley**, Allen & Company, LLC • **Mason Freeman, MD**, Mass General Hospital, Harvard Medical School & 5AM Ventures • **Brad Margus**, Envoy Therapeutics, Inc.

SCIENTIFIC ADVISORY BOARD

Nathaniel Heintz, PhD, The Rockefeller University, Howard Hughes Medical Institute • **Paul Greengard, PhD**, The Rockefeller University, The Fischer Center for Alzheimer's Research • **Jeffrey Friedman, MD, PhD**, The Rockefeller University, Howard Hughes Medical Institute • **Scott Biller, PhD**, Agios Pharmaceuticals • **Mark Gallop, PhD**, Former Senior Vice President and Co-founder, Xenoport • **Patrick Griffin, PhD**, The Scripps Research Institute • **Myriam Heiman, PhD**, Broad Institute of MIT and Harvard University, Picower Institute of Learning and Memory • **Eugene Johnson, PhD**, Washington University School of Medicine • **Clifford Woolf, MD, PhD**, Harvard Medical School, Children's Hospital Boston

FINANCING HISTORY

Round Date (Amount, US\$) 10/09/2009 (8.00 million)

Epiomed Therapeutics, Inc.

Presenting Company

Clinical Foci: Drug Development, Drug Discovery, CNS

David R. Helton
Chief Executive Officer

25 Mauchly, Ste 316
Irvine, CA 92618
USA

www.epiomed.com

1-949-398-7359

Incorporated: 2010

Employees: 2

Ownership: Private

CORPORATE MISSION

Epiomed Therapeutics, Inc., is a development-stage pharmaceutical organization focused on the discovery, development and partnering of novel central nervous system (CNS) drugs with a primary focus on anti-emetic (anti-vomiting and anti-nausea) and anxiety. Over a multi-year period and at a cost of several million dollars, the basic research and technology development leading to the discovery and pre-clinical characterization of a lead clinical compound, platform screening technology and discovery compound library has already been completed. Epiomed is poised to initiate human clinical studies of its lead compound within 6 months. In June 2011 the company completed its first round of venture funding with NDI Capital (Vancouver, Canada). The raise includes funding for a Phase I proof of concept human clinical study of its lead compound, ETI-385. Epiomed also has a genus of chemical compounds whose profile is believed to address multiple novel receptor targets. In addition to emesis and anxiety, these receptors modulate pathways for depression, psychosis, cognition, attention, pain and neurodegenerative disease. Epiomed is currently seeking capital to expand the scope of its Phase I clinical trials and to begin development of novel compounds as potential therapeutics for both human and veterinary applications.

PROPRIETARY TECHNOLOGY

Epiomed Therapeutics has acquired technology and assets from Cenomed, Inc. (technology developed by Cenomed BioSciences, LLC) relating to the discovery of a previously unknown but important inter-play between several receptors essential for development of potent anti-emetic, anti-anxiety therapeutic compounds. Epiomed Therapeutics' lead product is ETI-385 (formerly, CM-2,385), a novel anti-emetic, non-anxiogenic with multi-receptor pharmacology acting in the CNS at the common final pathway for emesis. Unlike all currently marketed anti-emetic drugs, ETI-385 blocks all emetic stimuli (motion, chemical, conditioned, etc.) in preclinical models. ETI-385 establishes the proof of the theory behind the Company's proprietary and broad ESP Discovery technology.

CORPORATE ALLIANCES

The Institute of Palliative Medicine (IPM) at the San Diego Hospice (www.sdhospice.org);
ChemPacific (www.chempacific.com) in Baltimore, MD (USA) and China (ChemPacific Zhapu);
MicroConstants (www.microconstants.com) in San Diego, California 92121;
NDI Capital (NDI) (www.ndicapital.com) in Vancouver, BC Canada, and Wright State University in Dayton Ohio.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
ETI-385	Emesis	Phase I	
ETI-601	PTSD	Preclinical	IND

SENIOR MANAGEMENT

David R. Helton, Chief Executive Officer • **Ernie Pfdenhauer**, Chief Operating Officer

BOARD OF DIRECTORS

James Miller, NDI Capital • **David R. Helton**, Epiomed Therapeutics • **Gordon McCauley**, NDI Capital • **Theodore Ming-Teh Yang**, ChemPacific

SCIENTIFIC ADVISORY BOARD

James Lucot, PhD, Wright State University • **Lakshmi Putcha**, PhD, NASA • **Marit I. Piacente**, DVM, DABT, Allergan • **Ernest H. Pfdenhauer**, MA, Epiomed Therapeutics • **Charles Von Gunten**, MD, San Diego Hospice • **Jay Huff**, MD, Consultant • **Laurence R. Meyerson**, PhD, Epiomed Therapeutics • **Douglas Harpel**, Aerospace Industry • **David Fleisher**, MD, University of Missouri School of Medicine

Epizyme, Inc.

BIO Member, Presenting Company

Robert J. Gould

Chief Executive Officer

325 Vassar Street, Suite 2B
Cambridge, MA 02139
USA

www.epizyme.com

1-617-229-5872

Incorporated: 2007

Employees: 42

Ownership: Private

CORPORATE MISSION

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-defined cancer patients, based on breakthroughs in the field of epigenetics. Epigenetic enzymes are strongly associated with the underlying causes of multiple human diseases and have been broadly validated as viable drug targets by the FDA approval of histone deacetylase and DNA methyltransferase enzyme inhibitors. Our hypothesis-driven approach to the creation of personalized therapeutics represents the future of cancer therapy creating better therapeutics for the right patients more quickly and at lower cost than traditional approaches. Epizyme's personalized therapeutics are exemplified by our two most advanced therapeutic product programs, targeting the HMTs DOT1L and EZH2.

CORPORATE ALLIANCES

GlaxoSmithKline (GSK), Multiple Myeloma Research Foundation (MMRF), Eisai, The Leukemia & Lymphoma Society (LLS)

SENIOR MANAGEMENT

Robert J. Gould, Chief Executive Officer • **Jason P. Rhodes**, Chief Business Officer • **Robert A. Copeland**, Chief Scientific Officer • **Victoria M. Richon**, Vice President • **Mikel Moyer**, Vice President

Esperion Therapeutics, Inc.

Presenting Company

Clinical Foci: Cardiovascular Disease, Metabolic Disease, Biopharmaceuticals

Roger S. Newton, PhD <i>President & CEO</i> 46701 Commerce Center Drive Plymouth, MI 48170 USA		www.esperion.com 1-734-862-4856	Incorporated: 2008 Employees: 15 Ownership: Private
---	--	--	---

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
ETC-1002, completed Phase 2 Lipid POC - August 2011. Lead protein selection for oxidation-resistant apoA-I program. Lead selection for follow-on small molecule program.	ETC-1002 - Top-line results and additional data analysis. Collaborative research agreement with biopharmaceutical company for the oxidation-resistant apoA-I program. ETC-1002 - Initiate a Phase 2 Glucose study in 1Q12.

CORPORATE MISSION

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to prevent, treat and reverse cardiovascular and metabolic diseases. We are developing novel therapies that enhance the body's ability to regulate lipid and carbohydrate metabolism as well as reduce inflammation, leading to improved health outcomes. Located in Plymouth, Michigan, Esperion is funded by top tier venture capital investors. Esperion Founder, President and CEO, Roger Newton, PhD, co-discovered and was the product champion of Lipitor®, while at Warner Lambert. Dr. Newton was also the co-founder and President/CEO of the original Esperion, purchased by Pfizer in 2004 for USD \$1.3 billion. Several members of the current Esperion team are accomplished drug developers from across the industry, including Warner Lambert/Pfizer and the original Esperion.

Esperion's most advanced product candidate just completed a Phase 2 Lipid POC. ETC-1002 -- a novel, once-daily, oral drug -- is being developed for patients who have, or are at risk for cardiovascular and metabolic diseases. ETC-1002 is a metabolic regulator of imbalances in carbohydrate and lipid metabolism and inflammation, unique in its ability to modulate LDL and HDL cholesterol, triglycerides, free fatty acids, glucose and other cardio-metabolic risk factors. Mechanistic studies indicate that treatment with ETC-1002 increases AMP-kinase phosphorylation, inhibits fatty acid and cholesterol synthesis and also enhances fatty acid oxidation. In addition, Esperion has completed discovery research on a number of promising follow-on candidates and has selected a lead compound.

PROPRIETARY TECHNOLOGY

In 2003 Esperion was the original developer of recombinant apoA-I Milano (ETC-216) and demonstrated regression of atherosclerotic plaques, after 5 weekly infusions, in stable ACS patients, via Intravascular Ultrasound (IVUS). This seminal moment in cardiovascular drug development led Pfizer to purchase the company in 2004.

Combining its legacy of innovation with significant advancements in recombinant protein production as well as improved sourcing, formulation and manufacturing, all factors leading to reductions in cost of goods, the new Esperion is developing a Proprietary, Optimized MPO Oxidation-Resistant ApoA-I Mimetic. The oxidation-resistant HDL mimetic therapy will preserve the function of HDL and its primary apolipoprotein (apoA-I).

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
ETC-1002	Dyslipidemia, diabetic dyslipidemia, pre-diabetic dyslipidemia	Phase II, IIa, IIb	Phase 2 Lipid POC completed in August 2011
Oxidation-Resistant ApoA-I - HDL Mimetic Therapy	Acute Coronary Syndrome	Optimized Lead	Pre-clinical, in vivo proof of concept completed in October 2011
Follow-on Small Molecule Compound	Dyslipidemia, diabetic dyslipidemia, pre-diabetic dyslipidemia	Optimized Lead	Evaluating partnerships

SENIOR MANAGEMENT

Roger S. Newton, PhD, President & CEO • **Troy Ignelzi**, Vice President

BOARD OF DIRECTORS

Alison Kiley, Alta Partners • **Dov Goldstein**, Aisling Capital • **Nicole Vitullo**, Domain Associates • **Lou Lange**, Asset Management • **Tim Mayleben**, Aastrom Biosciences • **Roger Newton**, Esperion Therapeutics

SCIENTIFIC ADVISORY BOARD

Michael Davidson, MD, Radiant Research • **Robert Eckel, MD**, University of Colorado, Denver • **Stephen Nicholls, MBBS, PhD, FRACP, FACC**, Cleveland Clinic • **Christie Ballantyne, MD**, Baylor College • **Lorenzo DiCarlo**, BioDev, LLC • **Stan Hazen, MD, PhD**, Cleveland Clinic

FINANCING HISTORY

Round Date (Amount, US\$) 05/01/2008 (22.75 million)

Investors: Alta Partners (28%) • Aisling Capital (28%) • Domain Associates (28%) • Arboretum Ventures (9%) • Asset Management Company (3%)

FasterCures

Presenting Company

Clinical Foci: Drug Development, Biopharmaceuticals, Drug Discovery

Margaret Anderson

Other

1101 New York Avenue NW, #620
Washington, DC 20005
USA

www.fastercures.org

1-202-336-8900

Incorporated: 2003

Employees: 13

Ownership: Patient Advocacy Group

HIGHLIGHTS

Recent

Partnering for Cures 2010: More than 800 medical leaders convened for this unique cross-sector partnering meeting, presentations on innovative collaborative initiatives, consultations with experts, and one-on-one partnering meetings.

"Crossing the Valley of Death" whitepaper: Highlights the importance of translational research in the therapeutic development process, identifies some of the major challenges to its conduct, and points the way toward possible solutions.

TRAIN Central Station: Online platform for venture philanthropists in medical research to come together to share best practices, exchange ideas, and find relevant tools and resources.

Upcoming

Partnering for Cures 2011: Scheduled for November 6-8 in New York City. Save the date for this one-of-a-kind partnering event.
www.partneringforcures.org

CORPORATE MISSION

FasterCures/The Center for Accelerating Medical Solutions is a nonprofit think tank and catalyst for action that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. Our mission is to accelerate the progress of discovery and development of new medical solutions for deadly and debilitating diseases. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.

Since 2003, FasterCures has been working on breaking down the barriers that exist across the research continuum - from basic research to drug development - to clear the path to faster medical progress. We are committed to facilitating a medical research culture that encourages innovation, collaboration, outcomes, effective and efficient use of resources and transparency.

Our strategic goals are:

1. To increase innovative, cross-sector collaborative science among all players in the medical research system;
2. To increase patient engagement in research and optimize use of patient data;
3. To improve the research policy and process to support efficient development and approval of new therapies;
4. Greater access to and strategic allocation of capital to support medical research.

SENIOR MANAGEMENT

Margaret Anderson, Other • **Cecilia Arradaza**, Other • **Kristin Schneeman**, Other • **Melissa Stevens**, Other • **Lisa Simms**, Other

BOARD OF DIRECTORS

Michael Milken, Milken Institute • **David Baltimore, PhD**, California Institute of Technology • **Ernest Bates, MD**, American Shared Hospital Services • **Gary Becker, PhD**, University of Chicago • **Leon D. Black**, Apollo Management • **Nancy G. Brinker**, Susan G. Komen for the Cure • **Larry Flax**, California Pizza Kitchen • **Shmuel Meitar**, Aurec Group • **Richard Merkin, MD**, Heritage Provider Network • **David A. Steinberg**, CAIVIS Acquisition Corp.

Flexion Therapeutics, Inc.

Presenting Company

Clinical Foci: Specialty Pharmaceutical, Biopharmaceuticals, Drug Development

Mike Clayman Chief Executive Officer

300 Trade Center
Woburn, MA 01801
USA

www.flexiontherapeutics.com

1-781-897-9977

Incorporated: 2007

Employees: 10

Ownership: Private

CORPORATE MISSION

Flexion has three novel assets in development for the treatment of Osteoarthritis (OA). Our approach combines local delivery (intra-articular injection) with sustained release technology to ensure high therapeutic concentrations at the site of disease. Two of our assets are in Phase II clinical trials and will have defining clinical data in 2012. Our programs will initially focus on relief of symptomatic OA pain, but both assets have disease modifying potential.

PROPRIETARY TECHNOLOGY

Flexion's approach combines local delivery (via injection) with sustained release technology to ensure high therapeutic concentrations at the site of disease. This also guarantees vanishingly low systemic concentrations and improves the safety profile of our molecules.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
FX005	Relief of symptomatic OA pain	Phase II, IIa, IIb	Proof of Concept Study completes 1Q12
FX006	Relief of symptomatic OA pain	Phase II, IIa, IIb	Dose Ranging Study completes 3Q12
FX007	Relief of symptomatic OA pain	Research	Preclinical testing in progress

SENIOR MANAGEMENT

Mike Clayman, Chief Executive Officer • **Neil Bodick**, Chief Medical Officer • **Lisa Davidson**, Vice President

BOARD OF DIRECTORS

Patrick Mahaffy, Clovis Oncology • **Sam Colella**, Versant • **Elaine Jones**, Pfizer • **Andy Schwab**, 5AM • **Brad Bolzon**, Versant • **Rafaele Tordjman**, Sofinnova

SCIENTIFIC ADVISORY BOARD

Virginia Kraus, Duke School of Medicine • **Tim Mcalindon**, Tufts School of Medicine • **Mark Genovese**, Stanford School of Medicine

FINANCING HISTORY

Round Date (Amount, US\$) 10/16/2009 (42.00 million)

Investors: Sofinnova Partners (0%) • Versant Ventures (0%) • Pfizer Ventures (0%) • 5AM Ventures (0%)

FluGen, Inc.

BIO Member, Presenting Company

Clinical Foci: Medical Device, Vaccines, Immunology

Paul V. Radspinner

President & CEO

545 Science Drive
Madison, WI 53711
USA

www.flugen.com

1-608-658-6095

Incorporated: 2007

Employees: 11

Ownership: Private

HIGHLIGHTS

Recent

Series A funding of USD \$7.8 million in February of 2011.
Manufacture and sterilization of devices for fill/finish validation, GLP toxicology studies and IRB saline human study.
REDEE FLU™ kinetics comparable to wild-type influenza without replication. In addition, heterosubtypic protection in mice.

Upcoming

Human IRB saline study with microneedle device to be completed in December 2011.
IND for microneedle device submitted by April 2012 with Phase I clinical trial to start thereafter.
REDEE FLU™ pivotal efficacy trials in animals initiated November 2011.

CORPORATE MISSION

FluGen is driving the combination of the engineering of intradermal delivery with the biology of vaccine development. Through the intradermal delivery of vaccines patients can receive substantially more efficacy as well as convenience. Targeted patient groups include those with compromised immune systems such as the elderly, cancer patients, the very young and the very sick.

PROPRIETARY TECHNOLOGY

FluGen's proprietary technologies include its intradermal delivery device which allows health care professionals to easily apply and deliver vaccines to diverse patient groups. In addition, the patchlike nature of the FluGen device would allow for patients to self administer vaccines and other payloads.

FluGen is also aggressively moving to the clinic with its REDEE FLU replication deficient influenza vaccine. This vaccine has shown in vivo results indicating a flu vaccine with all of the benefits of a live attenuated vaccine without the concerns of recombination, reversion and lack of efficacy in the elderly.

CORPORATE ALLIANCES

The company currently has alliances with the University of Wisconsin- Madison and the US Department of Defense, USAMRIID and TATRC.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Intradermal Delivery Device	Influenza	Preclinical	Phase I Clinical Trial
REDEE FLU™ Influenza Vaccine	Prevention of Influenza	Preclinical	Pivotal Animal Efficacy Studies
Multiple Vaccine Delivery Device	Intradermal Delivery of Multiple Vaccines at Once	Preclinical	Pivotal Animal Efficacy Studies

SENIOR MANAGEMENT

Paul V. Radspinner, President & CEO • **Dr. Pamuk Bilse**, Vice President • **Dr. Trent Gu**, Director • **Renee Herber**, Director

BOARD OF DIRECTORS

Paul V Radspinner, Founder, President & CEO • **Frederick Mancheski**, Investor • **David Walsh**, Investor • **Terence Kelly**, Investor • **Russel Smestad**, Independent • **Scott Klug**, Independent • **Deven McGlenn**, Founder Representative • **Bryan Renk**, Founder Representative

SCIENTIFIC ADVISORY BOARD

Dr. Yoshihiro Kawaoka, Founder • **Dr. Gabriele Neumann**, Founder • **Dr. Pamuk Bilse**, VP R&D

FINANCING HISTORY

Round Date (Amount, US\$) 12/27/2008 (2.20 million) • 02/26/2011 (7.80 million)

Investors: Knox Investment Group (24%) • P. Radspinner (13%) • Y. Kawaoka (13%) • G. Neumann (13%) • WARF (6%)

FreeMind Group, LLC

Eyal Schmidt
President & CEO

423 Brookline Avenue
Boston, MA 02215
USA

www.freemindconsultants.com

1-617-648-0340

Incorporated: 1999

Employees: 25

Ownership: Private

CORPORATE MISSION

FreeMind is the premier worldwide consultancy firm for Non Dilutive Funding and a proud member of the Bio Strategic Alliance Program. Over the past decade we have assisted hundreds of companies and academic institutions to secure grants and contracts, mainly from the NIH and DOD. FreeMind's systematic and methodological process, taking advantage of our experienced 25 full-time analysts and writers supports our clients' needs. On average we triple our clients' chances for success in comparison to the common statistics. We aim to turn non-dilutive funding to a strategic source of funding bringing millions of dollars to our clients annually. These awards average at over USD \$1.5 million per project and include large scale, multi-PI and multi-disciplinary mechanisms leading to over USD \$20 million awards per project.

SENIOR MANAGEMENT

Eyal Schmidt, President & CEO • **Ram May-Ron**, Vice President • **Ariel Shatz**, Vice President

Gamma Therapeutics, Inc.

Presenting Company

Clinical Foci: Cardiovascular Disease, Diagnostics, Medical Device

David H. Farrell, PhD <i>Chief Scientific Officer</i> 2611 SW Third Avenue Portland, OR 97201 USA	www.gamma-therapeutics.com 1-503-222-2313	Incorporated: 2009 Employees: 4 Ownership: Private
--	--	--

CORPORATE MISSION
 Gamma Therapeutics is an Oregon-based early-stage venture developing novel CVD risk diagnostic assays, surgical therapy and combat casualty care solutions based upon the application of human compatible proteins responsible for the clotting mechanism in human blood.

PROPRIETARY TECHNOLOGY
 Gamma Therapeutics holds the IP to the monoclonal antibody, Gamma Prime Fibrinogen a naturally occurring protein in human blood and the technology platform for its CVD risk and inflammation biomarkers and surgical incision and wound closure products.

CORPORATE ALLIANCES
 Gamma Therapeutics currently has strategic partnerships with Healthcare Diagnostic Laboratories, Pharming Technologies NV and the Armed Forces Institute of Pathology. It is in partnership discussions with Alere Medical, Luminex, Baxter BioSurgery, Diagnostica Stago, Zeus Scientific, Merck Pharmaceuticals, Novartis and a host of other small biopharmaceutical and biotechnology companies in the cardiovascular disease diagnostic assay, surgical therapy and combat casualty care market segments.

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
GammaCoeur CVD Risk Assay	a novel analyte for heart attack and stroke risk to capture at-risk patients mized by traditional cardiac biomarkers, i.e., cholesterol	Diagnostics	Presenting GammaCoeur to FDA OIVD on Sept. 27 and beginning (3) BETA tests with Coronary Heart Stud (Framingham Cohort)
GammaSeal Surgical Incision and Wound Closure Sealant	a natural non-immunogenic, pathogen-free, degradation resistant recombinantly derived sealant for surgery and trauma	Preclinical	signed partnership with Pharming to develop the recombinant gamma prime fibrinogen sealant, signed NDA with Baxter Healthcare
Gammarin Anticogulant Blood Thinner	a natural blood thinner for use during and after surgery to prevent venous thromboembolisms and avoid problems seen with heparin-induced thrombocytopenia	Research	Signed CDA and in discussions with Merck
GammaTF Warfighter Hemostatic Dressing	addresses military medicine need for a fast-clotting dressing that clots hemorrhaging wound in under 120 seconds.	Research	developed working prototypes and presented to US Army. Navy and Air Force medical research groups for assessment, submitted DARPA, BAA and AF grants
GammaMist Clotting Activator	restores natural clotting factors during coagulopathy	Research	developed first prototype to present to military in Fall, 2011

SENIOR MANAGEMENT
 David H. Farrell, PhD, Chief Scientific Officer • Steve Kazmierczak, PhD (Director, OHSU Division of Pathology), Consultant • David Forman (Tonkon Torp Law Firm), Attorney • Sheila Ramerman, PhD, FDA Regulatory, Consultant • Candace Clement (Comptroller), Corporate Finance • David F. Eastman, Chief Executive Officer

SCIENTIFIC ADVISORY BOARD
 Sanjiv Kaul, MD, Head, OHSU Division of Cardiovascular Medicine • Martin Schreiber, MD, Chief, OHSU Trauma Surgery, Adult and Acute Care • Steve Kazmierczak, PhD, Head, OHSU Department of Pathology • Jose Lopez, MD, Head, Research, Puget Sound Blood Center • Kent Thornburg, PhD, Director, OHSU Heart Institute • Michelle Guinness, PhD, OHSU Technology Transfer and Business Development

FINANCING HISTORY
Investors: David H. Farrell, PhD, Founder and CSO (67%) • Oregon Health Sciences University (OHSU) (15%) • David F. Eastman, CEO (5%) • Employee Pool (13%)

Genocea Biosciences, Inc.

Presenting Company

Clinical Foci: Vaccines, Infectious Disease, Oncology

Chip Clark

Chief Executive Officer

161 First St 2C
Cambridge, MA 02142
USA

www.genocea.com

1-781-876-8191

Incorporated: 2006

Employees: 40

Ownership: Private

HIGHLIGHTS

Recent

HSV-2 Tx: successful pre-IND meeting to set tox package and 1st clinical trial protocol; start of pre-IND tox studies; animal PoC demonstrating that unique mechanism of action provides significant benefits against spectrum of infection symptoms

Pneumococcus vaccine: publication of data from PATH/Children's Hospital of Boston in Cell; animal PoC with unique mechanism, showing that three proteins can prevent infection caused by spectrum of known Pneumococcus strains

Corporate:

Hired new CEO, CMO, and VP of BD - all with significant and relevant experience

Completed USD \$35 million Series B, co-led by JJDC and Skyline, with significant insider participation as well.

Upcoming

HSV-2 vaccine: 2012 start and completion of first human trial, investigating safety, immunology, and efficacy.

Pneumococcus: initiation of IND-enabling studies in 1Q12.

Chlamydia: initiation of IND-enabling studies in 3Q12.

CORPORATE MISSION

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), pneumococcus, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The most advanced program, a therapeutic vaccine for HSV-2, will enter the clinic in 2012.

The company, founded in 2006, has raised more than USD \$60 million to date in two venture rounds, from investors including Polaris, Johnson & Johnson Development Corp, SR One, Skyline, and Lux.

PROPRIETARY TECHNOLOGY

Each of Genocea's five vaccine programs (HSV2 Tx and Px, Pneumococcus, Chlamydia and Malaria) is wholly owned. They are the product of a technology invented by Darren Higgins, PhD, of Harvard Medical School. This proprietary technology, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations.

CORPORATE ALLIANCES

Pneumococcus: We collaborate with PATH and Children's Hospital of Boston.

Malaria: We collaborate with the Naval Medical Research Center.

Chlamydia: We collaborate with the University of Pittsburgh.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
HSV-2 vaccine	Herpes simplex-2 (therapeutic)	Preclinical	IND filing expected in 1Q12.
Pneumococcus vaccine	Pneumococcus	Preclinical	IND-enabling studies to start in 1Q12.
Chlamydia vaccine	Chlamydia	Preclinical	IND-enabling studies to start in 3Q12.
Malaria vaccine	Malaria	Research	

SENIOR MANAGEMENT

Chip Clark, Chief Executive Officer • **Seth Hetherington, MD**, Chief Medical Officer • **Bob Farrell (finance)**, Vice President • **Jessica Flechtner, PhD (research)**, Vice President • **Paul Giannasca, PhD (manufacturing)**, Vice President • **Ravi Venkatramani, PhD (BD)**, Vice President

BOARD OF DIRECTORS

George Siber, MD • **Kevin Bitterman, PhD**, Polaris Venture Partners • **Dalton Einhorn, JJDC** • **Simeon George, MD**, SR One • **Steve Hoffman, MD, PhD**, Skyline • **Rob Paull**, Lux • **Chip Clark**, CEO, Genocea Biosciences, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 01/01/2009 (23.00 million) • 01/01/2011 (35.00 million)

Genprex, Inc.

Presenting Company

Clinical Foci: Oncology, Genetic Disorders, Drug Delivery

David G. Nance

Chairman

6034 West Courtyard Drive
Austin, TX 78730
USA

www.genprex.com

1-512-597-5945

Incorporated: 2010

Employees: 12

Ownership: Private

HIGHLIGHTS

Recent

Positive data reported from phase I dose escalation trial evaluating intravenous Oncoprex™ (TUSC2/FUS1) monotherapy in stage IV, metastatic lung cancer patients. Drug well tolerated, dose established, responses in lung, liver, pancreas tumors.

Compelling in vivo study data with Oncoprex combined with multiple TKIs. Synergistic activity with EGFR TKIs in both EGFR mutation negative (EGFR wild type) cancers and EGFR mutation positive cancers as well as Kras-related cancers.

Ph II trial designed for Oncoprex + erlotinib in stage IV NSCLC without EGFR mutation. Represents 85% of America/Europe population & 70% Asian population.

Upcoming

Initiation of Ph II Oncoprex + erlotinib trial in 2012.

One or more corporate alliances for Oncoprex development.

Journal publication of Ph I Oncoprex monotherapy trial and interim data from Ph II trial.

CORPORATE MISSION

We are a clinical-stage biopharmaceutical company developing oncology products designed to unlock the unrealized potential of targeted therapies and currently available cancer drugs. We are initiating a phase II clinical trial of our lead product candidate Oncoprex™ used in combination with Tarceva® (erlotinib) in stage IV lung EGFR wildtype cancer patients who are not candidates for erlotinib monotherapy due to their EGFR status.

Oncoprex (CNVN202) harnesses the TUSC2 tumor suppressor to overcome genomic limitations and reduce drug resistance. Our tumor suppression technologies work to induce apoptosis in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level, without harming normal cells. TUSC2 (FUS1), the subject of more than 20 peer-reviewed journal publications, is associated with most major cancers including >85% of lung cancers. In early 2011 we completed and reported positive results from a phase I, dose escalation clinical study evaluating Oncoprex monotherapy in stage IV metastatic patients. The trial showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to human cancer cells using a nanoparticle vector, express high levels of mRNA and protein in cancer cells in the primary tumor and distant metastatic sites, alter relevant pathways in the cancer cell and mediate clinically beneficial anti-cancer activity. The study provided a therapeutic dosage and demonstrated that Oncoprex therapy was well tolerated.

We believe our product candidates can address unmet medical needs of cancer patients by making existing agents more effective and relevant to more patients. Our discoveries, research, technologies and product candidates have been supported by more than USD \$40 million from investigator grant awards and corporate funding.

PROPRIETARY TECHNOLOGY

Oncoprex™ has shown synergistic cancer killing activity when combined with a variety of Tyrosine Kinase Inhibitors (TKIs) including EGFR, VEGFR and PDGF targeted TKIs. Oncoprex™ works synergistically with EGFR TKIs (erlotinib and gefitinib) in both EGFR mutation negative (EGFR wild type) cancers and resistant EGFR mutation positive cancers, as well as Kras-related cancers. Oncoprex employs the TUSC2 (FUS1) tumor suppressor delivered via intravenous lipid nanoparticles to selectively kill cancer cells. By inducing apoptosis and controlling cell signaling and inflammatory pathways, Oncoprex can be combined with targeted therapies to overcome genomic limitations of receptor targets and can re-sensitize cancer to mutation targeted therapies to surmount intrinsic or acquired drug resistance.

CORPORATE ALLIANCES

We hold license, sponsored research and collaboration alliances with The University of Texas MD Anderson Cancer Center.

We seek commercial development collaborations and marketing partnerships.

PRODUCTS

Name	Indication	Phase	Milestone
Oncoprex	NSCLC and other solid tumors	Phase II, IIa, IIb	Ph. I complete; Initiating Ph II in combination with EGFR TKIs
GPRX203	NSCLC and other solid tumors	Preclinical	Developing protocols for combination use with platinum drugs and DNA damaging agents

SENIOR MANAGEMENT

David G. Nance, Chairman • Greg J. Heinlein, Chief Operating Officer

BOARD OF DIRECTORS

David Nance, Technology Capital Corporation

SCIENTIFIC ADVISORY BOARD

Jack Roth, MD, FACS, MD Anderson Cancer Center, Houston TX • **Dr. Nagahiro Saijo**, Deputy Director, National Cancer Center Hospital East, Chiba Japan • **Dr. Tony Mok**, Department of Clinical Oncology, Prince of Whales Hospital, Hong Kong, China

FINANCING HISTORY

Round Date (Amount, US\$) 05/01/2009 (0.20 million) • • 07/01/2011 (4.50 million)

Investors: Four Founding Investors (100%)

GenVec, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Biopharmaceuticals, Vaccines, Veterinary

Paul H. Fischer, PhD President & CEO

65 West Watkins Mill Road
Gaithersburg, MD 20878
USA

www.genvec.com

1-240-632-0740

NASDAQ: GNVC

Incorporated: 1992

Employees: 83

Ownership: Public

HIGHLIGHTS

Recent

Hearing loss program:

- (1) Novartis - global development and commercialization partnership;
- (2) Novartis - clinical supply manufacture partnership;
- (3) New research published.

New appointees to the GNVC Board of Directors:

Edward M. Connor, Jr., MD, former Chief Medical Officer and Exec. Vice President of MedImmune; and Adel A.F. Mahmoud, MD, PhD, former President of Merck Vaccines.

Animal health program:

- (1) Merial (animal health division of sanofi-aventis) - commercialization partnership, foot and mouth disease (FMD) vaccine;
- (2) Merial - agreement to explore indications in addition to FMD, beginning with swine disease.

Upcoming

Advance the hearing loss program to clinical testing under the Novartis partnership.

RSV Vaccine Program: Form corporate partnership for development and commercialization of the product.

HSV Vaccine Program: Generate proof of concept data.

Advance the Foot and Mouth Disease vaccine to Field Safety Testing under our collaboration with the US Dept of Homeland Security.

CORPORATE MISSION

GenVec's lead therapeutic product program is for the common, and poorly addressed, problem of hearing loss. This fully-funded program, based on our proprietary technology, is the subject of a global development and commercialization agreement with Novartis. Our vaccine programs, also based on our core technology, are for major medical needs including Respiratory Syncytial Virus and Herpes Simplex Virus. Our vaccine program for dengue fever is supported through a collaboration with the Naval Medical Research Center and malaria is the subject of a relationship with the US Military Malaria Vaccine Program. In animal health, we work with the Department of Homeland Security to develop vaccines for foot and mouth disease (FMD). We have partnered with Merial, the animal health division of sanofi-aventis, to commercialize FMD vaccines globally. Swine diseases are being targeted under a second agreement with Merial.

PROPRIETARY TECHNOLOGY

GenVec's technology delivers genes to cells of the body in order to produce desired proteins. Our core technology facilitates the rapid discovery and testing of new therapeutic and vaccine candidates designed to solve critical problems. Extensive production experience and clinical testing has demonstrated the clear manufacturing, stability and safety advantages conveyed by our technology.

CORPORATE ALLIANCES

Novartis - global development and commercialization of hearing loss biotherapeutic, including a second agreement with Novartis for clinical supply manufacture;

Naval Medical Research Center - dengue fever vaccine development;

US Military Malaria Vaccine Program - malaria vaccine development;

US Department of Homeland Security - foot and mouth disease vaccine development;

Merial (animal health division of sanofi-aventis) - foot and mouth disease vaccine commercialization;

Merial - swine disease vaccine research and development.

PRODUCTS


Name	Indication	Phase	Milestone
Hearing loss therapeutic	Hearing loss	Preclinical	Clinical testing under our collaboration with Novartis.
Respiratory Syncytial Virus (RSV) vaccine	RSV	Preclinical	Corporate partnership to develop and commercialize the vaccine.
Herpes Simplex Virus-2 (HSV-2) vaccine	genital herpes	Preclinical	Proof concept preclinical data.
Dengue fever vaccine	dengue fever	Preclinical	Generate immunological data in animal models in collaboration with the Naval Medical Research Center.
Malaria vaccine	malaria	Phase I	Vaccine optimization working with the US Military Malaria Vaccine Program.

PRODUCTS			
Name	Indication	Phase	Milestone
Foot and Mouth Disease vaccine	foot and mouth disease in herd animals	Other	Field Safety Testing under our collaboration with the US Department of Homeland Security.
Swine disease vaccine or vaccines	swine diseases	Pre-Target Validation	Exploratory data generated with Meril.

SENIOR MANAGEMENT
Paul H. Fischer, PhD, President & CEO • **Douglas J. Swirsky, CPA, CFA**, Chief Financial Officer • **Bryan T. Butman, PhD (Vector Operations)**, Senior Vice President • **Douglas E. Brough, PhD (Research)**, Vice President • **Michael Tucker (Business Development)**, Vice President

BOARD OF DIRECTORS
Zola P. Horovitz, PhD, Bristol-Myers Squibb, retired • **Edward M. Connor, Jr., MD**, Children's National Medical Center & George Washington University • **Paul H. Fischer, PhD**, GenVec • **Wayne T. Hockmeyer, PhD**, MedImmune, Inc., retired • **William N. Kelley, MD**, University of Pennsylvania • **Adel A.F. Mahmoud, MD, PhD**, Princeton University • **Kevin Rooney**, Beacon Consulting • **Marc R. Schneebaum**, Predictive Biosciences

TRADING STATUS AS OF OCTOBER 5, 2011 **NASDAQ: GNVC**



Market Data	First Call Data
Current Price 2.88	Market Cap (MM) 37.2
Currency US Dollar	Short Interest Shares 145,569
Net Change 0.70	Short Interest Ratio 3.08
Volume 35,397	PE (Trailing 12 Months) -0.71
YTD % Change -0.49	EPS (Last Fiscal Year) -0.57
52Wk Range 2.00–6.57	Consensus Estimate (Y) -0.71
Avg. Daily Volume (thousands) 115,263	Consensus Recommend --
	Price/Sales 1.83

Shareholders

Institution	Holding %
The Vanguard Group, Inc.	2.6%
BlackRock Fund Advisors 2.6%	
BAM Capital LLC 1.0%	
Dimensional Fund Advisors, Inc. 0.4%	
The California Public Employees Retirement System 0.3%	

Mutual Fund	Holding %
The Vanguard Group, Inc.	2.6%
BlackRock Fund Advisors 2.6%	
BAM Capital LLC 1.0%	
Dimensional Fund Advisors, Inc. 0.4%	
The California Public Employees Retirement System 0.3%	

Source: Thomson Reuters

Globelimmune, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Infectious Disease, Oncology, Vaccines

Timothy C. Rodell, MD
Chief Executive Officer

1450 Infinite Drive
Louisville, CO 80027
USA

www.globeimmune.com

1-303-625-2700

Incorporated: 1996

Employees: 35

Ownership: Private

HIGHLIGHTS

Recent

Positive SVR data from the GI-5005 phase 2b trial in treatment-naïve HCV patients. The greatest improvement in SVR occurred in IL28B T/T patients, those genetically predisposed to be hardest to treat (60% SVR / GI-5005+SOC vs. 0% SVR / SOC alone).

The GI-5005 phase 2b study is being expanded by 20 patients having the IL28B T/T genotype to better quantify the treatment effect seen in this high-need patient population.

In the GI-5005 phase 2b trial, in patients that had previously failed treatment with SOC including null responders, poor responders, and partial responders, GI-5005+SOC demonstrated a three-fold improvement in SVR over SOC alone (17% vs 5%).

Upcoming

Top line efficacy results from GI-4000-02, a randomized, active control, adjuvant trial in resected pancreas cancer year end 2011.

End of treatment virologic efficacy data from the 20-patient expansion of GI-5005 in chronically infected HCV patients with the IL28B T/T genotype in 1Q12.

Initiation of a phase 2 study of GI-6207 in patients with medullary thyroid cancer year end 2011.

CORPORATE MISSION

Globelimmune, Inc. is a private biopharmaceutical company developing therapeutic vaccines called Tarmogens® for the treatment of cancer and infectious diseases. The company's lead infectious disease product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). The company's lead oncology programs, GI-4000 and GI-6207, target cancers caused by mutated versions of the Ras oncoprotein and CEA expressing

tumors, respectively. GI-4000 is being investigated in clinical trials for the treatment of cancers expressing mutated Ras, including non-small cell lung cancer, pancreatic cancer and colorectal cancer. GI-6207 is being evaluated in clinical trials in patients with CEA expressing tumors. In clinical trials, Tarmogens have been well-tolerated, generated antigen-specific T cell immune responses and improved clinical outcomes in patients. Tarmogens are produced using fermentation processes which can be simply and economically scaled up to commercial levels.

PROPRIETARY TECHNOLOGY

All of the Company's Tarmogen® products are developed from its proprietary platform technology. Tarmogens, a contraction of targeted molecular immunogens, are whole, heat-killed recombinant *Saccharomyces cerevisiae* yeast that have been engineered to produce one or more target disease proteins, or antigens, inside the yeast. These target antigens distinguish diseased cells from normal cells, and can include viral proteins, mutated proteins unique to cancer cells and proteins that are over-expressed in cancer cells. Tarmogens activate T cells capable of locating and destroying the target cancer or virally-infected cells containing the same target antigen.

CORPORATE ALLIANCES

- 1) National Cancer Institute (NCI) / July 2008 – Globelimmune and NCI are jointly developing multiple Tarmogen® products under a Cooperative Research and Development Agreement (CRADA) intended to treat a variety of cancers.
- 2) Celgene Corporation (NASDAQ: CELG) / May 2009 – Global alliance with the Celgene Corporation in oncology that includes USD \$40 million upfront, >\$500 million in milestone payments, plus royalties.

PRODUCTS

Name	Indication	Phase	Milestone
GI-5005	Chronic HCV infection	Phase II, IIa, IIb	End of treatment virologic efficacy data from the 20 patient IL28B T/T expansion 1Q12.
GI-4000	Tumors expressing mutated Ras (pancreas, CRC, NSCLC)	Phase II, IIa, IIb	Preliminary survival data year end 2011.
GI-6207	Tumors expressing carcinoembryonic antigen (CEA)	Phase II, IIa, IIb	Initiation of phase 2 trial in medullary thyroid cancer
GI-6301	Brachyury expressing cancers	Preclinical	IND 2011
GI-13000	Chronic hepatitis B (HBV) infection	Preclinical	IND 2012

SENIOR MANAGEMENT

Timothy C. Rodell, MD, Chief Executive Officer • **David Apelian, MD, PhD, MBA**, Chief Medical Officer • **John Frenz, PhD**, Vice President • **Jeffrey Dekker**, Vice President

BOARD OF DIRECTORS

Timothy C. Rodell, MD, Chief Executive Officer, GlobalImmune, Inc. • **Ralph Christoffersen, PhD**, Morgenthaler • **Ehud Geller, PhD**, Medica Venture Partners • **Augustine Lawlor**, Healthcare Ventures • **Paul Mieyal, PhD, CFA**, Wexford Capital • **Dan Mitchell**, Sequel Venture Partners • **Edward Torres**, Lilly Ventures • **William Freytag, PhD**, Independent Director

FINANCING HISTORY

Round Date (Amount, US\$) 06/01/2003 (8.00 million) • 09/01/2005 (38.30 million) • 07/01/2007 (41.20 million)

Investors: Celgene, Inc. (0%) • Morgenthaler Ventures (0%) • HealthCare Ventures (0%) • Wexford Capital (0%) • Sequel Venture Partners (0%)

Glycoregimmune, Inc.

Presenting Company

Clinical Foci: Gastroenterology, Autoimmune, Immunology

Marc Hertz

President & CEO

3550 General Atomics Court, TPIMS 2-203
San Diego, CA 92121
USA

www.glycoregimmune.com

1-858-597-3859

Incorporated: 2009

Ownership: Private

HIGHLIGHTS

Recent

Identified pathway important in NKT I cell activation, previously unknown to be active in NKT cells, in collaboration with the Torrey Pines Institute for Molecular Studies; and licensed the world-wide rights to the subsequent intellectual property.

6/29/2011 - Entered into collaborative partnership with RxMD to expedite drug development in a highly efficient and cost effective risk-sharing model.

7/25/2011 - USPTO Notice of Allowance for US Patent Application No. 11/529,793.

Upcoming

Complete GRI-001 Phase 2b study in alcoholic liver disease patients by 4Q12, and initiate pivotal studies in 1H13.

File GRI-003 Sulfatide IND in 3Q2012 and initiate Phase 1b studies in 2Q13.

CORPORATE MISSION

Glycoregimmune, Inc. ("GRI") is a privately held startup biotech firm seeking to raise Series A financing to develop Natural Killer T ("NKT") cell targeted therapeutics for alcoholic liver disease ("ALD") and autoimmune disorders. GRI's lead program is a Type I NKT ("NKT I") cell inhibitor that is FDA-approved for an unrelated indication. A single generic oral formulation is marketed for an unrelated oncology indication and is priced around USD \$30/cap. GRI's medical use patents, and the significant cost of the available generic, would preclude generic bleed into the ALD indication. In addition, GRI is developing highly potent selective agonists active in the same pathway as follow-on and/or backup programs to the lead NKT I cell inhibitor program. The NKT I cell inhibitors address the USD \$30 billion ALD market, for which today there is no FDA approved drug, and GRI expects to file a 505b2 submission with the FDA by the second half of 2013. GRI is also developing Type II NKT ("NKT II") cell modulators as novel therapeutics for treating autoimmune disorders. GRI's lead NKT II cell modulator program is a glycolipid, cis-tetracosenoyl ("sulfatide"), that is a natural ligand for activating NKT II cells. GRI is also developing small molecule mimetics of sulfatide as follow-on and/or backup programs to the lead NKT II cell modulator program. The NKT II cell modulators address the USD \$25 billion autoimmune market, and will complete Phase 2 proof of concept clinical trials by the end of 2014. GRI is seeking to raise USD \$25 million to fund operations through 2012; to initiate pivotal trials of an NKT I cell inhibitor and file an IND for our NKT II cell modulator.

PROPRIETARY TECHNOLOGY

GRI develops novel Natural Killer T (NKT) cell targeted therapies, and has programs focused on Type I NKT (NKT I) cell inhibitors and Type II NKT (NKT II) cell modulators. NKT cells share properties of both NK and T cells, are a functional link between the innate and adaptive immune responses, regulate the expression of key cytokines and are critical in modulating the immune response. GRI's NKT I cell inhibitors act through a novel, currently undisclosed, pathway GRI recently discovered to be active in NKT cells. The pathway is independent of the NKT cell TCR. GRI's NKT II cell modulators activate NKT II cells in a CD1d-dependent manner. Cis-tetracosenoyl ("sulfatide"), a natural glycolipid ligand for NKT II cells, binds to CD1d and activates NKT II cells via their TCR.

CORPORATE ALLIANCES

GRI has a current alliance with RxMD to develop NKT targeted therapeutics. Under the alliance, RxMD will use its global drug development expertise, including its team of physician-scientists in Chennai, India, to advance GRI's portfolio of drug candidates. The collaboration represents a new model for risk-sharing, success-based drug development, and allows GRI to preserve resources for ongoing drug discovery while advancing our development candidates much more rapidly and efficiently than we could on our own.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
GRI-001	Alcoholic Liver Disease	Other	Expect to initiate pivotal trials 1Q13.
GRI-002 Sulfatide	Autoimmunity	Preclinical	Expect file IND 3Q12.
GRI-003	Alcoholic Liver Disease	Other	Back-up molecule to GRI-001, in-licensed 1Q12.
GRI-004	Autoimmunity	Optimized Lead	Back-up to GRI-002; expect to file IND 3Q13.

SENIOR MANAGEMENT

Marc Hertz, President & CEO • **Albert Agro**, Chief Medical Officer • **Vipin Kumar**, Chief Scientific Officer

BOARD OF DIRECTORS

Marc Hertz, President & CEO, Glycoregimmune, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 06/01/2011 (0.30 million)

HemaQuest Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Hematology

John P. Longenecker, PhD
Chief Executive Officer

11995 El Camino Real
San Diego, CA 92130
USA

www.hemaquest.com

1-858-356-5590

Incorporated: 2007

Ownership: Private

HIGHLIGHTS

Recent

HemaQuest is conducting a multicenter Phase 2 clinical trial to evaluate HQK-1001 taken orally at higher doses (30, 40, and 50 mg/kg daily) and for longer duration (up to six months) than previously evaluated. Data will be available in late 2011.

HemaQuest will support two investigator-sponsored Phase 2 clinical trials to evaluate HQK-1001 taken orally at 20 mg/kg daily for 6 months in patients with moderately severe beta thalassemia. Data is expected to be available in 1Q12.

Upcoming

Interim data is expected from the multicenter Phase 2 clinical trial to evaluate HQK-1001 in patients with sickle cell disease in late 2011 with final data expected during 1Q12.

CORPORATE MISSION

HemaQuest Pharmaceuticals, Inc., founded in 2007, is a San Diego and Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary Short Chain Fatty Acid Derivatives (SCFADs) technologies to treat hemoglobin diseases. HemaQuest is also developing a proprietary multi-drug therapeutic approach for treating viral-associated malignancies, with a primary focus on Epstein-Barr virus associated lymphomas. The Company's lead drug candidate, HQK-1001, belongs to the class of compounds, SCFADs, originally discovered at Boston University School of Medicine. These compounds have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia. Increased fetal hemoglobin production in red blood cells was shown to ameliorate the outcome of patients with these diseases. HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. Additionally, the compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia. Early preclinical studies have also shown the molecule may have activity in models of cystic fibrosis. HemaQuest initiated a Phase 2 multi-dosing clinical trial testing HQK-1001 in patients with sickle cell disease in April 2011 and expects to have data available in late 2011.

PROPRIETARY TECHNOLOGY

HQK-1001 is an orally administered short chain fatty acid (SCFA) derivative, which has a unique combination of biological effects - induction of fetal globin and stimulation of red blood cell production - that addresses the underlying pathological mechanisms in sickle cell disease and beta thalassemia. Extensive studies in both the laboratory and relevant animal models carried out in transgenic mice and non-human primates have demonstrated the potential therapeutic effects of this compound in treating these serious, chronic illnesses. HemaQuest has obtained an exclusive worldwide license for a series of patents and patent applications from Boston University for these technologies that give it a strong proprietary position.

PRODUCTS

Name	Indication	Phase	Milestone
HQ-1001	Sickle Cell Disease and Beta Thalassemia	Phase II, IIa, IIb	Phase II data available late 2011

SENIOR MANAGEMENT

John P. Longenecker, PhD, Chief Executive Officer • **Tamara A. Seymour, MBA**, Chief Financial Officer • **Richard G. Ghalie, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Fred Dotzler, De Novo Ventures • **Armen Shanafelt**, Lilly Ventures • **Ivor Royston MD**, Forward Ventures • **James Woody MD**, Latterell Venture Partners • **Naheed Misfeldt**, Aberdare Ventures • **Wayne Roe** • **George Stamatoyannopoulos MD**, Founder • **Paul Goddard** • **John P. Longenecker, PhD**, CEO, HemaQuest Pharmaceuticals, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 12/18/2008 (20.60 million) • 07/21/2010 (16.00 million)

Investors: Lilly Ventures (18%) • De Novo Ventures (18%) • Forward Ventures (18%) • Aberdare Ventures (11%) • Latterell Venture Partners (11%)

Heptares Therapeutics Limited

Presenting Company

Clinical Foci: CNS, Metabolic Disease, Oncology

Malcolm Weir, PhD Chief Executive Officer BioPark, Broadwater Road Welwyn Garden City AL7 3AX United Kingdom	www.heptares.com 44-170-7358629	Incorporated: 2007 Employees: 60 Ownership: Private
---	--	---

HIGHLIGHTS <i>Recent</i> <ul style="list-style-type: none"> • Four-year collaboration with AstraZeneca (2011) focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders • Exclusive option agreement with Shire (2011) for novel small molecule adenosine A2A antagonist with best-in-class potential for the treatment of CNS diseases. To our knowledge, this is the first-ever GPCR candidate to arise solely from SBDD. • Approximately USD \$100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.

CORPORATE MISSION Heptares Therapeutics Limited is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a best-in-class and first-in-class pipeline focused on CNS and metabolic disease. GPCRs represent the single most important family of drug targets in the human body, yet, due to their inherent instability when removed from cell membranes, little or no structural information about these valuable targets has been available to drive structure-based drug discovery (SBDD) programmes.

PROPRIETARY TECHNOLOGY Heptares' StaR® (Stabilised Receptor) technology enables the first-ever thermo-stabilisation of GPCRs. This breakthrough allows Heptares scientists to resolve GPCR structures and deploy structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets.
--

CORPORATE ALLIANCES AZ, Novartis, Takeda, Shire

PRODUCTS												
<table border="1"> <thead> <tr> <th><i>Name</i></th> <th><i>Indication</i></th> <th><i>Phase</i></th> </tr> </thead> <tbody> <tr> <td>Adenosine A2a antagonist</td> <td>Neurology/Parkinson's</td> <td>Preclinical</td> </tr> <tr> <td>Muscarinic M1 agonist</td> <td>Cognition</td> <td>Preclinical</td> </tr> <tr> <td>Orexin (DORA)</td> <td>Insomnia</td> <td>Preclinical</td> </tr> </tbody> </table>	<i>Name</i>	<i>Indication</i>	<i>Phase</i>	Adenosine A2a antagonist	Neurology/Parkinson's	Preclinical	Muscarinic M1 agonist	Cognition	Preclinical	Orexin (DORA)	Insomnia	Preclinical
<i>Name</i>	<i>Indication</i>	<i>Phase</i>										
Adenosine A2a antagonist	Neurology/Parkinson's	Preclinical										
Muscarinic M1 agonist	Cognition	Preclinical										
Orexin (DORA)	Insomnia	Preclinical										

SENIOR MANAGEMENT Malcolm Weir, PhD, Chief Executive Officer • Fiona Marshall, PhD, Chief Scientific Officer • Barry Kenny, PhD, Chief Business Officer

BOARD OF DIRECTORS John Berriman, Independent • Michael Steinmetz, Clarus • Anja Koenig, NOF • Martin Murphy, MVM • Richard Henderson, MRC
--

SCIENTIFIC ADVISORY BOARD Richard Henderson, MRC LMB • David Brown • Chris Tate, MRC LMB • Patrick Humphrey • Mike Tarbit • Paul Leeson • Greg Winter, MRC LMB • Gebhard Schertler, Paul Scherrer Institute

FINANCING HISTORY Investors: MVM Life Science (0%) • Clarus Ventures (0%) • Novartis Bioventures (0%) • Takeda Research Investments (0%)
--

Ikaria, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Pulmonary, Cardiovascular Disease, Other

Daniel Tassé

Chief Executive Officer

Perryville III Corporate Park
53 Frontage Road
Hampton, NJ 08827
USA

www.ikaria.com

1-908-238-6600

Incorporated: 2007

Employees: 440

Ownership: Private

CORPORATE MISSION

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria alone, or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.com.

PROPRIETARY TECHNOLOGY

As the first and only endogeneous signalling molecule in gas form approved for use as a drug in humans, INOMAX® (nitric oxide) for inhalation is used to treat newborns suffering from hypoxic respiratory failure (HRF). INOMAX drug therapy is delivered through Ikaria's proprietary drug-delivery systems, the INOMAX DS and INOMAX DSIR. Next-generation drug-delivery systems are on the horizon.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
INOMAX (nitric oxide) for inhalation	Hypoxic Respiratory Failure in term and near-term infants >36 weeks gestational age	Cleared for US Marketing
INOMAX (nitric oxide) for inhalation	Bronchopulmonary Dysplasia (BPD) in pre-term infants	Phase III
INOMAX (nitric oxide) for inhalation	Pulmonary Arterial Hypertension	Phase II, IIa, IIb
INOMAX (nitric oxide) for inhalation	Chronic Obstructive Pulmonary Disease (Phase IIb/III)	Phase II, IIa, IIb
LUCASSIN (terlipressin)	Hepatorenal Syndrome Type 1	Phase III
IK-5001	Prevention of Ventricular Remodeling and Congestive Heart Failure Post-AMI	Phase II, IIa, IIb

SENIOR MANAGEMENT

Daniel Tassé, Chief Executive Officer • **Douglas Greene, MD**, Executive Vice President • **Matthew M. Bennett**, Senior Vice President • **James Briggs**, Senior Vice President • **Lien-Lung (L.L.) Sheu, PhD**, Senior Vice President • **Stephen Ross**, Senior Vice President

BOARD OF DIRECTORS

Daniel Tassé, Chairman & CEO, Ikaria, Inc.

Immune Targeting Systems

Presenting Company

Clinical Foci: Infectious Disease, Oncology, Immunology

Carlton Brown

Chief Executive Officer

2 Royal College Street
London
NW1 0NH
United Kingdom

www.its-innovation.com

44-20-76914908

Incorporated: 2003

Ownership: Private

HIGHLIGHTS

Recent

Successful completion of Phase-I for the lead program culminating in decision to progress to Phase-Ib / 2a studies in 2012.

Initiation of 2nd candidate - a unique universal HBV immunotherapy targeting all major globally relevant viral genotypes relevant to the 7MM and China

Development of oncology vaccine platform - one vaccine for multiple cancer indications whilst eliminating the need for HLA subtyping.

Upcoming

Series-B funding targeting USD \$28 million.

CORPORATE MISSION

Immune Targeting Systems is a London-based biotech company developing vaccines for mutating viruses and cancer underpinned by its DepoVaccine™ & Densigen™ technology platforms. ITS' lead program, a synthetic universal influenza vaccine (Flunisyn™) targeting all potential seasonal and pandemic flu strains, has completed phase-I clinical testing. Phase-1b / 2a clinical studies will initiate in 2012.

ITS seeks to raise a USD \$28 million Series-B funding to expedite its universal Hepatitis-B therapeutic vaccine (targets major genotypes relevant to 7MM & China) through phase-I, lead optimise an oncology indication (potential to expedite IND) and provide a commercialisation run-way whilst a commercialisation partner is sought. ITS lead investors the Novartis Venture Fund, HealthCap and Truffle Capital will support this round.

Flunisyn will be used as an add on to the seasonal flu vaccine in the elderly to ensure a full complement of immunological correlates of protection are provided at immunisation. Today's seasonal flu vaccine is <30% effective and only generates antibodies, limiting its clinical benefit.

Phase-I data highlights an excellent safety profile and it's best-in-class potential when assessing key immunological performance parameters; vaccine responder frequency (eliminating need for HLA selection), breadth & magnitude of response, booster amplification (no requirement for a heterologous prime-boost strategy). The induced immune responses are able to target multiple variants of H1N1, H2N2, H3N2, H5N1, H7N7 & H9N2 strains including all pandemic / zoonotic flu strains. The Densigen platform fully predicts the human immune response.

Oncology: Overexpressed tumour associated antigens shared by 10 high unmet need cancers were mined for Densigens. Such Densigens frequently contain clinically validated peptides including those associated with survival benefits. Cancer vaccines will offer broad cancer indication utility whilst eliminating HLA sub-typing.

PROPRIETARY TECHNOLOGY

DepoVaccines deliver Densigens™ to the immune system by promoting a short-term vaccine injection site depot resulting in potent T-cell immunity. DepoVaccine™ delivered Densigens™ contain multiple different rationally selected long peptide antigen sequences (35aa) which are conjugated to a fluorocarbon molecule yielding a thermostable freeze dried nanoparticle formulation. Densigens are highly conserved (all strains/genotypes) immunoprevalent antigens. By combining 6-8 different Densigens we ensure a T-cell response capable of providing broad population coverage without restrictive HLA sub-type selection, a multi-peptide breadth of response exceeding best-in-class and a potent-durable magnitude of response. Immunogenesis can be significantly enhanced with proprietary depot forming adjuvants

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Flunisyn	Universal influenza-A vaccine	Phase I	Phase-I complete - progressing to Phase-Ib / 2a in 2012
FP-02	Universal Hepatitis-B immunotherapy	Optimized Lead	Progressing through lead optimisation (human in-vitro validation of Densigen selection)
FP-03	Oncology	Pre-Target Validation	In-silico optimised leads

SENIOR MANAGEMENT

Carlton Brown, Chief Executive Officer • **Dr. Campbell Bunce (R&D Director)**, Other • **Dr. Bertrand Georges**, Chief Technology Officer • **Dr. Jill Makin**, Other • **Tim Cowper**, Chief Financial Officer • **Florent Gros**, Chairman

BOARD OF DIRECTORS

Florent Gros, Novartis Venture Fund (Investor) • **Carlton Brown**, CEO • **Marten Steen**, HealthCap (Investor) • **Philippe Pouletty**, Truffle Capital (Investor) • **Sandy Primrose**, nominated director by the London Technology Fund

SCIENTIFIC ADVISORY BOARD

Professor John Treanor, University of Rochester (USA) • **Dr. Peter Patriarca**, Biologics Consulting Group (USA) • **Dr. Arthur Krieg**, Entrepreneur in residence (Atlas Ventures) • **Professor Hakan Mellstedt**, Professor of Oncologic Biotherapy, Karolinska University Hospital Solna • **Professor Mark Thursz**, Professor of hepatology at Imperial College, London (UK)

FINANCING HISTORY

Round Date (Amount, US\$) 06/28/2007 (21.50 million)

Investors: Novartis Venture Fund (co-lead) (0%) • HealthCap (co-lead) (0%) • Truffle Capital (co-lead) (0%) • Esperante Ventures (0%) • London Technology Fund (0%)

ImmunoCellular Therapeutics, Ltd.

BIO Member, Presenting Company

Clinical Foci: Oncology, Vaccines

Manish Singh, PhD

President & CEO

21900 Burbank Blvd
Woodland Hills, CA 91367
USA

www.imuc.com

1-818-992-2907

OTC BB: IMUC

Incorporated: 2006

Employees: 4

Ownership: Public

HIGHLIGHTS

Recent

Completed a Phase I clinical trial for glioblastoma with encouraging clinical outcomes. Data demonstrates significant improvements in PFS and OS which was presented at ASCO.

Initiated a randomized, double blinded, placebo controlled Phase II clinical Trial in glioblastoma.

Upcoming

Complete patient enrollment in phase II trial in 1Q12 and interim analysis in 3Q12.

Filing of an IND to initiate a cancer stem cell vaccine, 3Q11

Out-licensing of antibody technology platform for novel antibody and antigen expression.

CORPORATE MISSION

ImmunoCellular Therapeutics, Ltd. develops and commercializes new immune based products to treat cancers. Our approach is to harness the body's immune system to provide therapeutics with the ability to fight cancer. There are two arms of the adaptive immune system that provide natural protection to the body: the cellular immune system (T-cell based) and the humoral immune system (B-cell based), which uses antibodies to fight foreign invaders.

- Dendritic Cell Based Cancer Vaccine: Dendritic cells are critical facilitators of a T-cell response but are often not present in sufficient numbers and are often not aggressive enough against malignant tumors to permit an adequately potent immune response to fight cancer. Our lead product, ICT-107, is currently in a phase II clinical trial for Glioblastoma.
- Cancer Stem Cell Therapeutics for Brain and Other Cancers: The characterization of cancer stem cells from glioblastoma has provided an opportunity to study the etiology of this dreaded disease and to be engaged in the development of product candidates that would be able to target the cancer stem cells which are believed to be responsible for the initiation and maintenance of glioblastoma.
- Antibody ImmunoTherapy: The second strategy for our product development, which is in preclinical development, is to harness the other arm of the adaptive immune system, which uses antibodies that can bind and neutralize any foreign antigen. The antibody candidates that we acquired bind to certain tumor antigens which may be useful for the potential detection and treatment for multiple myeloma, small cell lung, pancreatic and ovarian cancers.

PROPRIETARY TECHNOLOGY

Our approach is to harness the body's immune system to provide therapeutics with the ability to fight cancer. There are two arms of the adaptive immune system that provide natural protection to the body: the cellular immune system (T-cell based) and the humoral immune system (B-cell based), which uses antibodies to fight foreign invaders. Our strategy is to utilize both of these mechanisms in our product development programs. Currently, we have three programs: Dendritic Cell Based Cancer Vaccine, Cancer Stem Cell Therapeutics for Brain and Other Cancers, and Antibody Immunotherapy.

CORPORATE ALLIANCES

Cedars-Sinai Technology License, MD Anderson Technology License
University of Pennsylvania License on Dendritic Cell technology

PRODUCTS

Name	Indication	Phase	Milestone
ICT-107	Glioblastoma (Brain cancer)	Phase II, IIa, IIb	Initiate Phase IIb in 1Q11.
ICT-121 (cancer stem cell vaccine)	Solid Tumors	Preclinical	IND in 3Q11.
ICT-109	Small cell lung cancer	Preclinical	Antibody humanization
ICT-69	Multiple Myeloma	Preclinical	Partnered with Roche Pharmaceuticals

SENIOR MANAGEMENT

Manish Singh, PhD, President & CEO • **John Yu, MD**, Chief Scientific Officer • **James Bender, PhD**, Vice President • **David Fractor, CFO**, Chief Financial Officer

BOARD OF DIRECTORS


John Yu, MD, Director, Dept. of Neuro-Oncology, Cedars-Sinai Medical Center • **Jacqui Brandwynne**, President & CEO, Brandwynne Corporation • **Col. Richard Cowell**, Principal, Booz Allen Hamilton Inc. • **Helen Kim**, Chief Business Officer, NGM Biopharmaceuticals • **Manish Singh, PhD**, President & CEO, ImmunoCellular Therapeutics • **Navdeep Jaikaria, PhD**, President & CEO, SGN Advisors • **Rahul Singhvi, DSc**, President and CEO of Novavax

SCIENTIFIC ADVISORY BOARD

Keith L. Black, MD, Chairman, Dept. of Neurosurgery, Cedars-Sinai Medical Center • **Cohava Gelber, PhD**, Chief Scientific Officer, ATCC • **Peter Brooks, PhD**, Senior Scientist, Maine Medical Center Research Institute for Molecular Medicine • **Sherie Morrison, PhD**, Professor, UCLA • **Constantin Ioannides, PhD**, Professor, MD Anderson Cancer Center • **Col George Peoples, MD**, US Military Cancer Institute • **John Bockavar, MD**, Cornell Medical Center • **Zvi Ram, MD**, Tel Aviv Medical Center

TRADING STATUS AS OF OCTOBER 5, 2011

OTC BB: IMUC



Market Data

Current Price	1.60
Currency	US Dollar
Net Change	5.96
Volume	19,383
YTD % Change	0.18
52Wk Range	0.89–2.55
Avg. Daily Volume (thousands).....	103,770

First Call Data

Market Cap (MM)	45.7
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.41
EPS (Last Fiscal Year)	-0.41
Consensus Estimate (Y)	-0.41
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
DAFNA Capital Management LLC	0.2%
Yellowstone Partners.....	0.1%
<i>Mutual Fund</i>	
DAFNA Capital Management LLC	0.2%
Yellowstone Partners.....	0.1%

Source: Thomson Reuters

ImmunoGenes AG

BIO Member, Presenting Company

Clinical Foci: Drug Development, Drug Discovery, Immunology

Imre Kacs Kovics

Chief Executive Officer

Innere Guterstrasse 4
CH-6304 Zug
Switzerland

www.immunogenes.com

1-917-327-6423

Incorporated: 2008

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

We have published three new articles in well respected journals indicating the scientific community's acceptance of the power of our tg mice.

A patent was issued on June 22, 2011, by the European Patent Office, number EP209744, and additional patent applications have been filed and are pending in all other major jurisdictions.

Additional experiments have demonstrated that the technology works in species other than mice.

Upcoming

Patent issuance in US

Publication of an article in a scientific journal showing increased diversity of the immune response.

CORPORATE MISSION

ImmunoGenes is a biotech company based in Hungary that specializes in the generation of monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) using animals that have been genetically modified to overexpress the neonatal Fc Receptor (FcRn). As a result of this overexpression, the company's animals produce a greater number of B cell clones than normal animals because of FcRn's role in antigen presentation. In addition, because of the improved antigen presentation, they are able to mount a strong immune response against weakly immunogenic targets. Also, in response to immunization, they produce 3-10x the quantity of antigen specific polyclonal antibody made by normal animals. As a result, this technology is of value for developers of antibodies against weakly immunogenic targets and for those interested in the production of a higher number of hybridomas than would be possible with a standard mouse process. In addition, it is attractive to those who would benefit from the capability of the animals to express a more diverse immune response against epitopes of an antigen (AG) that are typically not part of the standard response pattern.

PROPRIETARY TECHNOLOGY

The company's genetically modified animals result from the insertion of a specially chosen gene (the FcRn gene) that is delivered to a fertilized egg via a Bacterial Artificial Chromosome (BAC). The effects of neonatal Fc receptor (FcRn) overexpression result in a significant improvement of the humoral immune response in the generation of antibodies for immunotherapy, diagnostics and other uses. These improvements include: 1) improved IgG protection; 2) augmented antigen-specific humoral immune response with larger numbers of antigen specific B cells, offering a wider spectrum of clones; 3) generation of antibodies against weakly immunogenic antigens; 4) significant improvements in the number and diversity of hybridomas.

CORPORATE ALLIANCES

We have signed agreements and shipped our mice to a number of top 10 pharma companies as well as additional antibody producing companies. The first of these experiments have been completed and have confirmed that our partners were able to reproduce the success that we described with the experiments in their facilities demonstrating that our mice produce higher quantity of antibodies, greater numbers of antigen specific B cells and greater numbers of hybridomas than their control mice. We are currently discussing licensing terms with these companies.

SENIOR MANAGEMENT

Imre Kacs Kovics, Chief Executive Officer • **Lee Schalop**, Chief Operating Officer • **Zsuzsanna Bosze**, Chief Scientific Officer • **Wolfgang Oster**, Chairman • **Tonio Barlage**, Chief Financial Officer

SCIENTIFIC ADVISORY BOARD

Anna Erdei, PhD, DSc, Chair Immunology, Eötvös Loránd University • **John E. Butler, PhD**, Professor Immunology, University of Iowa • **Lennart Hammarström, MD, PhD**, Professor, Clinical Immunology, Karolinska Institute (Sweden) • **Richard A. Goldsby, PhD**, Professor of Biology, Amherst College • **Bruce Whitelaw, PhD**, Head of Division of Developmental Biology, The Roslin Institute (UK)

ImmusanT Inc.

Presenting Company

Clinical Foci: AutoImmune, Drug Development, Biopharmaceuticals

Leslie J Williams

Chief Executive Officer

One Broadway, 14th Floor
Cambridge, MA 02142
USA

www.immusant.com

1-617-401-2154

Incorporated: 2010

Employees: 3

Ownership: Private

CORPORATE MISSION

ImmusanT, Inc. is a privately-held emerging biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The Company, that acquired the technology from Australia based Nexpep Pty. Ltd., has a strong intellectual property position and foundational science which provides the basis for their peptide-based immunotherapy and diagnostics.

PROPRIETARY TECHNOLOGY

The Company is harnessing the specificity of the immune reaction to gluten (protein in wheat, rye and barley) to develop diagnostics and therapeutics. Nexvax2, a peptide-based therapeutic vaccine, consists of 3 immuno-dominant peptides which are designed to induce tolerance to the toxic effects of gluten in Celiac Disease. This introduces a new treatment paradigm for celiac disease by leveraging the immune response to gluten.

PRODUCTS

<u>Name</u>	<u>Indication</u>	<u>Phase</u>	<u>Milestone</u>
Nexax2	HLA DQ2 Celiac Disease	Phase II, IIa, IIb	PreIND meeting
Companion Diagnostic	Identify and Monitor response	Diagnostics	
Stand alone diagnostic	Diagnose DQ2 CD	Diagnostics	

SENIOR MANAGEMENT

Leslie J Williams, Chief Executive Officer • **Bob Anderson**, Chief Scientific Officer

SCIENTIFIC ADVISORY BOARD

Peter Green, MD, Columbia University • **Bana Jabri, MD, PhD**, University of Chicago • **Ludvig Sollid, MD, PhD**, University of Oslo • **Knut Lundin, MD, PhD**, University of Oslo • **Markku Maki, MD, PhD**, University of Tampere • **Joseph Murray, MD**, Mayo Clinic • **Ciaran Kelly, MD**, Beth Israel • **Wally Binder, PhD**, INOVA Diagnostics • **Michelle Pietzak, MD**, University of Southern California

Indel Therapeutics, Inc.

Presenting Company

Clinical Foci: Infectious Disease, Biodefense, PGH – Neglected Diseases

Malcolm Kendall

Chief Executive Officer

Suite 100, 4068 West 11th Avenue
Vancouver, BC V6R 2L#
Canada

www.indelrx.com

1-604-551-8464

Incorporated: 2008

Employees: 5

Ownership: Private

CORPORATE MISSION

Founded in 2008, Indel Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of new antibiotics to address the global health crisis caused by antibiotic resistance.

The company has a growing pipeline of novel small-molecule antibiotic drug discovery programs that aim to cure serious, life-threatening infections. These programs are based on Indel's paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.

The Indel platform technology allows it to identify and target discrete amino acid insertion/ deletion differences ("indels") between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans. Based on these structural differences, the company can selectively target the pathogen protein with small molecules without hitting the human counterpart protein, thereby reducing toxicity concerns.

Indel targets are considered one of the first new major classes of antimicrobial targets identified in decades and provide a way to attack drug-resistant microbes by inhibiting indel-differentiated targets with novel drugs.

Indel's lead program focuses on the treatment of methicillin resistant *Staphylococcus aureus* (MRSA), a multidrug resistant super bug responsible for a growing proportion of hospital-acquired and community-acquired infections that result in significant morbidity and mortality. The company is also working on a number of indel-related Gram Negative antibiotic drug discovery programs.

PROPRIETARY TECHNOLOGY

The Indel platform technology:

- Identifies novel targets in bacterial, fungal, parasitic, and viral pathogens – a truly novel, broad-based antimicrobial technology platform.
- Leverages a distinct advantage conferred against resistance – targeting highly conserved, critical hub bacterial targets that may have an advantage against the development of drug resistance.
- Allows for selection of targets with either broad spectrum or narrowly defined spectra of activity against one or a few pathogens that are clinically advantageous to combat resistance.
- Produces exact knowledge of the target every time.
- Enables quick, economical identification and validation of targets using an in silico (computer based) discovery platform.

CORPORATE ALLIANCES

The Indel platform technology has the ability to create a large and growing pipeline of novel antimicrobial drugs. The company is currently advancing a number of antibacterial programs and one anti-parasitic program internally and is continuing to enhance its antibacterial indel target database, which contains hundreds of attractive indel differentiated targets from a range of clinically and commercially interesting pathogens. Given the breadth of its platform, Indel is interested in establishing strategic relationships to advance its platform and programs to develop novel treatments for serious bacterial, fungal, parasitic and viral infections.

SENIOR MANAGEMENT

Malcolm Kendall, Chief Executive Officer • **Neil Reiner, MD**, Chief Scientific Officer • **Roger Leger, PhD**, Vice President

BOARD OF DIRECTORS

Michael Abrams, PhD, Inimex Pharmaceuticals Inc. (Anormed Inc.) • **Allan Collings, CGA**, ACM Advisors Ltd. • **Charles "Chuck" Fisher, MD**, CEO, Margaux Biologics Inc. (Cardiome, Abbot, Lilly, Cleveland Clinic) • **Malcolm Kendall, MBA**, CEO, Indel Therapeutics Inc. (MDS Capital, Intersouth Partners) • **Simon Pimstone, MD, PhD**, CEO, Xenon Pharmaceuticals Inc. • **Neil Reiner, MD**, CSO, Indel Therapeutics Inc. (Vancouver General Hospital, University of British Columbia) • **Patrick Scannon, MD, PhD**, CSO, Xoma Ltd. • **Richard White, PhD**, Half Moon Bay Biotechnology Consulting (Vicuron, BMS)

SCIENTIFIC ADVISORY BOARD

Neil Reiner, MD (Chairman), CSO, Indel Therapeutics Inc. (Vancouver General Hospital, University of British Columbia) • **Julian Davies, PhD**, Emeritus Professor of Microbiology & Immunology at the University of British Columbia • **Brett Finlay, PhD**, Peter Wall Distinguished Professor at the University of British Columbia • **Irwin Kuntz, PhD**, Professor Emeritus of Pharmaceutical Chemistry at the University of California San • **David Shlaes, MD, PhD**, Anti-infectives Consulting LLC (Idenix, Wyeth)

FINANCING HISTORY

Round Date (Amount, US\$) 03/23/2011 (1,400,000.00 million)

Inimex Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease, Drug Development, Pulmonary

Michael J. Abrams, PhD

President & CEO

8540 Baxter Place
Burnaby, BC V5A 4T8
Canada

www.inimexpharma.com

1-604-225-2251

Incorporated: 2001

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Phase 1 completed
Pre IND meeting completed
Phase II IND submitted

Upcoming

Release of clinical hold for Phase II
Series C VC funding Closed

CORPORATE MISSION

Inimex Pharmaceuticals, Inc. is a clinical-stage, venture-backed Canadian company developing a new class of drugs, Innate Defense Regulators (IDRs). IDRs are host-directed agents that protect against – and improve recovery from - damage caused by a variety of insults including pathogens, trauma and chemo- or radiation-therapy. IDRs increase survival after challenge with a broad range of pathogens and ameliorate tissue damage by selective modulation of the body's innate defenses.

Inimex' lead development candidate, IMX942, has shown excellent safety in Phase 1. An IND has been filed for a Phase 2 trial in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). A Phase 2 trial has also been designed for the amelioration of mucositis in head and neck cancer patients undergoing radiotherapy. Preclinical data indicate that IDRs are active in models of a wide range of indications including life threatening and antibiotic-resistant bacterial infections and the severe side-effects of chemo- and radiation-therapy.

The Company wishes to secure further financing and to initiate discussions with both North American and overseas potential partners in order to maximize the development opportunities for its R&D portfolio.

PROPRIETARY TECHNOLOGY

Extensive in vivo preclinical studies have shown that IMX942 and its analogs accelerate pathogen clearance and increase host survival in a broad spectrum of bacterial infections (including Gram positive and negative bacteria and both drug sensitive and resistant strains), while having no direct antibacterial activity and suppressing inflammation. As host-directed agents, IDRs do not select for antibiotic resistance. IMX942 also reduces tissue damage associated with chemotherapy, radiation, trauma and inflammation. While IDR action depends on monocytes and macrophages, there is no dependence on the presence of either the adaptive immune system (e.g., T cells) or neutrophils. IDRs are effective following immunosuppression.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
IMX942	ABSSSI	Phase II, IIa, IIb	Phase II IND filed

SENIOR MANAGEMENT

Michael J. Abrams, PhD, President & CEO • **John R. North, PhD**, Chief Operating Officer • **Marty McConnell, CA**, Chief Financial Officer

BOARD OF DIRECTORS

Robert Fildes, PhD, SB2 Inc. • **Michael Abrams, PhD**, Inimex • **Patrick Brady, MBA**, Growthworks • **Brenda Irwin, MBA**, BDC Venture Capital • **Stephanie O'Brien**, Morningside

SCIENTIFIC ADVISORY BOARD

B. Brett Finlay, PhD, University of British Columbia • **David Fitzpatrick, PhD**, Biotech Clarity • **Philippe Gros, PhD**, McGill University • **Eric Pamer, MD**, Memorial Sloan-Kettering Cancer Center • **G.Ralph Corey, MD**, Duke Clinical Research Institute • **Vance Fowler, MD**, Duke Clinical Research Institute

FINANCING HISTORY

Round Date (Amount, US\$) 06/28/2004 (6.50 million) • 05/23/2008 (22.00 million)

Intra-Cellular Therapies, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS, Drug Development, Drug Discovery

Sharon Mates, PhD Chief Executive Officer

3960 Broadway
New York, NY 10032
USA

www.intracellulartherapies.com

1-212-923-3344

Incorporated: 2002

Employees: 28

Ownership: Private

HIGHLIGHTS

Recent

Completed Phase Ib/II MAD study for ITI-007 in patients with schizophrenia demonstrating safety, tolerability and early signals for efficacy. ITI-007 is currently in Phase II studies.

February 2011: ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop PDE1 inhibitors for the treatment of schizophrenia and other CNS disorders.

Company identified a novel target for drug discovery in the Alzheimer's disease field called GSAP. GSAP participates in the formation of amyloid beta through the interaction with amyloid precursor protein and gamma secretase without inhibiting NOTCH.

CORPORATE MISSION

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the Central Nervous System (CNS). Compounds in clinical development include ITI-007 for the treatment of schizophrenia, bipolar disorder, depression, sleep disturbances in psychiatric and neurodegenerative diseases and other CNS disorders. The Company has concluded a positive Phase I/II study demonstrating the safety and tolerability of ITI-007 across a broad range of doses in patients with stable schizophrenia. Additionally, exploratory clinical measures revealed signals consistent with antipsychotic and antidepressant efficacy for ITI-007. ITI-007 is currently in Phase II studies for the treatment of schizophrenia. In February 2011, ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop PDE1 inhibitors for the treatment of schizophrenia and other CNS disorders. ITI has preclinical programs in the area of cognitive dysfunction in schizophrenia, depression, Parkinson's disease, Alzheimer's disease and Women's Health.

CORPORATE ALLIANCES

In February 2011, ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop PDE1 inhibitors for the treatment of schizophrenia and other CNS disorders.

PRODUCTS

Name	Indication	Phase
ITI-007	schizophrenia, bipolar disorder, depression, sleep disturbances in psychiatric and neurodegenerative diseases	Phase II, IIa, IIb
ITI-002	cognitive dysfunction in schizophrenia and Alzheimer's disease, Parkinson's disease	Preclinical
ITI-009	Alzheimer's disease	Optimized Lead
ITI-014	Vasomotor Symptoms, Major Depressive Disorder, Fibromyalgia	Lead Series

SENIOR MANAGEMENT

Sharon Mates, PhD, Chief Executive Officer • Lawrence Wennogle, PhD, Vice President • Kimberly Vanover, PhD, Vice President • Allen A. Fienberg, PhD, Business Development • Lawrence Hinline, Chief Financial Officer

InVasc Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Renal, Cardiovascular Disease, Metabolic Disease

William D. Schaeffer

Chief Operating Officer

3562 Habersham at Northlake
Tucker, GA 30084
USA

www.invasc.net

1-678-736-5903

Incorporated: 2006

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

June 2011: We announced the initiation of an 80 patient phase IIa clinical trial in hypertensive diabetic patients with chronic kidney disease. The primary endpoint is a reduction of proteinuria.

June 2011: The completion of a worldwide exclusive license with a exclusive supply agreement with the only cGMP manufacturer of the API for our lead drug, INV-144 for CKD. The license give us rights to 6 issued and 1 pending patent.

April 2011: We announce a worldwide exclusive license a salt of the R(+) enantiomer alpha lipoic acid, a component used in INV-144. This includes a pending patent filed in the primary CKD markets global.

Upcoming

Completion of the Phase IIa clinical trial of INV-144 in CKD patients. This will facilitate the initiation of one or more Phase IIa trials in 2012.

Filing of an IND for either our 400 Series for atherosclerosis, or for the 300 Series, a myeloperoxidase inhibitor that will most likely be evaluated in patients with an acute MI.

Completion of a Series B financing by early 2012.

CORPORATE MISSION

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a virtual biopharmaceutical company developing drugs for the treatment and prevention of chronic kidney (CKD) and cardiometabolic diseases. Due to the advancing age of baby-boomers and the obesity epidemic within western societies, the number of patients requiring drug intervention for these conditions is expanding significantly and enlarging global markets. Hypertensive diabetics, including those with CKD, account for the single largest segment of the US Medicare budget at 28%. InVasc's lead product, INV-144, is being developed for CKD. INV-144 is the combination of two distinct chemical entities: alpha Lipoic Acid (ALA), a powerful antioxidant and an approved drug in Europe with Generally Recognized as Safe (GRAS) nutraceutical status in the US, and a widely used generic antihypertensive drug, Losartan. The company has already demonstrated statistical significance for key endpoints in a placebo controlled, double-blind Phase II study in hypertensive diabetics with CKD utilizing an alternative antihypertensive agent. The company has an active IND with the Food & Drug Administration (FDA), which is a 505(b)(2) filing. Based on FDA's input, a well defined development plan through Phase III has been designed. A Phase IIa clinical trial involving 80 patients will begin near the end of 2Q11. The company believes the safety risk of this combination product is minimal based on prior human exposure to the two components. The need for new therapeutics for CKD is very strong as manifested by the USD \$450 million investment by Abbott this past fall.

PROPRIETARY TECHNOLOGY

INV-144, being developed for CKD, is the combination of two distinct chemical entities: alpha Lipoic Acid (ALA), a powerful antioxidant and an approved drug in Europe with Generally Recognized as Safe (GRAS) nutraceutical status in the US, and Losartan. The company has already demonstrated statistical significance for key endpoints in a placebo controlled, double-blind Phase II study in hypertensive diabetics with CKD utilizing an alternative antihypertensive agent. The company has an active IND with the Food & Drug Administration (FDA), and a Phase IIa clinical trial involving 80 patients will begin near the end of June. InVasc has a family of NMEs/NCEs directed at atherosclerosis, stroke, acute MI and inflammation. Two series of compounds are beginning ADME studies.

CORPORATE ALLIANCES

InVasc has two worldwide exclusive licenses. The first is with Labochim S.A., a subsidiary of Infa S.A. Under this license InVasc has exclusive rights to all IP associated with alpha lipoic acid for use in combination with any RAS inhibitor, anti-hypertensive for the treatment or prevention in chronic kidney disease. This license included 6 issued and 1 pending patent. The license also includes an exclusive supply agreement.

InVasc has a WW exclusive in-license from the magnesium salt of R(+) ALA for use in combination with antihypertensives for the prevention or treatment of chronic kidney disease.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
INV-144	Chronic kidney disease	Phase II, IIa, IIb	Completion of 80 patient IIa in mid-2012
400 Series	Atherosclerosis	Pre-Target Validation	IND filing near the end of 2012
300 Series	Acute MI, Inflammation	Pre-Target Validation	IND filing near the end of 2012

SENIOR MANAGEMENT

William D. Schaeffer, Chief Operating Officer • **Sang Le**, Director • **William D. Johnston, PhD**, Chief Executive Officer

BOARD OF DIRECTORS

William D. Johnston, PhD, InVasc Therapeutics, Inc. • **William D. Schaeffer**, InVasc Therapeutics, Inc. • **Daniele Cardoso**, Infa S.A. / Trois I Investments • **Larry Dillaha, MD**, Former Executive VP and CMO, Sciele/Shionogi • **Frank Kelly**, Retired Coke Cola Officer

SCIENTIFIC ADVISORY BOARD

Bobby Khan, MD, PhD, St. Joseph's Hospital, Atlanta • **Sanjay Rajagopalin, MD, PhD**, University of Ohio School of Medicine • **Sampath Parthasarathy, PhD**, University of Ohio School of Medicine • **Bertran Pitt, MD**, University of Michigan Medical School • **W. Virgil Brown**, Emory University School of Medicine

FINANCING HISTORY

Round Date (Amount, US\$) 06/01/2010 (3.20 million)

Investors: Trois I Investissements Industriels Internationaux S.A. (24%) • Bobby Khan - Founder (10%) • William D. Johnston - CEO (10%) • Sampath Parthasarathy - Founder (9%) • Sanjay Rajagopalin - Founder (8%)

Jennerex Biotherapeutics, Inc.

Presenting Company

Clinical Foci: Oncology, Immunology, Drug Delivery

Ken Newport

Chief Executive Officer

450 Sansome St, 16th Floor
San Francisco, CA 94111
USA

www.jennerex.com

1-415-281-8886

Incorporated: 2003

Employees: 35

Ownership: Private

HIGHLIGHTS

Recent

Presented positive JX-594 clinical data in combination with sorafenib in liver cancer. Presented positive randomized Phase 2 clinical data showing survival benefit in liver cancer.

Published proof of concept data in Nature showing the ability to deliver JX-594 intravenously.

Completed private financing providing cash balance at 8/31/11 of ~\$18 million USD.

Upcoming

Presenting randomized Phase 2 data of JX-594 in oral presentation at AASLD Meeting in November.

Launching Phase 2b clinical trial (TRAVERSE) of JX-594 in patients with hepatocellular carcinoma.

Completing enrollment in Phase 1/2 trial of JX-594 in colorectal cancer.

CORPORATE MISSION

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.

PROPRIETARY TECHNOLOGY

JX-594 is a proprietary, engineered oncolytic poxvirus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 115 treated to date). Objective tumor responses have been demonstrated in a variety of cancers.

CORPORATE ALLIANCES

Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
JX-594	Liver Cancer	Phase II, IIa, IIb	Initiate Phase 2b trial in 4Q11.
JX-594	Colorectal Cancer	Phase II, IIa, IIb	Present interim clinical data
JX-929	Pancreatic Cancer	Phase I	
JX-1395	Prostate Cancer	Preclinical	

SENIOR MANAGEMENT

Ken Newport, Chief Executive Officer • **David Kirn, MD**, Chief Medical Officer • **Gregory Schafer**, Chief Financial Officer • **John Bell**, Chief Scientific Officer • **Lara Longpre**, Chief Operating Officer

BOARD OF DIRECTORS

Brennan Mulcahy, Energy Saving Income Fund • **Hoyoung Huh**, BiPar Sciences • **Martin Murphy**, American Society for Clinical Oncology (Chairman) • **Ken Newport**, PRA International • **David Kirn**, Jennerex • **John Bell**, Jennerex • **Daniel Spiegelman**, Affymax, Inc.

SCIENTIFIC ADVISORY BOARD

David Bartlett, MD, University of Pittsburgh Medical Center • **Malcolm Brenner, MD, PhD**, Baylor College of Medicine • **William Dupere, MBA**, Five Points Therapeutics • **Douglas Hanahan, PhD**, UCSF • **Terry Hermiston, PhD**, Bayer Healthcare Pharmaceuticals • **Thomas Lynch, MD**, Yale Comprehensive Cancer Center • **Frank McCormick, PhD**, UCSF • **Grant McFadden, PhD**, University of Florida, College of Medicine • **Paul Polakis, PhD**, Genentech

Kareus Therapeutics, LLC

Presenting Company

Clinical Foci: CNS, Metabolic Disease, Drug Discovery

Dr. Patrick Doyle Chief Executive Officer

40 Rue Fritz-Courvoisier
2300 La Chaux-de-Fonds
Switzerland

www.kareustherapeutics.com

44-7871-309056

Incorporated: 2010

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Positive in vivo PK/PD and efficacy in Alzheimer's models. Decrease in transgenic mouse brain A β -42 with significant improvement in water maze cognition tests in same group.

GLP TOX & IND enabling started June 2011.

CMC scale-up completed.

In vivo Proof of Concept in Diabetes program with optimised lead.

Non GLP Tox package completed.

Positive in vivo proof of concept in Pain models for proprietary novel small molecules.

Upcoming

Alzheimer's program GLP box & IND studies completed end 2011.

Alzheimers IND file 3Q12.

KU-5001 to enter GLP box & CMC scale-up 4Q11.

In vivo Proof of concept on 2 novel small molecule series in Pain program.

CORPORATE MISSION

Kareus Therapeutics is a privately held company focused on discovery and development of novel small molecule drugs based upon its proprietary KARLECT chemistry platform. The technology allows novel combinations of drugs to be created with improved therapeutic and safety profiles using a new approach. Kareus also has small molecule drug discovery in Diabetes and Pain

Proof of concept in vivo animal model studies have been successfully completed in Alzheimer's and Cardiovascular diseases.

The KARLECT platform approach is applicable to any therapeutic area.

PROPRIETARY TECHNOLOGY

KARLECT chemistry platform for development of novel combination drug therapies.

Platform to facilitate brain entry

CORPORATE ALLIANCES

Quintiles Strategic Development Alliance signed June 2011

PRODUCTS

Name	Indication	Phase	Milestone
KU046	Alzheimer's	Preclinical	IND 1Q12.
KU-5001	Diabetes	Preclinical	IND 2H12.
Arthritis Discovery	Pain	Optimized Lead	GLP Tox 4Q11.

SENIOR MANAGEMENT

Dr. Patrick Doyle, Chief Executive Officer • **Dr. Anji Reddy**, Chairman • **Dr. Uday Saxena**, Chief Operating Officer

BOARD OF DIRECTORS

Dr. K. Anji Reddy, Dr. Reddys Laboratories • **Dr. Uday Saxena**, Kareus Therapeutics, SA • **Dr. Patrick Doyle**, Kareus Therapeutics, SA

SCIENTIFIC ADVISORY BOARD

Akella Venkateswarlu

FINANCING HISTORY

Investors: Dr. K Anji Reddy (1%) • Management (1%) • Quintiles (1%)

LigoCyte Pharmaceuticals, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Vaccines

Donald P Beeman
Chief Executive Officer

2155 Analysis Drive
Bozeman, MT 59718-6831
USA

www.ligocYTE.com

1-406-585-2733

Incorporated: 1998

Employees: 37

Ownership: Private

HIGHLIGHTS

Recent

LigoCyte has shown in a Phase I/II human vaccination plus live virus challenge study that its Norwalk VLP vaccine effectively reduced clinical illness. The full results will be presented at the IDSA conference in October.

The Company also initiated a Phase I study of a bivalent intramuscular norovirus vaccine in 2010.

CORPORATE MISSION

LigoCyte Pharmaceuticals, Inc. is a private, biopharmaceutical company focused on the development of innovative vaccine products based on the company's proprietary virus-like particle (VLP) platform technology. LigoCyte's lead candidate recently completed a Phase I/IIa clinical trial designed to study the prevention of norovirus acute gastroenteritis (AGE), a ubiquitous and prostrating illness characterized by a fever, vomiting and diarrhea. This proof-of-principle study tested the company's VLP Norwalk vaccine candidate in conjunction with a live-virus challenge in healthy adult volunteers. Notably, the trial met its primary endpoints of statistically significant reductions of illness, infection and severity. LigoCyte also has a novel respiratory syncytial virus vaccine in preclinical development that has demonstrated protection in cotton rat challenge studies - without vaccine-associated histopathology. Utilizing the company's core VLP expertise, LigoCyte's vaccine development programs focus on gastrointestinal and respiratory targets in commercially attractive markets.

PROPRIETARY TECHNOLOGY

LigoCyte's core expertise is virus-like particle, or VLP, based vaccines. VLP technology presents vaccine antigens in a highly immunogenic, native form for anti-viral protection without the complexity associated with live viruses. The company has developed simple, scalable and high-yield production processes to support advanced development. Additionally, the VLP platform technology can be rapidly engineered for emerging targets or to add other vaccine antigens for multivalent, combination products. LigoCyte has also developed dry powder, intranasal-delivery vaccine formulations for enhancing mucosal immune responses. These formulations can improve commercial cold-chain distribution options, address stockpile constraints and do not require needles or trained personnel for delivery.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
VLP Norwalk Vaccine	Human Proof-of-Principal for Vaccination against Norwalk Infection	Phase II, IIa, IIb	Met primary study objectives
Intramuscular, Bivalent VLP Norovirus Vaccine	Prevention of Norovirus Acute Gastroenteritis	Phase I	
Intranasal, Bivalent VLP Norovirus Vaccine	Prevention of Norovirus Acute Gastroenteritis	Preclinical	

SENIOR MANAGEMENT

Donald P Beeman, Chief Executive Officer • **Robert R Goodwin, PhD**, Chief Operating Officer • **Robert F Bargatze, PhD**, Chief Scientific Officer • **Charles E Richardson, PhD**, Executive Vice President • **Paul M Mendelman, MD**, Chief Medical Officer • **Larry W Mikkola**, Director

BOARD OF DIRECTORS

Ivor Royston, MD, Forward Ventures • **Donald Beeman**, CEO, LigoCyte Pharmaceuticals, Inc. • **J. Donald deBethizy, PhD**, CEO, Targacept, Inc. • **Markus Goebel, PhD, MD**, Novartis Ventures • **Hironori Hozoji**, JAFCO Life Science Investment • **Ben Auspitz**, Fidelity Biosciences • **C. Boyd Clarke**, Chairman, QLT Inc. and Mersana Therapeutics • **Peter Greenleaf**, MedImmune, LLC

SCIENTIFIC ADVISORY BOARD

Harry Greenberg, MD, Joseph D. Grant Professor and Co-Chairman, Department of Medicine, Stanford University • **Jerry R McGhee, PhD**, Profeseor of Microbiology, University of Alabama, Birmingham • **Charles Russell Middaugh, PhD**, A. & T. Higuichi Distinguished Professor of Pharmaceutical Chemistry, University of Kansas • **Bryan S Finkle, PhD**, Director of Pharmacology (retired), Genetech, Inc. • **Marian Neutra, PhD**, E. & M. Gordon Distinguished Professor of Pediatrics, Children's Hospital Harvard University • **George R Siber, MD**, Executive Chairman of Genocea Biosciences

FINANCING HISTORY

Round Date (Amount, US\$) • 03/15/2008 (28.00 million)

Lipocine, Inc.

Presenting Company

Clinical Foci: Hormone Therapy, Specialty Pharmaceutical, Drug Delivery

Mahesh Patel

Chief Executive Officer

675 Arapeen Drive
Salt Lake City, UT 84108
USA

www.lipocine.com

1-801-994-7383

Incorporated: 1997

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Completed license out of the first oral testosterone (Abbott Products). Second milestone received.
Phase I data for first oral progesterone product (Development for Pre Term Birth)
Phase I data for first oral testosterone for females (Development for Hypoactive Sexual Desire Disorder - HSDD)

Upcoming

Phase II data for Preterm Birth
Phase II data for HSDD
Marketing partner for cough/cold products (LPCN 1084,1087, and 1090)

CORPORATE MISSION

Specialty Pharmaceutical Company with eight products in clinical development. Therapeutic Focus: Womens's health (first oral progesterone for Pre-Term Birth and first oral treatment for Female Sexual Disorder/HSDD). Male Hormone treatment (first oral testosterone). Cough/Cold (three unique 505(b)(2) candidates).

Lipocine products are available for out-licensing/partnering. Lipocine is also actively looking to in-license Proof of Concept verified products in the Men's Health, Women's Health and Urology sectors.

PROPRIETARY TECHNOLOGY

21 issued patents for the improved oral delivery of poorly water soluble drugs.

CORPORATE ALLIANCES

Abbott Products, UCB, Elan

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
LPCN 1021	First oral Oral testosterone for male hypogonadism	Phase I
LPCN 1098	First oral for HSDD (Hypoactive sexual desire disorder)	Phase I
LPCN 1084	First long acting combination of a safe narcotic and a antihistamine to treat runny nose symptoms	Phase I
LPCN 1090	First long acting Rx combination product for Productive Cough	Optimized Lead
LPCN 1087	First long acting RX combo for productive cough	Optimized Lead
LPCN 1002	Hormone Replacement Therapy	Phase I
LPCN 1110	First oral for Preterm Birth	Phase I
LPCN 1022	Natural Progesterone/Natural Estradiol combination oral	Phase I
LPCN 1109	Progesterone Only Pill (ER)	Phase I

SENIOR MANAGEMENT

Mahesh Patel, Chief Executive Officer • **Srinivasan Venkateshwaran**, Chief Scientific Officer • **Jerry Simmons**, Chief Business Officer • **Robert Merrell**, Corporate Finance

BOARD OF DIRECTORS

Dr. William Higuchi, Retired Head of Department of Pharmaceutics (U of U) • **Gordhan Patel**, Entrepreneur • **John Higuchi**, CEO Acliont Pharmaceuticals • **Dr. Mahesh Patel**, CEO Lipocine Inc.

FINANCING HISTORY

Investors: Management/founders (73%) • UCB (23%) • Elan (4%)

MabVax Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Immunology, Vaccines

David Hansen

President & CEO

11588 Sorrento Valley Road, Suite 20
San Diego, CA 92121
USA

www.mabvax.com

1-858-259-9405

Incorporated: 2006

Employees: 7

Ownership: Private

HIGHLIGHTS

Recent

Initiated Phase II sarcoma and ovarian cancer vaccine trials July 2010. Both studies have more than 14 sites enrolling patients in the US. Enrollment is on track for both studies.

Multiple NCI/NIH Grant Awards: STTR 2 Grant for antibody research USD \$1.1 million and SBIR Fast-Track Award for sarcoma vaccine research. Phase 1 is USD \$150,000 and Phase 2 award was \$1.8 million.

SCLC vaccine manufactured and revised IND submitted to FDA. Phase I trial initiated in July 2011.

Upcoming

SCLC Vaccine: Phase 1 trial complete end of 2011 and Phase II trial initiated in 1H12.

Achieve target enrollment for both the sarcoma and ovarian cancer Phase 2 clinical trials by 3Q12.

Completion of early preclinical development, including animal model testing, of anti-sialyl Lewis(a) antibody by 3Q. Complete characterization of additional antibody candidates from the 11 antigens incorporated into the vaccines licensed from MSKCC

CORPORATE MISSION

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. Certain types of cancer have high metastatic potential and therefore very high recurrence rates even after patients have initially been rendered free of detectable disease using optimal current therapies. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence. Successful development of our therapeutic products will result in significantly improving patient quality of life and prolonging overall survival.

We have established multiple licenses with Memorial Sloan Kettering Cancer Center (MSKCC) which has already established proof of principal for both its cancer vaccine products. MabVax is focused on the clinical development of our sarcoma, small cell lung cancer, and ovarian cancer vaccine products which entered Phase 2 clinical trials in July 2010.

MabVax is leveraging the ongoing clinical programs along with the antigenic components of the vaccines to create a pipeline of monoclonal antibody products based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers. MabVax has already demonstrated the ability to isolate and preserve the antibody responses from patients immunized with a monovalent breast cancer vaccine as well as a bivalent melanoma vaccine. These fully human monoclonal antibodies have high affinity, specificity, and pronounced cytotoxic activity against cells displaying the targeted antigens on their surface. We will continue to build our library of high potential antibodies as both MSKCC and MabVax continue the planned vaccine clinical program.

PROPRIETARY TECHNOLOGY

The company has secured rights from Memorial Sloan-Kettering Cancer Center to a series of highly immunogenic vaccines against cancers of neuroectodermal and epithelial origin as well as small cell lung cancer. These vaccines target extensively expressed carbohydrates molecules on malignant cells on these types of cancers. These vaccines have been tested and refined in multiple clinical trials establishing immunogenicity, tolerability, and therapeutic utility. MabVax is leveraging the ongoing clinical programs along with the antigenic components of the vaccines to create a pipeline of monoclonal antibody products based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers.

CORPORATE ALLIANCES

Multiple licenses in place with Memorial Sloan-Kettering Cancer Center

PRODUCTS

Name	Indication	Phase	Milestone
Trivalent Sarcoma Vaccine	Sarcoma	Phase II, IIa, IIb	Initiated Phase II trial in July 2010.
Tetavalent SCLC Vaccine	Small Cell Lung Cancer	Phase I	Initiated Phase I trial in July 2011 at MSKCC. Phase II to be initiated 1H12.
Ovarian Cancer Vaccine	Ovarian Cancer	Phase II, IIa, IIb	Initiated Phase II trial in July 2010.
Fully Human Monoclonal Antibody 5B1	Metastatic pancreatic, colon and breast cancer	Preclinical	Completion of animal model testing 3Q11.

SENIOR MANAGEMENT

David Hansen, President & CEO • Philip Livingston, MD, Chief Scientific Officer • Wolfgang Scholz, PhD, Vice President • Govind Ragupathi, MD, Vice President

BOARD OF DIRECTORS

David Hansen, MabVax Therapeutics, Inc. • **Douglas Lind, MD**, Greenwich Biotech Partners • **Philip Livingston, MD**, MabVax Therapeutics, Inc. • **Nicholas Stephens**, RTP Venture Fund

SCIENTIFIC ADVISORY BOARD

Philip Livingston, MD, Memorial Sloan Kettering Cancer Center • **Samuel Danishefsky, PhD**, Memorial Sloan Kettering Cancer Center • **Jeff Gildersleeve**, National Cancer Institute

FINANCING HISTORY

Round Date (Amount, US\$) 02/01/2008 (2,000,000.00 million) • 08/01/2009 (4,000,000.00 million) • 09/01/2011 (2,500,000.00 million)

MannKind Corporation

BIO Member

Clinical Foci: Metabolic Disease, Oncology, Drug Delivery

Alfred Mann

President & CEO

28903 North Avenue Paine
Valencia, CA 91355
USA

www.mannkindcorp.com

1-661-775-5300

NASDAQ: MNKD

Incorporated: 1991

Employees: 250

Ownership: Public

CORPORATE MISSION

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, metabolic disorders and cancer.

PROPRIETARY TECHNOLOGY

- (1) Technosphere® Insulin [CRL - Restarting pivotal studies].
- (2) Technosphere GLP-1 [Phase 1].
- (3) MKC-1106MT active immunotherapy for melanoma [Phase 2].
- (4) MKC-1106PP active immunotherapy for solid-tumor cancers [Phase 1].
- (5) IRE-1 alpha small molecule program for multiple myeloma and autoimmune disease [Preclinical].

CORPORATE ALLIANCES


Multiple

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
AFREZZA	Diabetes	NDA/BLA filed, or in process
MKC1106-MT	Melanoma	Phase II, IIa, IIb
MKC1106-PP	Select solid tumors	Phase I
MKC1106-NS	Hematological malignancies	Preclinical
MKC204 (IRE-1 alpha inhibitor)	Multiple myeloma	Preclinical
Technosphere Technology	Pulmonary Drug Delivery Platform	NDA/BLA filed, or in process

SENIOR MANAGEMENT

Alfred Mann, President & CEO • **Matthew Pfeffer**, Chief Financial Officer



Market Data

Current Price	3.49
Currency	U.S. Dollar
Net Change	-5.68
Volume	675,654
YTD % Change	-0.57
52Wk Range	2.20-10.05
Avg. Daily Volume (thousands).....	2,030,710

First Call Data

Market Cap (MM)	457.1
Short Interest Shares	25,075,272
Short Interest Ratio	27.45
PE (Trailing 12 Months)	-1.25
EPS (Last Fiscal Year)	-1.44
Consensus Estimate (Y)	-1.25
Consensus Recommend	-1.26
Price/Sales	9137.21

Shareholders

<i>Institution</i>	<i>Holding %</i>
BlackRock Fund Advisors	3.7%
The Vanguard Group, Inc.	3.1%
Chou Associates Management, Inc.	1.9%
State Street Global Advisors	1.0%
Northern Trust Investments	0.7%
<i>Mutual Fund</i>	<i>Holding %</i>
BlackRock Fund Advisors	3.7%
The Vanguard Group, Inc.	3.1%
Chou Associates Management, Inc.	1.9%
State Street Global Advisors	1.0%
Northern Trust Investments	0.7%

Source: Thomson Reuters

Maruho Co., Ltd.

Clinical Foci: Skin/Dermatological, Drug Delivery, Specialty Pharmaceutical

Koichi Takagi President & CEO

1-5-22, Nakatsu, Kita-ku
Osaka 531-0071
Japan

www.maruho.co.jp/english

81-6-63718438

Incorporated: 1915

Employees: 1076

Ownership: Private

HIGHLIGHTS

Recent

Dainippon Sumitomo Pharma and Maruho entered into a License Agreement for a Novel Topical Analgesic Drug (DSR18424) (Apr 2011).

Marketing Collaboration with Astellas Pharma on Protopic® Ointment for Atopic Dermatitis in Japan (Dec 2010).

Maruho received Gold Triangle Awards 2010 by American Academy of Dermatology. This award recognizes Maruho Derma Report Issue #3 "Vitiligo Advancements" for raising public awareness of dermatologic issues (Mar 2010).

CORPORATE MISSION

Maruho Co., Ltd. is a specialty pharmaceutical company focused on dermatology and topical products. Maruho ranks #1 in dermatology market in Japan and #1 as a manufacturer of ethical semi-solid products in Japan. We have oversea offices in New York, London and Düsseldorf to expand its business globally now. We are looking for in-license development pipelines in the field of dermatology from early stage to late stage including ethical drugs, diagnostic drugs, cosmeceuticals, skin care products, aesthetic dermatology products, medical devices and research programs with academia.

CORPORATE ALLIANCES

Maruho has been collaborating in dermatology field with many leading pharmaceutical companies including MSD, Abbott, Novartis, Astellas, Chugai, Mitsubishi Tanabe Pharma and Dainippon Sumitomo Pharma in several business structures, for example, sales alliance, co-development, and so on.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
M5180	Anti-psoriasis	Phase II, IIa, IIb
M5160	Anti-pruritic	Phase II, IIa, IIb
M5120	Anti-acne	Phase II, IIa, IIb
M5200	Anti-allergic dermatitis	Phase I
DSR18424	Anti-pain	Preclinical
M5210	Anti-herpes simplex	Phase III

SENIOR MANAGEMENT

Koichi Takagi, President & CEO

Mersana Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology

Nick G. Bacopoulos, PhD <i>Chief Executive Officer</i> 840 Memorial Drive Cambridge, MA 02139 USA		www.mersana.com 1-617-715-8236	Incorporated: 2005 Employees: 25 Ownership: Private
--	--	--	---

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
Achieved high potency in vivo POC for antibody drug conjugates.	1-2 high impact antibody drug conjugate collaborations with pharma in 2011/2012.
Initiation of Phase IB extension study in NSCLC Cancer, March 2011.	Completion of XMT-1001 Phase Ib extension study, 1H12.
Initiation of Phase I study for XMT-1107 in refractory, advanced solid tumors, April 2010.	Initiation of Phase II study for XMT-1107, 2H12.

CORPORATE MISSION

Mersana engineers novel drug conjugates to maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next generation drugs with best-in-class potential to address multiple unmet needs in oncology. Our versatile conjugation system integrates Fleximer, a clinically validated biodegradable polymer, with a broad array of customizable linker chemistries matched to therapeutic payloads. Our technology is being leveraged in multiple therapeutic areas through partnerships with major pharmaceutical companies.

PROPRIETARY TECHNOLOGY

Mersana's proprietary platform, Fleximer, is a novel, biodegradable and biocompatible polymer that can be covalently conjugated to biologics, small molecules, peptides, and nucleic acids to enhance their pharmacokinetic and safety profiles, as well. Fleximer has been proven to transform existing and experimental agents into new, patentable drugs with superior properties. The Fleximer platform has broad and versatile applications across therapeutic categories and enhances the delivery of small molecule, protein, and nucleic acid therapeutics. Two such Fleximer conjugates, XMT-1001, a novel camptothecin-based cytotoxic conjugate, and XMT-1107, a novel fumagillin-based anti-angiogenic conjugate, are both in Phase 1 trials and are each the subject of their own composition of matter patents.

CORPORATE ALLIANCES

Mersana has an alliance with Teva Pharmaceuticals for the development and commercialization of XMT-1107 on a world-wide basis excluding Japan where Mersana has retained rights. Mersana is currently pursuing alliances with companies to advance its next generation antibody drug conjugate technology.

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
XMT-1001	oncology, multiple tumor types	Phase I	Phase II start in 2H12.
XMT-1107	oncology, multiple tumor types	Phase I	Outlicense Japanese Rights in 1H12.
Antibody Drug Conjugates	Oncology, multiple tumor types	Preclinical	Major collaborations with pharma in 2011/2012
Antibody Drug Conjugate	Oncology, multiple tumor types	Preclinical	In-license novel antibody technology in 2011/2012

SENIOR MANAGEMENT

Nick G. Bacopoulos, PhD, Chief Executive Officer • **Michael A. Metzger**, Chief Operating Officer • **Timothy B. Lowinger, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Boyd Clarke • **Nick G. Bacopoulos** • **Thomas Beck**, Fidelity Biosciences • **Joyce Tsang**, ProQuest Investments • **Martin Vogelbaum**, Rho Ventures

Metasignal Therapeutics Inc.

Presenting Company

Clinical Foci: Oncology, Drug Development, Drug Discovery

Dr. Jasbinder Sanghera

President & CEO

8880 Sidaway Road
Richmond, BC V6W 1G8
Canada

www.metasignal.ca

1-604-790-5623

Incorporated: 2010

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

MST 100 Program: Three lead candidate small molecule compounds in assessment to select optimum IND Candidate. To conclude within four months of securing CAD\$1.25 million financing and cGMP Pre-Clinical Studies to support an IND submission will begin.

MST 200 Program: Three lead candidate small molecule compounds in assessment to select optimum IND Candidate. To conclude within four months of securing CAD\$1.25 million financing and cGMP Pre-Clinical Studies to support an IND submission will begin.

Upcoming

One IND submission completed with US FDA 10 months after securing a CAD \$2.5 million investment. One or more IND Candidates will move to cGMP preclinical studies with \$1.25 million. First IND Candidate will be submitted to FDA with 2nd \$1.25 million.

Successful IND candidate will move to two Principal Investigator Phase I trials using the 3rd tranche of investment CAD \$3 - \$5.25 million to be completed within 24 to 36 months from the seed financing.

CORPORATE MISSION

MetaSignal Therapeutics Inc. is a private drug development company developing innovative targeted therapies to block metastasis and cancer cell survival. Cancer metastasis is the cause of mortality in 90% of cancer patient deaths. Currently marketed anticancer treatments and therapeutics do NOT specifically or adequately treat metastasis and cancer stem cell survival. MetaSignal develops drugs that address this unmet therapeutic need by targeting druggable cell surface enzyme proteins that are unique to the cancer stem cells that are normally resistant to current treatments and therapeutics. Metasignal's drug candidates kill these cancer stem cells that are the driving force for metastasis. Current data indicates that MetaSignal's therapies and drugs may have application in >10 different major cancers and that they may be used as monotherapy and combination therapy with cytotoxic agents and other cancer treatments. Presently MetaSignal has three drug development programs each targeting a separate mechanism of action of cancer stem cell survival. MetaSignal is seeking seed investment to advance the first small molecule lead compound in its Hypoxia program from its preclinical stage of development to a completed Phase I Clinical trial.

PROPRIETARY TECHNOLOGY

First-in-class small molecule compounds and antibody therapeutics targeted to block one or more of three driving forces of cancer cell metastasis and cancer cell survival. These driving forces are hypoxic environments created within primary tumors, altered cell metabolism of cancer stem cells, invasion/migration of tissues at remote sites from the primary tumor by cancer stem cells. Also biomarkers of these altered cellular metabolic states that are useful in patient selection for treatment with MetaSignal's therapies and for assessing the effects of the therapy during and after treatment of the patient.

CORPORATE ALLIANCES

SignalChem Pharmaceutical Ltd. for assessment and validation of biological targets, screening, assay reagent production, biomarker reagent production. Advinus Therapeutics Inc. for medicinal chemistry services, preclinical testing services, preparation and submission of IND. BC Cancer Agency service agreement for assay services. University of Florence for medicinal chemistry small molecule design. BC Cancer Agency, MD Anderson Cancer Centre, Ontario Cancer Research Institute for Phase I clinical trials.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
MST 100	Cancer	Lead Series	IND Candidate Selection
MST 200	Cancer	Lead Series	IND Candidate Selection

SENIOR MANAGEMENT

Dr. Jasbinder Sanghera, President & CEO • **Kevin McDuffie**, Chief Business Officer • **Dan DeBeyer**, Chief Operating Officer

FINANCING HISTORY

Investors: Dr. Jasbinder Sanghera (Founder) (20%) • Dr. Shoukat Dedhar (Founder) (20%) • Dr. Claudiu Supuran (Founder) (20%) • Mr. Jun Yan (Founder) (20%)

Mirna Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Ophthalmic, Skin/Dermatological

Paul Lammers, MD, MSc

President & CEO

2150 Woodward Street
Austin, TX 78744
USA

www.mirnatherapeutics.com

1-512-901-0900

Incorporated: 2007

Employees: 12

Ownership: Private

HIGHLIGHTS

Recent

August 2010: Mirna Therapeutics Announces USD \$10.3 million Award from the Cancer Prevention and Research Institute of Texas (CPRIT).

August 2011: Mirna completes USD \$1.5 million financing round.

July 2011: Mirna Therapeutics Announces Allowance of Multiple Patents

for Therapeutic Use of Tumor Suppressor miRNAs.

Upcoming

Selection of optimal systemic delivery technology by End of 2011, based on strong data out of the Company's delivery program for its miRNA mimics.

Initiation of IND-enabling tox program 4Q11.

IND filing late 2012.

CORPORATE MISSION

Mirna Therapeutics, Inc. (Mirna) is a biotechnology company founded in late 2007 as a spin-off from Asuragen Inc. and is located in Austin, Texas. Mirna is focused on the development of miRNA-directed therapeutics for the treatment of cancer and other diseases. Mirna is developing "MicroRNA Replacement Therapy" approaches which involves introducing microRNAs back into tumors to boost cellular tumor suppressor abilities, ultimately leading to cancer cell death and tumor shrinkage. For more information, visit www.mirnax.com.

PROPRIETARY TECHNOLOGY

Mirna is focused on the discovery and development of microRNA (miRNA) therapeutics called miRNA mimics. The Company possesses extensive research capabilities in the miRNA field, and has identified to date eight miRNA mimics as potential therapeutics against a wide range of cancer types.

CORPORATE ALLIANCES

Working with several top 10 pharmaceutical companies interested in testing the efficacy and safety of several of Mirna's miRNA mimic product candidates.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
miR-34a	Solid and hematological cancers	Optimized Lead	IND Submission late 2012

SENIOR MANAGEMENT

Paul Lammers, MD, MSc, President & CEO • **Lynne Hohlfeld**, Chief Financial Officer • **Ana Ward**, General Counsel • **David Brown, PhD**, Director • **Jay Stoudemire, PhD**, Director • **Andy Bader, PhD**, Other

BOARD OF DIRECTORS

Dr. Matt Winkler, CEO/CSO Asuragen • **Dr. Corey Goodman**, Partner, VenBio • **Dr. Chris Earl** • **Dr. Evan Melrose**, Partner, PTV Sciences • **Dr. Paul Lammers**, President & Chief Executive Officer

SCIENTIFIC ADVISORY BOARD

Dr. Daniel Von Hoff, TGen; US Oncology, University of Arizona, Scottsdale, AZ • **Dr. David Johnson**, UT Southwestern, Dallas, TX • **Dr. Steve McKnight**, UT Southwestern, Dallas, TX • **Dr. Frank Slack**, Yale University, New Haven, CT • **Dr. Arthur Krieg**, Entrepreneur in Residence, Atlas Ventures

FINANCING HISTORY

Round Date (Amount, US\$) • 08/01/2011 (1.50 million)

Mithridion, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS, Drug Development, Other

Trevor M Twose, BSc, PhD

Chief Executive Officer

505 Science Drive, Ste C
Madison, WI 53711
USA

www.mithridion.com

1-608-443-2430

Incorporated: 2004

Ownership: Private

HIGHLIGHTS

Recent

Completion of Phase Ib for MCD-386CR in 57 subjects; safety, tolerability, food-effect, pharmacokinetic, metabolism and cognition studies; proof-of-concept for sustained release; successful dose-ranging for low parasympathetic side-effect incidence.

Selection of MI-10-022 as a drug candidate; preparing for IND-enabling studies

Demonstrated disease-modifying potential. MCD-386 and MI-10-022 reduced hippocampal A-beta in transgenic Tg-2576 mice. Demonstrated potent anti-psychotic activity of MI-10-022. Orphan status for MCD-386 for Progressive Supranuclear Palsy (PSP).

Upcoming

Exploratory Phase II for MCD-386CR in PSP, Parkinson's disease dementia, Dementia with Lewy Bodies, Autosomal Dominant Inherited Alzheimer's. Acute, statistically powerful cross-over studies using specific neuropsych test and biomarker endpoints.

Corporate partnership and Series C funding

MI-10-022 into IND enabling studies.

CORPORATE MISSION

Mithridion, Inc. develops drugs for the unmet needs of serious CNS disorders, initially for neurodegenerative diseases (ND), which are multi-billion drug and market opportunities. Lead drug candidate MCD-386CR has completed Phase I clinical evaluations and is being prepared for exploratory Phase II proof-of-pharmacology trials. MCD-386CR is a controlled-release oral formulation of a small molecule NCE, potentially a first-in-class disease-modifying drug for ND and to treat memory/cognition impairment.

Drug candidate MI-10-022 is being prepared for IND-enabling studies. It is potentially a first-in-class single agent for schizophrenia (S) and ND, addressing cognition/memory, psychosis/behavior in S and ND and underlying disease processes in ND.

Mithridion has in house medicinal chemistry, neuropharmacology, PK/ADME and other preclinical development capabilities, and a virtual early clinical development capabilities.

Mithridion has demonstrated preclinical proof-of-concept of therapeutic potential for S and cognition/disease-modifying potential for ND of its drug leads in laboratory models, and has announced several exciting partnering opportunities created with our platform technology.

We aim to add great value in preclinical and clinical development, partnering drugs with major pharma or biotech companies at latest after demonstrating proof-of-concept in Phase II.

Mithridion is capital efficient. It has raised US\$8.6m to date from Rosetta Partners, Wisconsin Investment Partners, Venture Investors LLC, State of Wisconsin Investment Board (SWIB), Rocket Ventures.

PROPRIETARY TECHNOLOGY

Oral, small-molecule muscarinic receptor sub-type selective M1 agonists(MCD-386CR). M1 agonists improve cognition./memory and have potentially beneficial actions on several ND disease mechanisms, including Amyloid Protein Precursor/A-beta metabolism, Tau phosphorylation, GSKIII-beta inhibition, PKC activation and apoptosis - effectively several drug actions in one molecule.

Oral, small-molecule muscarinic receptor sub-type selective M1/M4 agonists (MI-10-022). Potent, powerful potential anti-psychotic actions by a novel mechanism driven by the M4 agonist activity. Also has all the actions of M1 agonists (above). Potential first-in-class.

Oral controlled-release tablet dosage forms.

Forte high-dose drug product options.

Transdermal dosage options.

PRODUCTS

Name	Indication	Phase	Milestone
MCD-386CR (oral controlled release)	Cognition, memory, disease-modification in neurodegenerative diseases	Phase I	Phase II
MCD-386CR	Cognition in schizophrenia	Preclinical	IND
MI-08-016 Series	MCD-386 follow-on	Preclinical	IND
MCD-386CR Forte (/glycopyrrolate combination)	Cognition, memory, disease-modification in neurodegenerative diseases	Preclinical	IND
MI-10-022	Cognition, primary, secondary symptoms in schizophrenia; cognition, memory, disease-modification in neurodegenerative diseases	Preclinical	IND

SENIOR MANAGEMENT

Trevor M Twose, BSc, PhD, Chief Executive Officer • Alex Kasper, Chief Financial Officer • Wayne Hoss, PhD, Director • Patti Twose, BSc, Chief Operating Officer • William S. Messer, Jr., PhD, Chief Scientific Officer • Richard Copp, PhD, Vice President

BOARD OF DIRECTORS

Trevor M Twose, BSc, PhD, Mithridion, Inc. • **Wayne P Hoss, PhD**, University of Toledo; Cognitive Pharmaceuticals Ltd • **John Neis**, Venture Investors LLC • **Paul Weiss, PhD, MBA**, Venture Investors LLC • **Frederick A. Robertson MD MBA**, Independent

SCIENTIFIC ADVISORY BOARD

William S. Messer, Jr., PhD, Professor, University of Toledo • **Franklin P. Bymaster**, Independent; Formerly with Eli Lilly

FINANCING HISTORY

Round Date (Amount, US\$) 02/01/2006 (2.20 million) • 01/09/2009 (5.20 million) • 01/06/2011 (1.30 million)

Molecular Templates, Inc.

Presenting Company

Clinical Foci: Biopharmaceuticals, Oncology, Hematology

Eric Poma

Chief Executive Officer

111 W. Cooperative Way
Georgetown, TX 78626
USA

www.moleculartemplates.com

1-512-930-0304

Incorporated: 2009

Ownership: Private

CORPORATE MISSION

Molecular Templates (MTEM) is a biopharmaceutical company focused on the development of a new class of biologics called Engineered Toxin Bodies (ETBs) for a variety of oncology indications. ETBs derive their biologically active properties from a toxin-based scaffold that possesses a differentiated mechanism of action over traditional antibody based or small molecule approaches. MTEM's lead ETB program is being developed for hematological cancer indications. The company plans to be in the clinic in the next 12-18 months.

CORPORATE ALLIANCES

ImClone/Lilly, Alnylam Pharmaceuticals, Memorial Sloan Kettering, NYU Cancer Institute

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
MT-3724	Hematological	Preclinical

SENIOR MANAGEMENT

Eric Poma, Chief Executive Officer • **Jason Kim**, Chief Financial Officer

Muscular Dystrophy Association

Presenting Company

Clinical Foci: Genetic Disorders, Drug Discovery, Drug Development

Gerald C. Weinberg

President & CEO

3300 E Sunrise Dr
Tucson, AZ 85718
USA

www.mdausa.org

1-520-615-6702

Incorporated: 1952

Ownership: Patient Advocacy Group

HIGHLIGHTS

Recent

Since initiating the MVP program in 2009, MVP has funded 15 projects. All but two of these projects have proceeded as planned, and the therapeutics are moving forwards in development.

With MVP funding, three potential therapeutics either have just entered the clinic for the first time, or will very soon.

CORPORATE MISSION

MDA Venture Philanthropy (MVP) is the Muscular Dystrophy Association's drug development program, which operates within MDA's Translational Research program. MVP is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases.

MVP does not provide traditional grants, but rather makes targeted investments in drug development for neuromuscular disease. Projects will be milestone-driven, contract-mediated and a return on investment will be negotiated. MVP utilizes a professional diligence process and is committed to a 16-week turnaround on investment decisions.

Investment Profile: MVP invests in small pharmaceutical and biotech companies and in academics developing treatments and therapies for neuromuscular diseases. Companies may be public or private, and MVP does not discriminate between US and international projects. MVP funds academic investigators doing appropriate studies but encourages corporate collaboration. MVP seeks to apply funding where it will achieve the greatest leverage to increase the number of effective drugs in development for neuromuscular diseases. As such, well-financed projects that will proceed without MVP investment may not be selected for funding.

SENIOR MANAGEMENT

Gerald C. Weinberg, President & CEO • **Valerie Cwik, MD**, Senior Vice President • **Sanjay Bidichandani, MBBS, PhD**, Vice President • **Jane Larkindale, DPhil**, Director • **Gerald C. Weinberg**, President & CEO • **Valerie Cwik, MD**, Senior Vice President • **Sanjay Bidichandani, MBBS, PhD**, Vice President • **Jane Larkindale, DPhil**, Director

BOARD OF DIRECTORS

R. Rodney Howell, MD • **Olin Morris** • **Lori West** • **Timmi Masters** • **Suzanne Lowden** • **Stanley Appel** • **Lous Kunkel** • **Christopher J Rosa** • **Charles D Schoor** • **Brad Henry**

SCIENTIFIC ADVISORY BOARD

Stanley Appel, Methodist Neurological Institute • **Cristina Csimma** • **Merit Cudkowicz**, Massachusetts General Hospital • **Kenneth Fischbeck**, National Institute of Neurological Disorders and Stroke • **Louis Kunkel**, Harvard Medical School • **Elizabeth McNally**, University of Chicago Medical School • **John Porter**, National Institute of Neurological Disorders and Stroke • **Jeffrey Rothstein**, Johns Hopkins School of Medicine • **Charles Thornton**, University of Rochester

MyeloRx LLC

Clinical Foci: Oncology, Hematology, AutoImmune

John H. Musser Chief Executive Officer

941 Railroad Avenue
Vallejo, CA 94592
USA

www.myelorex.com

1-650-759-3595

Incorporated: 2007

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

Awarded Fast Track SBIR contract from National Cancer Institute worth US\$2.0 million in September, 2009 to fund development of MRx102; Phase I and Phase II, Year 1 successfully completed; and Phase II, Year 2 initiated in March, 2011.

Allowance of MRx102 patent in the US and other patents in US, EU and China

Publication of paper in Nature Chemistry Biology on the target of triptolide in February, 2011 and publication of a paper describing MRx102 in the journal Leukemia in September, 2011 by members of the MD Anderson Cancer Center and MyeloRx

Upcoming

Complete all preclinical work in 2012 and file an IND
Additional funding via government sources

Generation of data demonstrating utility of MRx102 in combination with radiation as well as in models of melanoma

CORPORATE MISSION

MyeloRx LLC is a Northern California biotechnology company which develops drugs for oncology and immune-based diseases based on the natural product triptolide. Triptolide has been shown clinically active in acute leukemias as well as in immune-based diseases. As shown in a recent Nature Chemistry Biology paper triptolide binds to a protein termed XPB leading to an inhibition RNA polymerase II thereby affecting a number of cell signaling pathways. The nuclear excision repair (NER) pathway is also blocked leading to inhibition of DNA repair following damage caused by a variety of anti-cancer modalities including cisplatin treatment and perhaps radiation exposure as well. The lead compound, MRx102, is being developed initially for acute myeloid leukemia (AML) and is expected to be active in other leukemias including Gleevec-insensitive CML. Our clinical consultant, Dr. Michael Andreeff of the MD Anderson Cancer Center, found MRx102 effective in killing blast cells from AML patients as well as AML stem cells. Based on preliminary safety and efficacy studies MyeloRx was awarded a US\$2.0 million SBIR contract by the National Cancer Institute to develop MRx102 for AML. MRx102 also demonstrated significant activity in a variety of melanoma screens performed by the NCI and is undergoing tertiary testing by that organization as well as testing by investigators at UCSF Helen Diller Family Comprehensive Cancer Center. The company plans to have MRx102 enter clinical trials in AML patients in 2013. The second triptolide-based product in the pipeline is MRx109. It has demonstrated activity in a series of transplantation models performed in rodents and primates as well as in a rodent collagen arthritis model. It has undergone extensive toxicology studies in rodents and primates. The principals in the company have extensive experience in both large pharmaceutical companies (Pfizer, Wyeth, DuPont) as well as in the biotechnology industry (Cetus/Chiron, Glycomed, Pharmagenesis).

PROPRIETARY TECHNOLOGY

Three of the company principals have been working with triptolide for more than 15 years. They have a strong understanding of the structure-activity of the core compound and have developed five patent families consisting of numerous prodrugs and derivatives of triptolide which have been exclusively licensed to MyeloRx. They also have extensive manufacturing experience and have produced cGMP drug supply.

CORPORATE ALLIANCES

The company has an alliance with the MD Anderson Cancer Center as well as with a number of subcontractors which are performing IND-enabling R&D. It also has been awarded a Fast Track SBIR contract from the National Cancer Institute to fund development of MRx102.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
MRx102	Acute Myeloid Leukemia	Optimized Lead	Completed preclinical efficacy in AML models and pilot toxicology in rodents.
MRx109	Immune based diseases	Optimized Lead	Completed efficacy in organ transplantation and RA as well as pilot toxicology in rodents and monkeys.

SENIOR MANAGEMENT

John H. Musser, Chief Executive Officer • **John M. Fidler**, Vice President • **Jinhua An**, Vice President • **Neil R. Ackerman**, Vice President

SCIENTIFIC ADVISORY BOARD

Michael Andreeff, M.D., Ph.D., MD Anderson Cancer Center • **Adil Daud, M.D.**, UCSF Helen Diller Family Comprehensive Cancer Center • **Anne Welton, Ph.D.**, Consultant

FINANCING HISTORY

Investors: John H. Musser (25%) • John M. Fidler (25%) • Jinhua An (25%) • Neil R. Ackerman (25%)

Nanocarrier Co., Ltd.

Presenting Company

Clinical Foci: Drug Delivery, Drug Development, Biopharmaceuticals

Ichiro Nakatomi

President & CEO

Yaesu Yamagata Bldg.
Tokyo 103 0027
Japan

www.nanocarrier.co.jp

81-3-3548-0213

Tokyo: 4571

Incorporated: 1996

Employees: 40

Ownership: Public

HIGHLIGHTS

Recent

NanoCarrier has completed PI of DachPlatin Micelles in Europe and is looking for a development partner worldwide.

CORPORATE MISSION

NanoCarrier is a pharmaceutical company that focuses on development of drug delivery systems based on micellar technology. In addition to its proprietary drug delivery platform, NanoCarrier developed several products such as NK105, NC-6004, or NC-4016 that are in clinical development as far as PIII for treatment of different cancer indications. The company was founded in 1996 and is located in Tokyo, Japan.

In 2008 NanoCarrier was listed on Tokyo stock exchange. NanoCarrier's core technology, micellar nanoparticles technology, was proposed and has been researched by Professor Kazunori Kataoka of University of Tokyo, Professor Teruo Okano of Tokyo Women's Medical University. The aforementioned professors demonstrated that when drug-encapsulating micellar nanoparticles were intravenously administered, the micellar nanoparticles could function as stable drug carriers in the bloodstream and they accumulated in cancerous tissues. It is hoped that, if efficacy and safety of drugs are further improved by utilizing our technology, we will be able to contribute to the advance in medication of cancer and other intractable diseases.

NanoCarrier has been working on the design of advanced Biomaterials for drug delivery using its proprietary processes. NanoCarrier has more than 10-years of experience in the design and development of polymeric micellar drugs and a broad intellectual property position. NanoCarrier is consolidating its position as the leading pharmaceutical company focused on the application of polymeric micelle technology to drug development.

NanoCarrier's leading projects, includes a Paclitaxel (NK105), a Cisplatin-analogue (NC-6004) and a Dachplatin-analogue (NC-4016) formulations that are ongoing in clinical development. The pre-clinical development program includes an Epirubicin based formulation. Moreover the technology was used successfully with client's API to deliver different products that had low solubility or its use was limited by high toxicity.

PROPRIETARY TECHNOLOGY

NanoCarrier has three broad product technology platforms. First, NanoCarrier developed the NanoCap™ system to encapsulate Poorly Water-Soluble Drugs, such as Paclitaxel, for intravenous administration. Second, the MediCelle™ system provides a highly versatile technology that addresses Hydrophilic compounds, including peptides, proteins, metal-chelating conjugates, and genes, for incorporation in the polymeric micelles. Third, the NanoCoat™ system is designed to have specialized functionality on the surface of the micelles by attachment of a specific ligand.

Micellar nanoparticles are composed of biocompatible block copolymers, comprising of hydrophilic polyethylene glycol (PEG) and hydrophobic polyamino acids.

CORPORATE ALLIANCES

NK105 – Nippon Kayaku;

NC-6004 – Oriental Europharma;

NC-4016 – Self development/Partner identified for Japan, undisclosed;

NC-6300 – Japan partner identified, undisclosed;

Dozen of other undisclosed alliances were established mainly for the use of technology.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
NK105	Gastric Cancer	Phase II, IIa, IIb	Completed PII
NC-6004 Micelle	Pancreatic cancer	Phase II, IIa, IIb	Completed PI in EU
NC-4016 DachPlatin Micelle	Undisclosed	Phase I	Finished PI in EU
NC-6003 Epirubicin Micelle	Undisclosed	Preclinical	
Protein Micelles Delivery Platform	Hemophilia; others	Research	
siRNA Micelle Delivery Platform	Cancer	Research	

SENIOR MANAGEMENT


Ichiro Nakatomi, President & CEO • **Takuma Nakatsuka**, Chief Financial Officer • **Hiroyuki Hanada**, Chief Business Officer • **Yasuki Kato**, Chief Scientific Officer • **Okano Teruo**, Academic

BOARD OF DIRECTORS

Akira Ohashi

TRADING STATUS AS OF OCTOBER 5, 2011

TOKYO: 4571



Market Data

Current Price	22930.00
Currency	Japanese Yen
Net Change	-4.06
Volume	1,618
YTD % Change	0.81
52Wk Range	9,258.33–64100.00
Avg. Daily Volume (thousands)	5,391

First Call Data

Market Cap (MM)	5,133.7
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-2215.20
EPS (Last Fiscal Year)	-3354.08
Consensus Estimate (Y)	-2215.20
Consensus Recommend	--
Price/Sales	65.46

Shareholders

Institution

	<i> Holding %</i>
Siemens Kapitalanlagegesellschaft mbH	0.0%
Nikko Asset Management Co. Ltd.	0.0%
Nomura Asset Management Co., Ltd.	0.0%
--	--
--	--

Mutual Fund

	<i> Holding %</i>
Siemens Kapitalanlagegesellschaft mbH	0.0%
Nikko Asset Management Co. Ltd.	0.0%
Nomura Asset Management Co., Ltd.	0.0%
--	--
--	--

Source: Thomson Reuters

NeurogesX, Inc.

Clinical Foci: Biopharmaceuticals, Specialty Pharmaceutical, Neurology

Anthony DiTonno President & CEO

2215 Bridgepointe Parkway, Suite 200
San Mateo, CA 94404
USA

www.neurogesx.com

1-650-358-3300

NASDAQ: NGSX

Incorporated: 2000

Employees: 106

Ownership: Public

HIGHLIGHTS

Recent

Completed USD \$40 million financing comprised of \$20 million private placement to a group of institutional accredited investors and \$20 million loan with Hercules Technology Growth Capital.

Following FDA approval in November 2009, accelerating US launch of Qutenza® (capsaicin) 8% patch with dedicated sales force and established Medicare Part B / commercial payer coverage.

Completed enrollment in Phase 2 clinical study for NGX-1998, a topical formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN) and top-line data expected by year end 2011.

Upcoming

Report data from Phase 2 study of NGX-1998 by year end 2011.

FDA acceptance of sNDA for Qutenza, for the management of pain associated with HIV-associated neuropathy (HIV-AN).

Approval of Qutenza sNDA.

CORPORATE MISSION

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. NeurogesX has leveraged its passion for helping people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the US label for Qutenza for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN) also known as HIV-associated neuropathy (HIV-AN) and HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 clinical trials and patient enrollment has been completed in a Phase 2 clinical trial of NGX-1998 in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds, including a number of acetaminophen prodrugs. The Company has evaluated certain of these compounds in vitro and in vivo.

PROPRIETARY TECHNOLOGY

Qutenza (capsaicin) 8% patch: localized, dermal delivery system that contains prescription strength capsaicin, approved and commercially available in the United States and European Union. Qutenza is designed to reduce the pain associated with PHN or other peripheral neuropathic pain syndromes after a single one-hour administration.

NGX-1998: topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. Enrollment in the Phase 2 study has been completed and three Phase 1 studies were previously completed.

Acetaminophen Prodrugs and Opioid Analgesic Prodrugs: pre-clinical product pipeline evaluated in vitro and in vivo, for which NeurogesX seeking development partners.

CORPORATE ALLIANCES

June 2009: NeurogesX entered agreement with Astellas Pharma Europe Ltd., for commercialization of Qutenza in Europe, Middle East and Africa, including licensing option and development funding for NGX-1998. NeurogesX received two upfront payments, €30 million (~\$42 million USD) for Qutenza commercialization rights and €5 million (~\$7 million USD) for NGX-1998 option and Phase 2 development. In addition, NeurogesX is eligible to receive up to €70 million (~\$97 million) total potential milestone payments; and royalties based on double-digit percentage of Qutenza net sales. Astellas is responsible for funding and conducting post-marketing studies to support Qutenza EU marketing. If Astellas takes option for NGX-1998, the companies anticipate collaborating on Phase 3 clinical development.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Qutenza (capsaicin) 8% patch	Pain associated with postherpetic neuralgia	Cleared for US Marketing	sNDA filed for management of pain due to HIV-associated peripheral neuropathy (HIV-PN)
NGX-1998	Pain associated with postherpetic neuralgia	Phase II, Ila, IIb	Report data from Phase 2 study

SENIOR MANAGEMENT

Anthony DiTonno, President & CEO • **Stephen Ghiglieri**, Chief Financial Officer • **Jeffrey Tobias, MD**, Chief Medical Officer • **Michael Markels**, Business Development

BOARD OF DIRECTORS


Gary A. Lyons, Existing Director, Neurocrine Biosciences Inc. • **Jean-Jacques Bienaimé**, CEO, BioMarin • **Bradford Goodwin**, President and CEO, Keren Pharmaceutical • **Neil Kurtz, MD**, President & CEO, Golden Living • **Robert Nelsen**, ARCH Ventures • **Steven Nelson**, CEO, Western Region, UnitedHealthcare • **John Orwin**, CEO, Affymax, Inc. • **Anthony DiTonno**, CEO, NeurogesX

SCIENTIFIC ADVISORY BOARD

Allan I. Basbaum, PhD, Professor and Chair of the Department of Anatomy at the University of California, San Francisco • **Gary Bennett, PhD**, Faculty, Dept. of Anesthesia, McGill University; Director of Pain Research, Montreal General Hospital • **Robert Dworkin, PhD**, Professor of Anesthesiology, Neurology, Oncology and Psychiatry, University of Rochester Medical Center • **Nathaniel Katz, MD**, Adjunct Assistant Professor of Anesthesia, Tufts University School of Medicine • **Marco Pappagallo, MD**, Professor, Dept. of Anesthesiology and Pain Medicine; Director, pain medicine R&D, Mount Sinai School of Medicine

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: NGSX



Market Data

Current Price	0.78
Currency	US Dollar
Net Change	-2.50
Volume	38,400
YTD % Change	-0.88
52Wk Range	0.66–7.55
Avg. Daily Volume (thousands)	78,257

First Call Data

Market Cap (MM)	23.2
Short Interest Shares	411,912
Short Interest Ratio	10.38
PE (Trailing 12 Months)	-1.75
EPS (Last Fiscal Year)	-2.97
Consensus Estimate (Y)	-1.75
Consensus Recommend	-1.75
Price/Sales	2.30

Shareholders

<i>Institution</i>	<i> Holding %</i>
Wasatch Advisors, Inc.	18.8%
The Dow Chemical Co. Pension Fund	1.5%
Sphera Fund Management Ltd.	0.5%
Dimensional Fund Advisors, Inc.	0.5%
GRT Capital Partners LLC	0.5%
<i>Mutual Fund</i>	<i> Holding %</i>
Wasatch Advisors, Inc.	18.8%
The Dow Chemical Co. Pension Fund	1.5%
Sphera Fund Management Ltd.	0.5%
Dimensional Fund Advisors, Inc.	0.5%
GRT Capital Partners LLC	0.5%

Source: Thomson Reuters

OncoMed Pharmaceuticals, Inc.

BIO Member, BIO Board Member

Clinical Foci: Drug Development, Biopharmaceuticals

Paul J. Hastings

President & CEO

800 Chesapeake Drive
Redwood City, CA 94063
USA

www.oncomed.com

1-650-995-8200

Incorporated: 2004

Employees: 81

Ownership: Private

HIGHLIGHTS

Recent

April 2011: Initiate phase I for OMP-18R5, OncoMed's third clinical antibody and first targeting the Wnt pathway under the collaboration with Bayer. Milestone generated USD \$20 million payment.

Dec. 2010: Initiate phase I for OMP-59R5, OncoMed's second antibody to enter the clinic targeting the Notch pathway.

Dec. 2010: Third clinical candidate selected by GSK in the Notch pathway collaboration.

CORPORATE MISSION

OncoMed Pharmaceuticals is a clinical-stage biotechnology company dedicated to improving cancer treatment, by developing therapeutics that target the pathways critical to tumor initiating cells, also known as cancer stem cells. The company has leveraged its robust scientific platform to generate a rich pipeline of compounds inhibiting cancer stem cell proteins for the treatment of solid tumors. OncoMed's lead candidate, OMP-21M18, is currently in Phase 1 and Phase Ib clinical trials. In addition, OncoMed has initiated a clinical study for the company's second and third anti-cancer stem cell candidates, OMP-59R5 and OMP-18R5.

A leader in cancer stem cell research, OncoMed has established a library of antibodies targeting multiple cancer stem cell pathways for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers.

PROPRIETARY TECHNOLOGY

OncoMed utilizes proprietary tumor models created with human primary tumor xenografts. These models, developed under intellectual property licensed exclusively to OncoMed, are much more representative of human tumors than the cell line approach relied upon in traditional cancer research. Candidate therapeutics active against these primary human tumor xenografts are much more likely to also be effective against these tumors in the clinic. The ability to measure and purify tumor initiating cells has enabled OncoMed to assess the importance of specific target proteins implicated in human cancer and associated with biological pathways that regulate stem cell biology.

CORPORATE ALLIANCES

In December 2007, OncoMed and GlaxoSmithKline entered into a strategic where OncoMed is eligible to receive USD \$1.4 billion from GSK based on the achievement of specified discovery, development, regulatory and commercial milestones as well as double-digit royalties on all product sales.

In June of 2010, OncoMed entered into strategic alliance with Bayer Schering Pharma AG (BSP). BSP made an upfront payment of USD \$40 million to OncoMed and the company is eligible to receive milestone payments on up to five compounds. For each of three biotherapeutics, OncoMed is eligible for up to USD \$387.5 million, and for two small molecules up to \$112 million as well as double-digit royalties on net product sales.

PRODUCTS

Name	Indication	Phase
OMP-21M18	Anti-DLL4, Oncology	Phase I
OMP-59R5	Notch pathway, Oncology	Phase I
OMP-18R5	Wnt pathway, Oncology	Phase I
OMP-52M51	Notch pathway, Oncology	Preclinical

SENIOR MANAGEMENT

Paul J. Hastings, President & CEO • **John Lewicki, PhD**, Chief Scientific Officer • **Sunil Patel**, Senior Vice President • **Austin Gurney, PhD**, Senior Vice President • **Steven E. Benner, MD**, Chief Medical Officer • **Timothy Hoey**, Senior Vice President • **William D. Waddill**, Chief Financial Officer • **Michael Mulkerrin, PhD**, Vice President • **Jakob Dupont**, Vice President • **Alicia J. Hager, JD, PhD**, Vice President

BOARD OF DIRECTORS

James N. Woody, MD, PhD, Latterell Venture Partners • **James Broderick, MD**, Morgenthaler Partners • **Terry Gould**, Adam Street Partners • **Jack Lasersohn, JD**, Vertical Group • **Jonathan D. Root, MD**, US Venture Partners • **Paul J. Hastings**, OncoMed Pharmaceuticals, Inc. • **Laurence A. Lasky, PhD**, US Venture Partners • **Denise Pollard-Knight, PhD**, Phase4 Ventures Limited • **Deepa Pakianathan, PhD**, Delphi Ventures

FINANCING HISTORY

Round Date (Amount, US\$) 04/01/2006 (17.80 million) • 08/01/2006 (43.10 million) • 12/01/2008 (126.20 million)

Investors: US Venture Partners (16%) • Latterell Venture Partners (11%) • Verticle Fund (10%) • Morgenthaler Partners (10%) • Phase4 Ventures Limited (8%)

PharmaNeuroBoost NV

Presenting Company

Clinical Foci: CNS, Specialty Pharmaceutical, Biopharmaceuticals

Remi Van Den Broeck, MD, MSc

Chief Operating Officer

Alkerstraat 30a
3570 Alken
Belgium

www.pharmaneuroboost.com

32-473-861 079

Incorporated: 2006

Employees: 10

Ownership: Private

HIGHLIGHTS

Recent

February 2011: Grant US Composition of Matter Patent on PNB01, the Fixed Dose Combination (FDC) comprising 5-15 mg pipamperone and 10-40 mg citalopram.

March 2011: FDA Special Protocol Approval (SPA) of the Phase III PNB01-C301 Acute Efficacy Trial in Major Depression with agreement on the new primary end point Early and Sustained Response Rate (ESR) to demonstrate superiority over standard of care.

August 2011: Central IRB approval of the Phase III PNB01-C301 Clinical Trial in Major Depression

Upcoming

October 2012: First randomized patient in the Phase III PNB01-C301 Clinical Trial in Major Depression (n=555), a centrally randomized, double-blind, multicenter, 3-arm, fixed dose study with a 10-week treatment phase and 1-week safety follow-up.

December 2012: Expected Top Line Results of the Phase III PNB01-C301 Clinical Trial in Major Depression (n=555).

December 2012: Expected Top Line Results of the Phase IIa PNB02-C201 Clinical Trial in Schizophrenia with Residual Stage (n=60).

CORPORATE MISSION

PharmaNeuroBoost (PNB), founded in 2006 by Dr. Erik Buntinx, psychiatrist and inventor of PNB's technology, is a specialty biopharmaceutical company dedicated to developing best in class CNS therapeutics. As such, PNB is specialized in boosting current standard of care on major CNS disorders addressing high unmet medical needs.

PNB has brought two proprietary Fixed Dose Combinations (FDC) in late and mid clinical development stage: the antidepressant PNB01 in Phase III and the antipsychotic PNB02 in Phase IIa.

These two front-running projects result from discoveries made using PNB's unique IP platform claiming the use of high selective Serotonin 2A / Dopamine 4 receptor antagonists. In that respect, PNB has globally granted Composition of Matter (CoM) and use patents for the individual compounds in its pipeline.

The lead product PNB01, a novel antidepressant (AD) with an early and sustained response (ESR), has entered globally (US, Canada and Europe) phase III in August 2011 after FDA and IRB approval of the study protocol. This includes ESR as the new, unique primary end point demonstrating the superiority of PNB01 over standard of care. If successful, PNB01 would be the first AD claiming a faster antidepressant effect and addressing the unmet medical need of latency of response of current AD's.

PNB's second FDC product PNB02, has entered phase II in September 2011 and is targeted against the residual phase of schizophrenia, a high unmet medical need up until date.

PNB' Business Plan is oriented to collaborate with high value partners for co-development and/or commercialization of the late stage products. Like any drug development company, PharmaNeuroBoost needs to show the efficacy of its products. PNB faces the additional challenge of that need to demonstrate superiority over standard of care, rather than placebo. However, if PNB can achieve this, the PNB products could have a potential step up into a large and lucrative market.

PROPRIETARY TECHNOLOGY

The MOA of PNB's technology is based on the induction of a highly selective antagonism on the 5-HT_{2A} and D₄ receptors in the CNS resulting in a boosting effect on the efficacy of different standard of care CNS compounds by adding low dose pipamperone (5-15 mg/day).

PNB01 is the Fixed Dose Combination (FDC) with the SSRI citalopram. This generates additive and potentially synergistic antidepressant effects by restoring the dopamine-serotonin balance in the limbic system and cortical areas of the CNS, thus increasing both dopamine and serotonin tonus.

PNB02, the FDC with the atypical antipsychotic risperidone, mimics the receptor occupancy profile of the first in class antipsychotic clozapine, without the unwanted antagonism towards receptors responsible for important adverse events.

CORPORATE ALLIANCES

The PharmaNeuroBoost team is currently working with J&J to initiate and lead discussions with interested investors regarding a Development Stage Company focused on a mid stage Fast Dissociating D₂ Antagonist for the Treatment of Early Stage Schizophrenia.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PNB01	Major Depressive Disorder	Phase III	December 2012: Top Line Results of the first Phase III study PNB01-C301 (n=555) showing a superior Early and Sustained Response Rate over standard of care
PNB02	Schizophrenia, residual stage	Phase II, IIa, IIb	December 2012: Top Line Results of the Phase IIa study PNB02-C201 (n=60) showing a clinical relevant effect over standard of care.
PNB03	Parkinson Disease	Preclinical	Validation of the concept

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PNB04	Alzheimer Disease	Preclinical	Validation of the concept
PNB05	Obsessive-Compulsive Disorder	Preclinical	Results first Phase III study with PNB01 in Major Depression

SENIOR MANAGEMENT
Remi Van Den Broeck, MD, MSc , Chief Operating Officer • Ludo Haazen, MD, QPPV , Chief Medical Officer • Didier de Chaffoy, PhD , Chief Scientific Officer • Lieven Baert, PhD - MBA , Director • Philippe Lemmens, PhD , Director • Erik Buntinx, MD-Psychiatrist , Chief Operating Officer • Patricia Baede, PhD , Director • Arthur Noach, PhD , Director

BOARD OF DIRECTORS
Peter Verhaeghe, LL.M Harvard • Ruth Devenyns, KBC PE • Rudi Mariën, Biovest Life Science • Jos Sluys, Saffelberg Investments • Erik Buntinx, Anima bvba • Floris Vansina, KBC PE • Roger Pinder, Independent • John Fullen, Biopharma Investment Ltd.

SCIENTIFIC ADVISORY BOARD
Prof. Dr. Charles Nemeroff, MD, PhD , University of Miami • Prof. Dr. Thomas E. Schlaepfer, MD , University of Bonn and John Hopkins University, Baltimore • Prof. Dr. Alan F. Schatzberg, MD , Stanford University • Dr. Erik Buntinx, MD , Anima Research Centre - PharmaNeuroBoost

FINANCING HISTORY
<i>Round Date (Amount, US\$)</i> 01/12/2006 (2.70 million) • 01/10/2008 (8.78 million) • 09/28/2011 (23.52 million)
<i>Investors:</i> Saffelberg Investments/PNBSaffel NV (23%) • KBC PE NV (21%) • KBC ARKIV NV (7%) • Biovest Comm VA (20%) • Finanima GmbH (13%)

PLx Pharma, Inc.

BIO Member, Presenting Company

Clinical Foci: Cardiovascular Disease, Musculoskeletal, Drug Delivery

Ron Zimmerman

President & CEO

8285 El Rio, Suite 130
Houston, TX 77054
USA

www.plxpharma.com

1-713-842-1249

Incorporated: 2002

Ownership: Private

CORPORATE MISSION

PLx Pharma uses its proprietary PLxGuard technology to delivery GI safer formulations of drugs. The lead product is a GI safer aspirin formulation in late stage of development nearing an NDA submission. Another product with clinical data is a GI safer ibuprofen. Other GI safer NSAIDs are in the pipeline. These products are for OTC and Rx markets and include oral and parenteral dose forms.

PROPRIETARY TECHNOLOGY

The PLxGuard technology complexes a soy derived oil rich in phosphatidylcholine with an API to mitigate its GI toxicity.

CORPORATE ALLIANCES

Have licensed the PLxGuard technology for use by Cambrex Corporation and Tillotts Pharma for use with a 5-ASA mesalamine based product.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PL2200 Aspirin 325 mg	cardiovascular, antiplatelet agent, analgesic, anti-inflammatory, anti-pyretic and colorectal cancer prevention	Phase III	Preparing for NDA submission
PL 1200 Ibuprofen 200 mg - OTC	analgesic, anti-inflammatory, arthritis	Other	
PL1100 Ibuprofen - Rx	analgesic, anti-inflammatory, arthritis	Other	
PL4500 Indomethacin	patent ductus arteriosus, post operative pain	Preclinical	
Multiple NSAID-PC products	analgesic, anti-inflammatory	Preclinical	

SENIOR MANAGEMENT

Ron Zimmerman, President & CEO • **Gary Mossman**, Chief Operating Officer • **Upendra Marathi, PhD**, Senior Vice President • **Jason Moore, MS, MBA, RAC**, Vice President

BOARD OF DIRECTORS

David Anderson, formerly COO with Tanox • **Tim Black**, Partner with Integra Ventures • **David Jorden**, Director with Opexa Therapeutics and Cytomedix • **Lenard M. Lichtenberger, Ph.D.**, Professor with University of Texas Health Science Center at Houston, scientific founder of PLx • **Gary Mossman**, PLx • **Ron Zimmerman**, PLx • **Mike Valentino**, formerly CEO of Adams Respiratory and Xanodyne Phama and head of Novartis Consumer Health worldwide

SCIENTIFIC ADVISORY BOARD

Barry Marshall, MD, Nobel Laureate, Founder of Ondek Pharma • **Ferid Murad, MD, PhD**, Nobel Laureate, formerly VP of R&D Abbott Labs • **Haile Debas, MD**, Former Chancellor and Dean of the Medical School with UCSF • **Joe Wernicke, MD, PhD**, Senior Reseacher with Eli Lilly • **Brendan Whittle, PhD, DSc**, NSAID expert • **Kim Rainsford, PhD**, NSAID expert • **Susumu Okabe, PhD**, NSAID expert • **Tom Gutshall**, Cepheid Chairman of the Board, formerly with CV Therapeutics, Syntex and Mallinckrodt

ProNAi Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Biopharmaceuticals, Drug Development

Charlie Bisgaier

Chief Executive Officer

2725 S. Industrial Highway, Suite 200
Ann Arbor, MI 48104
USA

www.pronai.com

1-734-369-9953

Incorporated: 2004

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Clinical Progress: With approved IND by FDA, started Phase 1a trials in the US in 3Q10. To date, safely treated 16 patients with over 100x the starting dose.

Commercial Approach: Assembled an experienced pharma/biotech team, manufactured cost-effectively cGMP drug supply for Phase 1a study, and received newly granted patents from USPTO.

Capital Efficient: Raised USD \$20 million since inception from Apjohn Ventures & Angels (Series A, B, B-1) to bring an novel idea to a product to the clinic.

Upcoming

Clinical Safety: Completion of the Phase 1a study in a few months (4Q11/1Q12) with safety data (for novel drug/delivery), PK data, Biomarker data (bcl2 and immune markers), and Activity data showing signals of efficacy (images)

Clinical Efficacy: Conduct Phase 1b Trial (2012-2013) for safety & tolerability of PNT2258 in combination while exploring efficacy (~50 patients, 2-3 solid & liquid cancers); then Conduct POC Phase II Trial (2013-2014) in ~90 targeted cancer patients

Platform Validation: Work with strategic and non-profit industry partners to bring forward to the clinic the next cancer pipeline leads using novel DNAi oligos and novel liposome delivery

CORPORATE MISSION

ProNAi is a clinical stage cancer company with a novel approach to 'silencing' DNA of cancer causing genes. ProNAi's lead cancer drug can be used multiple cancers including melanoma, CLL, NHL, prostate, breast, and lung cancer. ProNAi is treating patients in a Phase 1a dose-escalating safety and tolerability study of PNT2258. PNT2258 is differentiated as an unmodified, short single-stranded bcl2 targeted DNA encapsulated in a SMARTICLE®, administered IV allowing long half-life and systemic delivery. PNT2258's safety and its ability to turn off oncogenes more upstream than RNAi, antisense, protein or small molecule targets, plus its single and combined agent synergy in four preclinical cancer models opens a potential treatment option for many refractory cancer patients. ProNAi is seeking venture capital and/or strategic partners to further develop PNT2258 and its pipeline.

PROPRIETARY TECHNOLOGY

ProNAi has discovered a new, patent-protected way to attack cancer and prolong survival by targeting sections of DNA of oncogenes (as opposed to antisense or RNAi that target mRNA) to silence cancer causing genes. ProNAi's first product candidate, PNT2258, is delivered IV and consists of the active ingredient PNT100, a 24-base, single-strand, chemically unmodified (natural phosphodiester backbone) oligonucleotide encapsulated in net-negatively charged SMARTICLES®. PNT2258 targets a well known and validated oncogene Bcl-2 involved in the apoptosis pathway. PNT2258 demonstrates potent single agent anti-tumor effects in multiple tumor types that express Bcl-2 and has striking synergistic activity in combination with Rituximab or Docetaxel in these refractory xenograft cancer models.

CORPORATE ALLIANCES

Marina/Novosom - Delivery Licensing Agreement.

PRODUCTS

Name	Indication	Phase	Milestone
PNT2258	Multiple Cancers (bcl-2 target)	Phase I	Completion of Safety & Tolerability in 4Q11.
PNT200	Multiple Cancers (c-myc target)	Preclinical	In-Vivo Efficacy Studies by 1H12.
PNT300	Multiple Cancers (k-ras target)	Preclinical	In-Vivo Efficacy Studies with Partner

SENIOR MANAGEMENT

Charlie Bisgaier, Chief Executive Officer • Wendi Rodriguez, Vice President • Christopher Whitehead, Manager

BOARD OF DIRECTORS

Don Parfet, Apjohn Ventures • Mina Sooch, Apjohn Ventures • Charlie Bisgaier, ProNAi CEO • Jack Luderer, Western Michigan University, Upjohn/Pfizer • Bob Forgey, Former COO, Monsanto/Pfizer • John Puisis, Tolera CEO, Third Wave

FINANCING HISTORY

Investors: Apjohn Ventures (20%) • Angels (50%) • Other/Management (30%)

Psyadon Pharmaceuticals, Inc.

Clinical Foci: CNS, Neurology, Drug Development

Richard E. Chipkin, PhD President & CEO

20451 Seneca Meadows Parkway
Germantown, MD 20876
USA

www.psyadonrx.com

1-301-919-2020

Incorporated: 2008

Employees: 1

Ownership: Private

HIGHLIGHTS

Recent

Completion of Safety, Tolerability and Pilot Activity Clinical Study of Ecopipam for the Treatment of Self-Injurious Behaviors in Patients with Lesch-Nyhan Disease.

Initiation of Phase 2 Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome.

Initiation of Phase 2 Clinical Trial of Ecopipam for the Treatment of Pathological Gambling.

Upcoming

Initiation of Phase 3 Clinical Trial of Ecopipam for the Treatment of the Self-Injurious Behavior Seen in Patients With Lesch-Nyhan Disease.

Completion of Phase 2 Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome.

Completion of Phase 2 Clinical Trial of Ecopipam for the Treatment of Pathological Gambling.

CORPORATE MISSION

Psyadon Pharmaceuticals, Inc. is a privately-held pharmaceutical company that develops drugs for the treatment of diseases afflicting the central nervous system. Our strategy is to license mechanism-specific drugs whose primary indication has not been identified, and to do targeted development programs to bring them to market. In particular, we focus on rare and orphan diseases. Psyadon Pharmaceuticals was founded in 2008 and is based in Germantown, Maryland. It receives financial support from New Enterprise Associates (Chevy Chase, MD) whose partner Dr. James Barrett acts as the Chairman of Psyadon's Board of Directors. For more information visit our Web site at www.psyadonrx.com.

PROPRIETARY TECHNOLOGY

Our first licensed compound is ecopipam. This is a novel drug that selectively antagonizes the one of the receptors for dopamine in the brain (the D1-receptor). Ecopipam has a very large clinical safety database and a complete NDA-ready pre-clinical package.

CORPORATE ALLIANCES

We currently have an alliance with the Tourette Syndrome Association who is collaborating with us on the development of ecopipam for the treatment of Tourette Syndrome.

PRODUCTS

Name	Indication	Phase	Milestone
Ecopipam	Treatment of Self-Injurious Behaviors in Patients with Lesch-Nyhan Disease	Phase III	Initiation of Phase 3
Ecopipam	Tourette's Syndrome	Phase II, IIa, IIb	Completion of On-Going Phase 2 Trial
Ecopipam	Pathological Gambling	Phase II, IIa, IIb	Completion of On-Going Phase 2 Trial
Ecopipam	Controlled Release Formulation	Phase I	Completion of On-Going Phase 1 Trial

SENIOR MANAGEMENT

Richard E. Chipkin, PhD, President & CEO • **Rudolf Kwan**, Other • **David Christ**, Other • **Rick Soltero**, Other • **Harold Amkraut**, Other

BOARD OF DIRECTORS

James Barrett, PhD, Partner, New Enterprise Associates • **Jeff Rothstein, MD, PhD**, Professor, Dept. Neurology, Johns Hopkins Medical School

FINANCING HISTORY

Round Date (Amount, US\$) 10/01/2008 (8,000,000.00 million)

Investors: New Enterprise Associates (NEA) (100%)

Rediens, Inc.

Clinical Foci: Musculoskeletal, Immunology, Biopharmaceuticals

Francois Binette <i>Chief Executive Officer</i> 868 Minnesota St., Suite #513 San Francisco, CA 94107 USA		1-415-404-6417	Incorporated: 2010 Employees: 1 Ownership: Private
--	--	----------------	--

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
API has nearly complete pre-clinical tox package supporting human clinical in different (topical) application. Data in animal models for pain and degenerative disc disease support both pain/function recovery and disease modification.	IND plan for Phase I/II will provide early proof of concept. The product will be tested in a dose escalation manner on clinical population in first trial.

CORPORATE MISSION

Rediens, Inc. is a San Francisco-based biotech company developing a novel therapeutic approach for the treatment of chronic back pain caused by degenerative disc disease. RED-101 is a first-in-class small molecule drug that antagonizes a master switch controlling inflammation and tissue turnover, the NF-kB transcription factor. The broad activity spectrum of RED-101 is expected to not only modulate pain and function, but also slow or reverse the disease process itself. RED-101 will be delivered by intra-discal injection, which will limit systemic exposure while enhancing local dose in a targeted image-based diagnostic patient population to maximize safety and effectiveness. Rediens is closing a large gap in the continuum of care for the majority of chronic back pain patients with no obvious anatomical deficiencies, addressing by far one of the largest healthcare market opportunity.

PROPRIETARY TECHNOLOGY

RED-101 acts on the NF-kB pathway, which is a master regulator of pain, inflammation, immunity and tissue remodeling. RED-101 is expected to clinically impact both mechanical and inflammatory pain, and suppress/reverse tissue damages resulting from over active inflammatory cytokines and degrading enzymes. Multiple actions on several biological pathways will result in profound effects and a broad therapeutic window of intervention, increasing its likelihood of clinical success.

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
RED-101	Chronic Back Pain	Preclinical	IND

SENIOR MANAGEMENT

Francois Binette, Chief Executive Officer • **Lars Boerger**, Business Development

BOARD OF DIRECTORS

Francois Binette, Rediens Inc

SCIENTIFIC ADVISORY BOARD

Prof. Koichi Masuda, MD, University of California San Diego Medical Center • **Prof. Jaro Karppinen, MD, PhD**, University of Oulu, Dept. of Physical Medicine and Rehabilitation, Finland

FINANCING HISTORY

Investors: Francois Binette (100%)

Relypsa, Inc.

BIO Member, Presenting Company

Clinical Foci: Renal, Cardiovascular Disease, Gastroenterology

Gerrit Klaerner, PhD

President

5301 Patrick Henry Drive
Santa Clara, CA 95054
USA

www.relypsa.com

1-408-200-9500

Incorporated: 2007

Employees: 45

Ownership: Private

HIGHLIGHTS

Recent

Positive data from an Phase 2 dose titration study of RLY5016 in patients with heart failure and CKD were presented at two medical conferences. The study showed that normal serum potassium levels could be maintained with few titrations required.

A Phase 2b study of RLY5016 was initiated to treat hyperkalemia in diabetic nephropathy patients with CKD. Up to 300 patients are being enrolled to assess the ability to reduce serum potassium levels in patients treated with RAAS inhibitors.

Upcoming

Complete enrollment of ongoing Phase 2b study in diabetic nephropathy/CKD patients and present data.

Initiate pivotal studies of RLY5016 for the treatment of hyperkalemia.

CORPORATE MISSION

Relypsa is a clinical-stage biopharmaceutical company that is leading the discovery and development of novel, non-absorbed, polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. Privately-held, Relypsa's investors include: OrbiMed Advisors, 5AM Ventures, Delphi Ventures, New Leaf Venture Partners, Sprout Group, Amgen and Mediphase Venture Partners.

PROPRIETARY TECHNOLOGY

Relypsa's current drug candidates are proprietary non-absorbed polymers, where the polymer itself provides the drug function. By binding specific biologic molecules, our polymeric drugs act locally in the gastrointestinal (GI) tract and clear these molecules from the human body through the digestive system. Relypsa's compounds are not systemically absorbed into the bloodstream, which limits side effects, if any, to the GI tract and hence potentially improved safety profiles. Therapeutic candidates are designed for enhanced ease of patient use and compliance.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
RLY5016	Hyperkalemia	Phase II, IIa, IIb	Positive data from Phase 2 trial recently reported. Phase 2b underway. Pivotal studies being planned for 2012.
RLY106	Bile Acid Sequestrant	Preclinical	Advancing toward IND

SENIOR MANAGEMENT

Gerrit Klaerner, PhD, President • **Jerry M. Buysse, PhD**, Chief Scientific Officer • **Ronald Krasnow**, General Counsel • **James A. Johnson**, Chief Financial Officer • **Claire Lockey**, Senior Vice President • **Wilhelm Stahl, PhD**, Senior Vice President • **I-Zu Huang, MD**, Vice President • **Klaus Veitinger, MD**, Consultant • **Mason Freeman, MD**, Consultant

BOARD OF DIRECTORS

Scott M. Rocklage, Ph.D., 5AM Ventures • **Gerrit Klaerner, PhD**, Relypsa • **Vijay Lathi**, New Leaf Venture Partners • **Jonathan T. Silverstein**, OrbiMed Advisors • **Deepa Pakianathan, PhD**, Delphi Ventures • **Thomas J. Schuetz, MD, PhD**, OrbiMed Advisors • **Klaus Veitinger, MD**, OrbiMed Advisors

SCIENTIFIC ADVISORY BOARD

Mason Freeman, MD, Massachusetts General Hospital, Harvard Medical School • **Bertram Pitt, MD**, University Of Michigan School Of Medicine • **George Bakris, MD**, University of Chicago Department of Medicine • **David A. Bushinsky, MD**, University of Rochester School of Medicine • **John Fordtran, MD**, Baylor University Medical Center • **Robert Alpern, MD**, Yale School of Medicine • **Sandra Coufal, MD**, Novartis Research Foundation • **Craig J. Hawker, PhD**, University of California, Santa Barbara

FINANCING HISTORY

Round Date (Amount, US\$) 10/01/2007 (43.00 million) • 09/01/2010 (70.00 million)

Rib-X Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease

Mark Leuchtenberger

Chief Executive Officer

300 George Street
New Haven, CT 06511
USA

www.rib-x.com

1-203-848-6260

Incorporated: 2001

Employees: 42

Ownership: Private

CORPORATE MISSION

Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company's Nobel Prize winning, innovative platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development.

PROPRIETARY TECHNOLOGY

The Company's key competitive advantage is its focus on the three-dimensional properties of antibiotics. Rib-X has proprietary understanding of the atomic-level details of the bacterial ribosome – the richest and best validated antibacterial target – and the ability to use those insights in the prospective design of next-generation and completely new antibiotics, two factors central to the discovery process. In addition to designing for greater target potency, Rib-X uses this structural information to design antibiotics with efficacy against highly-resistant Gram-positive and Gram-negative bacteria. Rib-X's unique approach has resulted in the development of a fully integrated, complementary pipeline of next generation compounds and novel classes of antibiotics to combat drug resistance.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Delafloxacin	ABSSSI, CAP/HAP, IAI	Phase II, IIa, IIb	
Radezolid	ABSSSI, Osteomyelitis, CAP	Phase II, IIa, IIb	
RX-04	Gram Negative Infections	Preclinical	Partnered
RX-05	Antibacterial	Research	
RX-06	Fungal Infections	Research	

SENIOR MANAGEMENT

Mark Leuchtenberger, Chief Executive Officer • **Bob Conerly**, Chief Financial Officer • **Jarrod Longcor**, Executive Vice President • **Erin Duffy**, Chief Scientific Officer

Rodman & Renshaw, LLC

Sponsor

Edward Rubin

Chief Executive Officer

1251 Avenue of the Americas
New York, NY 10020-1806
USA

www.rodman.com

1-212-356-0500

NASDAQ: RODM

Incorporated: 2003

Ownership: Public

CORPORATE MISSION

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

SENIOR MANAGEMENT


Edward Rubin, Chief Executive Officer • Anthony Sanfilippo, President • David J. Horin, Chief Financial Officer • Michael Vasinkevich, Partner • John J. Borer, III, Director • Ajay Sareen, Chief Operating Officer

BOARD OF DIRECTORS

Wesley K. Clark, Wesley K. Clark & Associates

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: RODM



Market Data

Current Price	0.86
Currency	U.S. Dollar
Net Change	-1.14
Volume	28,535
YTD % Change	-0.68
52Wk Range	0.82–3.33
Avg. Daily Volume (thousands)	113,698

First Call Data

Market Cap (MM)	29.9
Short Interest Shares	591,492
Short Interest Ratio	9.08
PE (Trailing 12 Months)	0.12
EPS (Last Fiscal Year)	-0.31
Consensus Estimate (Y)	0.12
Consensus Recommend	0.12
Price/Sales	0.35

Shareholders

Institution	Holding %
Sandler O'Neill Asset Management LLC	2.2%
CQS (UK) LLP	1.2%
Dimensional Fund Advisors, Inc.	1.1%
BlackRock Fund Advisors	0.6%
Ancora Advisors LLC	0.5%
<i>Mutual Fund</i>	
Sandler O'Neill Asset Management LLC	2.2%
CQS (UK) LLP	1.2%
Dimensional Fund Advisors, Inc.	1.1%
BlackRock Fund Advisors	0.6%
Ancora Advisors LLC	0.5%

Source: Thomson Reuters

Savara Inc.

Presenting Company

Clinical Foci: Pulmonary, Drug Development, Infectious Disease

Rob Neville

President & CEO

5900 Shepherd Mountain Cove #2-205
Austin, TX 78730
USA

www.savarapharma.com

1-512-970-4740

Incorporated: 2007

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

GMP manufacture complete. Release testing underway of lead product.

Multiple SBIR Grants

Upcoming

Phase 1 and proof-of-concept trial in CF patients this year

CORPORATE MISSION

Savara is an inhalation drug development company targeting niche therapeutic areas with high unmet medical need and high commercial opportunity.

The lead product addresses an unmet clinical need in the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in patients with cystic fibrosis (CF) and in other high risk patient populations. MRSA is a growing problem, with a six year reduction in life expectancy for infected CF patients and no suitable treatment. Savara's product is a high efficiency inhaled antibiotic powder administered using an easy-to-use capsule inhaler. The product is in preparation for its first human clinical trial.

The second product is a third-generation inhaled corticosteroid intended for the maintenance treatment of pediatric asthma, an underserved segment of the largest respiratory product category. The disease is inadequately controlled in the majority of asthmatic children, attributed largely to inefficient and inconvenient devices, such as nebulizers. The product uses an established corticosteroid drug delivered by a novel pediatric-friendly dry powder inhaler, which is designed to ensure delivery accuracy, patient compliance and convenience. The product is ready for its first human exploratory clinical trial.

PROPRIETARY TECHNOLOGY

Two pulmonary delivery platform technologies as follows:

1. NanoCluster – this technology utilizes nanotechnology to formulate small molecules and peptides into high performance inhalation powder without the need for novel excipients or carrier particles.
2. NanoNucleic – this technology provides a safe, simple, and effective method of delivering genetic material into lung cells. Our formulation consists of cell-penetrating-peptides containing genetic material, complexed with a simple condensing agent. This technology has been validated in vivo with pulmonary delivery with no cyto-toxicity at high levels of concentration.

CORPORATE ALLIANCES

Co-development partnership with top five pharmaceutical companies.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Dry Powder Pediatric Corticosteroid	Asthma	Phase II, IIa, IIb	Ready for Phase 2 Pilot trial
Inhaled Antibiotic	MRSA infections in CF	Phase I	GMP manufacture complete

SENIOR MANAGEMENT

Rob Neville, President & CEO • **Taneli Jouhikainen, MD, PhD, MBA**, Chief Operating Officer • **Chris Marich, MBA**, Chief Business Officer • **Cory Berkland, PhD**, Chief Technology Officer • **John Lord**, Other

BOARD OF DIRECTORS

Rob Neville, President & CEO, Savara Inc. • **Nevan Elam**, Former Head of Nektar Pulmonary • **Richard Benkendorf**, Co-founder and Managing Principal, Technology Impact Partners • **Rick Hawkins**, Founder, Former CEO, PPD

SCIENTIFIC ADVISORY BOARD

Dr. Elliott Dasenbrook • **Dr. Thomas Hofmann** • **Prof. Grant Waterer**

FINANCING HISTORY

Round Date (Amount, US\$) 12/01/2009 (3.30 million) • 05/31/2010 (2.90 million)

Sirius Genomics, Inc.

BIO Member, Presenting Company

Clinical Foci: Diagnostics, Pharmacogenetics, Genetic Disorders

Chris Wagner

President & CEO

603-1125 Howe Street
Vancouver, BC V6Z 2K8
Canada

www.siriusgenomics.com

1-604-484-7195

Incorporated: 2001

Employees: 9

Ownership: Private

HIGHLIGHTS

Recent

Series A2 financing completed in June 2011.
Validation study (phase III) initiated. n=3500.
(1000 APC treated patients and 2500 Non-APC treated controls).
Expected completion 1Q12.

Upcoming

Commercial launch in 2012.

CORPORATE MISSION

Sirius Genomics, Inc. is a private biotechnology company that develops companion diagnostics (CDx) for critical care medicine. The company's focus is on developing companion diagnostics for therapeutics, leading to better patient outcomes through personalized medicine. Currently, therapeutics follow a one-size-fits-all pattern. However, the inherent genetic differences between individuals can lead to low efficacy or adverse side effects for a drug, which can limit its clinical utility. Sirius addresses this problem by developing companion diagnostics which identify patient populations that will benefit the most from pharmaceutical therapeutics, enabling patients to get the right medication, doctors to more effectively treat the critically ill and, drug companies to fully realize the market potential for their therapeutics. By correlating patient genetics and other markers with clinical outcomes, Sirius' CDx products aim to enable more effective drug treatment.

Sirius Genomics is preparing for a 2012 market launch of a pharmacogenomic CDx for Xigris, a recombinant form of human activated protein C, sold by Eli Lilly for the treatment of severe sepsis, a systemic infection. Although Xigris is currently the only approved therapeutic for severe sepsis, its usage has been limited due to controversy surrounding its safety and efficacy. Sirius' Xigris CDx aims to genetically identify patients with a higher likelihood of survival after Xigris treatment and thus reduce the overall mortality of sepsis patients. The availability of such a predictive test has the potential to significantly increase Xigris utilization and revenues.

Sirius Genomics is seeking funding to commercialize its Xigris CDx, and advance the development of its pipeline, including a companion diagnostic for vasopressors. Vasopressors are used in a variety of critical care diseases.

PROPRIETARY TECHNOLOGY

Sirius Genomics' expertise lies in our ability to correlate genes to physical attributes. Specifically, we look at Single Nucleotide Polymorphisms (SNPs) within genes of interest to determine the phenotypes that are associated with the individual SNPs. In studying these correlations, we look for SNPs that function as biomarkers and are predictive of response to a drug. Linking these genetic correlations to clinical outcomes form the proprietary foundation for the companion diagnostics that Sirius Genomics develops. To date the company has filed 13 patent families and has a commercial assay ready for market launch.

CORPORATE ALLIANCES

Eli Lilly, Luminex, Specialty Pharmaceutical Company, UBC, Golden Helix, Genome BC.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
APC (Xigris) Companion Diagnostic	Severe Sepsis	Diagnostics	Validation Study Complete 1Q12; Assay Ready For Launch
Vasopressin Companion Diagnostic	Severe Sepeis	Diagnostics	Replication Study Complete
Anti TNF Companion Diagnostic	Severe Sepsis	Diagnostics	Replication Study Complete

SENIOR MANAGEMENT

Chris Wagner, President & CEO • **Alexandra Mancini**, Senior Vice President • **Celia Courchene**, Vice President • **Jennifer Kaufman-Shaw**, Vice President

BOARD OF DIRECTORS

James A. McEwen • **Patrick Terry** • **Heiner Dreismann** • **Jim Heppell** • **Amos Michelson** • **Bradley Popovich** • **Chris Wagner**

SCIENTIFIC ADVISORY BOARD

James Russell, University of British Columbia, St. Paul's Hospital • **Patrick Heagerty**, University of Washington • **Rob Belshaw**, Syreon Corp • **Nik Schork**, Scripps Genomic Medicine

Sorbent Therapeutics, Inc.

Presenting Company

Clinical Foci: Cardiovascular Disease, Renal, Metabolic Disease

Detlef Albrecht, MD

Chief Business Officer

710 Lakeway Dr. Ste 290
Sunnyvale, CA 94085
USA

www.sorbent.com

1-408-738-8240

Incorporated: 2006

Employees: 4

Ownership: Private

CORPORATE MISSION

Sorbent is a private, venture capital backed company in the Silicon Valley in California. Sorbent is developing polymeric drugs for the treatment of patients with congestive heart failure (CHF), chronic kidney disease (CKD; including dialysis) and hypertension. The company is run by a group of experienced biotechnology executives and drug developers.

The company's lead drug candidate, CLP1001, is a superabsorbent polymer that binds potassium (K), sodium (Na) and fluid and removes them through the gastrointestinal (GI) tract, effectively providing a kidney-independent mechanism for removing ions and fluid from the body. CLP1001 is currently in a 100 patient Phase 2a clinical trial in congestive heart failure CHF patients with concomitant CKD. Specifically, the study is assessing the ability of CLP1001 to prevent hyperkalemia and to improve symptoms caused by Na and fluid imbalances.

Renin-angiotensin-aldosterone system (RAAS) blocker, such as ACE inhibitors, ARBs and aldosterone antagonists (AAs), are prescribed for CHF to reduce mortality and hospitalizations. However, RAAS blockers, especially AAs lead to retention of potassium and increase the risk of hyperkalemia, especially in patients who have CKD, diabetes or are older. This leads many physicians to reduce RAAS blocker doses to sub-optimal levels, or to not prescribe these important life-saving drugs at all. In addition, CHF patients are frequently hospitalized due to dietary sodium related fluid overload, in spite of using high doses of diuretics. Through its effects on potassium, sodium and fluid, CLP1001 is expected to allow the optimization of RAAS blockers and to improve subjective symptoms and exercise capacity in CHF patients with CKD.

PROPRIETARY TECHNOLOGY

CLP is a platform technology based on a superabsorbent polymer that is orally administered, non-absorbed, and removes targeted cations from the GI tract. CLP1001 is a potent K and Na/fluid binder. In Phase 1 studies in dialysis patients, CLP1001 was shown to remove clinically significant amounts of K, Na, fluid and to lower serum potassium, body weight and blood pressure. Tolerability is excellent with no inherent taste or odor.

CORPORATE ALLIANCES

Currently exploring partnering opportunities.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
CLP1001	Ion and fluid balance management in Congestive Heart Failure with concomitant Chronic Kidney Disease	Phase II, IIa, IIb	Phase IIa data at December 2011
CLP1004	Hyperkalemia in Dialysis patients	Phase II, IIa, IIb	Trial not yet started
CLP1001	Hyperkalemia and interdialytic weight management in Dialysis patients	Phase II, IIa, IIb	Trial not yet started

SENIOR MANAGEMENT

Detlef Albrecht, MD, Chief Business Officer • **Linda Ara**, Chief Financial Officer • **Linda De Young, PhD**, Senior Vice President • **Giovanni Ferrara, MBA**, Business Development • **Philip Sager, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Detlef Albrecht, MD, Sorbent Therapeutics • **David Collier, MD**, CMEA Ventures • **Markus Goebel, MD PhD**, Novartis Venture Funds • **Jim Healy, MD PhD**, Sofinnova Ventures • **Donald Joseph**, Founder • **Scott Minick, MBA**, ARCH Venture Partners

SCIENTIFIC ADVISORY BOARD

Maria Rosa Costanza, MD, Midwest Heart Institute • **Lee Henderson, MD**, Founder • **Thomas Heywood, MD**, University of California, San Diego • **Barry Massie, MD**, University of California, San Francisco

FINANCING HISTORY

Round Date (Amount, US\$) 01/03/2006 (14.30 million) • 06/14/2011 (36.00 million)

Spinifex Pharmaceuticals Pty. Ltd.

Presenting Company

Clinical Foci: Neurology, CNS

Tom McCarthy

Chief Executive Officer

South Yarra Corporate Centre, Suite T18,
Level 1, 122 Toorak Rd, South Yarra
Melbourne, VIC 3141
Australia

www.spinifexpharma.com.au

61-3-99381205

Incorporated: 2005

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

Close of AUD \$ 18.25 million Series B round, which allows the company to complete our initial three Phase 2 studies on EMA401.
Completion of the EMA401 Phase 1 program under an IND with US FDA. Safety database of 118 healthy volunteers.

Upcoming

First patient first dose in the initial EMA401 Phase 2 study in post herpetic neuralgia patients (September 2011).

Initiation of two further Phase 2 clinical trials of EMA401 in (i) patients with pain and hypersensitivity following cancer chemotherapy and (ii) patients with pain and hypersensitivity following peripheral nerve injury (4Q11-1Q12).

Publication of the inventor's and KOL's foundational non-clinical data establishing that blockade of the AT2 receptor is an attractive target for the treatment of chronic pain (2H11-1H12).

CORPORATE MISSION

Spinifex Pharmaceuticals is a pain drug development company focused on taking innovative new pain treatments from discovery through to clinical proof of concept.

PROPRIETARY TECHNOLOGY

EMA401 is an orally bioavailable, first in class potential treatment for neuropathic and inflammatory pain and related disorders.

PRODUCTS

Name	Indication	Phase	Milestone
EMA401	Neuropathic pain, inflammatory pain and related neurological disorders	Phase II, IIa, IIb	Phase 1 studies completed under a US FDA IND

SENIOR MANAGEMENT

Tom McCarthy, Chief Executive Officer • **Geoff Kitson**, Chief Medical Officer • **Nuket Desem**, Vice President

BOARD OF DIRECTORS

Andrew Baker, GBS Venture Partners • **Tom McCarthy**, Managing Director • **Eliot Forster**, Independent Non-Executive Director • **Josh Funder**, GBS Venture Partners • **Chris Nave**, Brandon Capital Partners • **John Kurek**, Uniseed

SCIENTIFIC ADVISORY BOARD

Chas Bountra, Oxford University • **Praveen Anand**, Hammersmith Hospital and Imperial College London • **Andrew Rice**, Chelsea and Westminster Hospital and Imperial College London • **Alan Naylor**, Drug Discovery/Medicinal Chemistry Consultant

FINANCING HISTORY

Round Date (Amount, US\$) 03/01/2006 (4.00 million) • 08/01/2011 (18.25 million)

Investors: GBS Venture Partners (65%) • Brandon Capital Partners (19%) • Uniseed (8%) • UniQuest (8%)

STATegics, Inc.

Clinical Foci: CNS, Hematology

Juha Punnonen, MD, PhD Chief Executive Officer

1455 Adams Dr.
Menlo Park, CA 94025
USA

www.stategics.com

1-650-804-2051

Incorporated: 2007

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

STATegics announced on 08/02/11 that the Friedreich's Ataxia Research Alliance (FARA) awarded the Company USD \$152,690 to advance its proprietary small molecule erythropoietin mimetic compounds for the treatment of Friedreich's ataxia (FRDA).

STATegics presented positive preclinical results for its proprietary erythropoietin mimetic, STS-E15, at the American Academy of Neurology (AAN) 63rd Annual Meeting on April 12, 2011.

STATegics announced on 11/16/10 that the Department of Defense awarded the Company USD \$1.7 million to advance its proprietary small molecule mimetics of erythropoietin for the treatment of traumatic brain injury.

CORPORATE MISSION

STATegics, Inc. is focused on the discovery and development of orally available cytokine receptor modulators acting through novel, allosteric sites. STATegics' small molecules, Allomimetics, offer unique competitive advantages when compared to recombinant proteins particularly when bioavailability in the central nervous system (CNS) is required.

STATegics has identified small molecule erythropoietin (EPO) Allomimetics with demonstrated activities in several cellular models of neurological diseases and penetrance into the CNS. Extensive prior literature on recombinant human (rh) EPO in preclinical and clinical settings has validated EPO as a target in several neurological diseases, while STATegics has focused on Friedreich's ataxia and Parkinson's disease. The company has also identified a proprietary thrombopoietin (TPO) Allomimetic that demonstrates best-in-class properties, including improved solubility and potency in vitro when compared to GlaxoSmithKline's (GSK) Promacta®, the first orally available cytokine mimetic on the market.

STATegics' initial focus for clinical development is in Friedreich's ataxia, a debilitating neurodegenerative disease that affects approximately 6,000-10,000 patients in the USA. In Friedreich's ataxia, clinically meaningful results can be obtained in early Phase I trials based on analysis of frataxin levels, reduced expression of which is the underlying cause of the disease. Additional opportunities exist in neurological diseases with significant unmet needs, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, depression and peripheral neuropathy. TPO Allomimetics have broad applicability in treating thrombocytopenias associated with for example cancer chemotherapy, immune thrombocytopenic purpura or chronic liver diseases. In addition, the direct anti-proliferative effect of the TPO Allomimetic on leukemic cells has opened the opportunity in the treatment of bone marrow malignancies.

PROPRIETARY TECHNOLOGY

STATegics has identified proprietary small molecule product candidates for CNS diseases, acute myeloid leukemia and thrombocytopenia. In addition, the company has demonstrated a proof-of-concept for a platform approach to screen for novel small molecule compounds specific for other cytokine receptors with major clinical and commercial interests.

CORPORATE ALLIANCES

STATegics is collaborating with Friedreich's Ataxia Research Alliance (FARA) and Department of Defense to advance its EPO Allomimetic for the treatment of Friedreich's ataxia and traumatic brain injury, respectively. The programs are supported with approximately USD \$2 million in grant funding. The company is seeking additional investments and partnerships to advance EPO Allomimetic to clinical studies in Friedreich's ataxia, and to facilitate the technology development and partnering efforts for TPO Allomimetic.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
STS-E15	Friedreich's ataxia, Parkinson's disease	Preclinical
STS-E206	Traumatic brain injury, stroke	Preclinical
STS-T4	Thrombocytopenia, hematological malignancies	Preclinical

SENIOR MANAGEMENT

Juha Punnonen, MD, PhD, Chief Executive Officer • **Jeffrey R. Spencer, PhD**, Senior Vice President

BOARD OF DIRECTORS

Juha Punnonen, MD, PhD, STATegics • **Jeffrey R. Spencer, PhD**, STATegics

Susavion Biosciences, Inc.

Clinical Foci: Infectious Disease, Oncology, Immunology

Gregory R. Wolfe, PhD
Chief Executive Officer

1615 W. University Drive
Tempe, AZ 85281
USA

www.susavion.com

1-480-921-3795

Incorporated: 2006

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

Completed funding round in August 2011 for commencement of preclinical studies.

Awarded Qualifying Therapeutic Discovery Project grant, November 2010.

Eggink LL, Salas M, Hanson CV, Hooper JK., 2010, Peptide sugar mimetics prevent HIV type 1 replication in peripheral blood mononuclear cells in the presence of HIV-positive antiserum. AIDS Research and Human Retroviruses 26:149-160.

CORPORATE MISSION

Susavion Biosciences, Inc., has a robust platform to identify novel peptidic drugs that trigger activation of several types of immune effector cells. Susavion's current focus is on infectious diseases. Susavion's lead peptide, SVH1C, is effective at sub-nanomolar concentrations to neutralize HIV-1 in cultures of peripheral blood mononuclear cells in the presence of serum from HIV-positive patients. This peptide is currently moving through the preclinical IND stage. SVL4, another peptide in our pipeline, significantly extends life when administered in conjunction with low doses of radiation in a glioblastoma mouse model system. The peptides have shown no toxicity in rats at 1000-fold greater doses than anticipated for therapeutic use. Additional peptides in our pipeline show potential in diabetic wound healing. These drugs have promise as biological response modifiers and should strongly enhance the immune defense in treatment of viral infections and cancer.

PROPRIETARY TECHNOLOGY

Susavion's platform identifies peptidic drugs that are predicted to engage cell surface receptors. The peptides are designed by computational modeling of binding to receptor analogs and validated by direct binding assays. Ability of the peptides to activate several types of cells provides a valuable approach to enhancing an immune response.

CORPORATE ALLIANCES

Susavion has engaged Russell W. Blacher, Biopharmaceutical Development Consulting to guide the path to the FDA for IND status. Secondly, he has contracted with Jeffrey Miller, JP Miller Associates, a regulatory expert, and Brian Rogers, Pacific BioDevelopment LLC, for toxicology review.

Peptide synthesis is contracted to CBL Biopharma LLC, Patras, Greece.

Viral replication assays are contracted in collaboration with the California Department of Public Health, Viral & Rickettsial Disease Laboratory.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
SVH1C	Infectious diseases	Preclinical
SVL4	Oncology	Preclinical
SV6C	Infectious diseases	Preclinical
SVC2	Infectious diseases	Preclinical
SV6B	Infectious diseases	Preclinical
SV6D	Wound healing	Research
SVH1B	Wound healing	Research
SVD2	Autoimmune diseases	Research

SENIOR MANAGEMENT

Gregory R. Wolfe, PhD, Chief Executive Officer • **Laura L. Eggink, PhD**, President • **J. Kenneth Hooper, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Gregory R. Wolfe, PhD, CEO, Susavion Biosciences, Inc. • **Laura L. Eggink, PhD**, President, Susavion Biosciences, Inc. • **J. Kenneth Hooper, PhD**, Chief Scientific Officer, Susavion Biosciences, Inc.

SCIENTIFIC ADVISORY BOARD

Russell W. Blacher, Biopharmaceutical Development Consulting • **Brian C. Rogers, PhD**, Pacific Biodevelopment LLC, Toxicology • **Jeffrey P. Miller**, JP Miller Associates: Regulatory Affairs and Compliance

FINANCING HISTORY

Round Date (Amount, US\$) 08/01/2011 (1.30 million)

Investors: Richard Rockefeller, MD (4%) • Pamela Omidyar, MS (6%) • J. Kenneth Hooper, PhD (50%) • Laura Eggink, PhD (20%) • Gregory Wolfe, PhD (20%)

Syndax Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology

Joanna Horobin, MD President & CEO

460 Totten Pond Road
Waltham, MA 02451
USA

www.syndax.com

1-781-419-1400

Incorporated: 2005

Employees: 12

Ownership: Private

CORPORATE MISSION

Syndax Pharmaceuticals Inc. is a late-stage epigenetics oncology company focused on mechanisms of drug resistance in solid tumors with worldwide rights to entinostat. Syndax was founded in 2005 by Eckard Weber, MD, Domain Associates, and Ron Evans, PhD, Salk Institute.

PROPRIETARY TECHNOLOGY

We recently completed a randomized, placebo-controlled phase 2 trial evaluating entinostat with Aromasin® in patients with advanced/metastatic breast cancer, hitting the primary endpoint of an improvement in progression-free survival (PFS) and are moving that program into phase 3 testing. Also, results from a placebo controlled, randomized phase 2 study showed a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. In collaboration with investigators at Johns Hopkins University and the NCI, Phase 2 'double' epigenetic clinical studies are being conducted with entinostat and the DNA methyltransferase inhibitor, Vidaza® in solid tumors, based on the objective clinical responses previously reported in a lung

CORPORATE ALLIANCES

Syndax is seeking development and marketing partners. The company is also interested in corporate collaborations involving synergistic combinations with approved products with significant commercial potential.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Entinostat	Oncology	Phase III

SENIOR MANAGEMENT

Joanna Horobin, MD, President & CEO • **Bob Goodenow, PhD**, Chief Business Officer • **Miranda Rees**, Vice President • **William McCulloch, MB, ChB, FRCP, FFPM**, Chief Medical Officer • **Caryn Peterson**, Vice President

BOARD OF DIRECTORS

Dennis Podlesak, Domain Associates • **Kim Kamdar, PhD**, Domain Associates • **Steven St. Peter, MD**, MPM Capital • **Rosina Maar Pavia**, Pappas Ventures • **Joanna Horobin**, Syndax • **Arlene morris**, Independent

SCIENTIFIC ADVISORY BOARD

Gail Eckhardt, MD, University of Colorado • **Jean-Pierre Issa, MD**, MD Anderson Cancer Center • **Edward Sausville, MD, PhD**, University of Maryland • **George W Sledge, MD**, Indiana University • **Stephen Baylin, MD**, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

FINANCING HISTORY

Round Date (Amount, US\$) 04/15/2007 (49.00 million) • 07/01/2010 (6.00 million)

Investors: Domain Associates (0%) • MPM Capital (0%) • Pappas Ventures (0%) • Forward Ventures (0%) • Avalon Ventures (0%)

SynTara LLC

Presenting Company

Clinical Foci: Vaccines, Drug Delivery, Oncology

Sterling C. Johnson <i>Chairman</i> 7117 Rockrose Terrace Carlsbad, CA 92011 USA			www.syntara.com 1-760-804-0114	Incorporated: 2010 Ownership: Private
---	--	--	--	--

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
Formation of SynTara LLC by Midatech Ltd. and Immunotope, Inc. in July 2010. Launch of SynTara at BioPharm America 2011 meeting in Boston with announcement of lung cancer progress.	POC Studies to validate the selected lung cancer antigens can be efficiently and effectively delivered with nanoparticle technology.

CORPORATE MISSION
<p>SynTara is a joint venture between Immunotope, Inc. and Midatech Ltd. with the first and possibly only company with a comprehensive CTL (cytotoxic T-lymphocyte) based vaccine. The CTL antigens have been selected and validated for the first project, a lung cancer immunotherapeutic vaccine. These antigens are combined with a delivery system that specifically targets dendritic cells and delivers both antigens and adjuvants for efficient activation of cancer specific CTL. Immunotope is the source of validated antigens and is a clinical stage biotechnology company developing immunotherapy products for the treatment and prevention of cancer and chronic viral infections. Its products activate the patient's own immune system to fight disease and prevent recurrence. This comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Immunotope's immunoproteomics antigen discovery platform identifies comprehensive antigenic signatures consisting of peptides and parent proteins from tumor pathways that are critical for the development of immunotherapeutic vaccines and antibody therapeutics.</p> <p>Midatech is at the forefront of designing, developing, synthesizing and manufacturing nanomedicines based on its proprietary, self-assembling biocompatible nanoparticle technology. The company has successfully employed its nanotechnology platform and know-how to transition discovery and engineering sciences to practical nanomedicine applications through in-house and partnered drug development programs. Midatech's unique nanoparticles allow rapid targeting of drugs or drug combinations to specific tissues or cells as well as potentially enabling transport across the blood brain barrier. In the field of diabetes Midatech's program to deliver nanoparticle insulin via transbuccal delivery using the technology of MonoSol Rx will enter the clinic later in 2011.</p>

PROPRIETARY TECHNOLOGY
<p>Immunotope's immunoproteomics antigen discovery platform identifies comprehensive antigenic signatures consisting of peptides and parent proteins from tumor pathways that are critical for the development of immunotherapeutic vaccines and antibody therapeutics. Antigen discovery is based on three different strategies:</p> <ol style="list-style-type: none"> 1) MHC class I-processed proteins; 2) Proteins that generate autoantibodies in patients with cancer 3) Glycoproteins with cancer specific aberrant glycosylation. <p>Midatech provides to SynTara the gold-core glyconanoparticles (GNP) for delivery of the selected antigens.</p>

CORPORATE ALLIANCES
<p>SynTara is still at an early stage but has demonstrated preliminary POM and POC in its lung cancer program. Alliances will be forthcoming once POC in man is demonstrated in 2012.</p>

PRODUCTS		
<i>Name</i>	<i>Indication</i>	<i>Phase</i>
No Trade Name	Lung cancer	Optimized Lead
No Trade Name	Pancreatic Cancer	Lead Series

SENIOR MANAGEMENT
<p>Sterling C. Johnson, Chairman • Ramila Philip, PhD, Chief Scientific Officer • Mohan Philip, PhD, MBA, Chief Financial Officer • Professor Thomas Rademacher, Chief Technology Officer</p>

BOARD OF DIRECTORS
<p>Sterling C. Johnson, Midatech • Thomas Rademacher, PhD, Midatech • Ramila Philip, PhD, Immunotope • Mohan Philip, PhD, Immunotope</p>

FINANCING HISTORY
<p><i>Investors:</i> Immunotope, Inc. (50%) • Midatech Ltd. (50%)</p>

Syntaxin Limited

Presenting Company

Clinical Foci: Biopharmaceuticals, Oncology, Drug Development

Dr. Melanie Lee

Chief Executive Officer

Units 4 The Quadrant, Barton Lane
Abingdon
OX14 3YS
United Kingdom

www.syntaxin.com

44-1235-552112

Incorporated: 2006

Employees: 40

Ownership: Private

HIGHLIGHTS

Recent

11 November 2010: Syntaxin Raises £18 million in New Financing.

02 March 2011: Syntaxin announces its partner Allergan enters Phase II trials with Re-Targeted Endopeptidase Drug.

11 May 2011: Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V.

CORPORATE MISSION

The company discovers and develops a new class of biopharmaceuticals, termed Targeted Secretion Inhibitors (TSI), which treat disease through selective inhibition of cell secretory processes. It is backed by a blue chip investor base including: Abingworth, Lundbeckfond Ventures, LSP, Ipsen, JJDC, Quest, Seventure, and SR One. In November 2011, the company raised £18m in a series C financing.

Syntaxin's Targeted Secretion Inhibitor (TSI) platform enables the design and development of therapeutics for treating diseases where inappropriate cell secretion is a primary cause. The TSI molecules selectively bind to targeted cells to prevent secretion, can be administered locally or systemically, and offer the potential of long duration of action from a single dose (from weeks to months). The technology platform has the potential for developing new treatments across multiple disease areas. These include CNS disorders such as neuropathic pain, endocrine disorders such as acromegaly, and certain types of cancers.

Syntaxin's Executive Management brings a wealth of industry experience to the company. Chief Executive Officer, Dr. Melanie Lee, spent a decade in research with GlaxoSmithKline and subsequently held leadership positions at Celltech and UCB. Chief Business Officer, Dr. Nigel Clark, was formerly Vice President Business Development with Vernalis and has a strong track record in building strategic alliances. Dr. John Court, Chief Development Officer, was previously founder and CEO of Fulcrum Pharma, an international contract drug development business, following R&D roles at Roche and Wellcome.

Syntaxin Chairman Dr. Russell Greig has over 30 years experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. Prior to joining the company, Dr. Greig was President of SR One, GSK's Corporate Venture Group.

PROPRIETARY TECHNOLOGY

Syntaxin's drugs exploit the natural pharmacology of botulinum neurotoxins. The botulinum neurotoxins are potent inhibitors of the vesicular secretion of neurotransmitters from peripheral nerves, particularly acetylcholine at the neuromuscular junction. The result is profound muscle relaxation, which had initial clinical application in the treatment of muscular dystonias. The mechanism of action of the neurotoxins involves three discrete functional domains: targeting, membrane translocation and intracellular inhibition of vesicular secretion via proteolytic cleavage of SNARE proteins (a ubiquitous and essential component of vesicular secretion).

CORPORATE ALLIANCES

Syntaxin has an alliance with Allergan, Inc. a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans. AGN-214868 was discovered under the collaboration with Allergan and is now in Phase II trials in patients with post herpetic neuralgia (PHN) and overactive bladder.

Syntaxin's innovative technology platform offers enormous potential to develop new treatments for a range of diseases. The company plans to maximise the both potential of its unique technology platform and pipeline of products in collaboration with industry partners.

PRODUCTS

Name	Indication	Phase	Milestone
AGN-214868	PHN and OAB	Phase II, IIa, IIb	
SXN101959	Acromegaly	Preclinical	Phase I

SENIOR MANAGEMENT

Dr. Melanie Lee, Chief Executive Officer • **Dr. Nigel Clark**, Chief Business Officer • **Dr. Phil Boyd**, Chief Financial Officer • **Dr. Richard Jones**, Chief Medical Officer • **Dr. Keith Foster**, Chief Technology Officer • **Dr. John Chaddock**, Other • **Dr. Jon Court**, Other

BOARD OF DIRECTORS

Dr. Russel Greig • **Dr. Deborah Harland**, SR One • **Dr. Edward Holdener**, Non-Exec • **Dr. Genghis Lloyd-Harris**, Abingworth Management • **Dr. René Kuijten**, LSP • **Dr. Johan Kördel**, Lundbeckfond Ventures • **Dr. Zeev Zehavi**, JJDC • **Professor Pierre Denys**, Non Executive Director • **Iain Wilcock**, Seventure

SCIENTIFIC ADVISORY BOARD

Professor Julian Jack • **Sir Tom Blundell** • **Professor Peter Goodfellow** • **Barry Furr**

TeraDiscoveries, Inc.

Clinical Foci: Drug Discovery, Drug Development, Diagnostics

Edwin R. Addison Chief Executive Officer

2 Davis Dr.
Research Triangle Park, NC 27709
USA

www.teradiscoveries.com

1-910-398-1200

Incorporated: 2009

Employees: 15

Ownership: Private

HIGHLIGHTS

Recent

TeraDiscoveries Presents its Potential "Best in Class" JAK2 Inhibitor G6 - at the EHA June, 2011 in London.

Patent filed for vitamin, a biomarker for Jak2 mutation.

May 1, 2011: Research Triangle Park, NC. TeraDiscoveries announced the offering of its patented Inverse Design technology for in-silico drug discovery on the Microsoft Azure high performance computing platform.

Upcoming

TeraDiscoveries is at the forefront of a new wave of drug discovery that combines high performance computing with molecular biology, bioinformatics, high throughput screening and sophisticated preclinical development.

Dr. Peter Sayeski to present Jak2 inhibitor G6 as ASH

Protein Symphony™ is an emerging drug discovery search engine and database that will, upon issuing a target protein as a query, will produce immediately the best inhibitors for that protein and their properties, candidate relevant biomarkers,

CORPORATE MISSION

TeraDiscoveries discovers new drugs and develops them by using a leading edge computational chemistry platform. The company is seeking a partner for its "best in class" Jak2 inhibitor, for a Jak2 mutation biomarker, and for its drug discovery platform, as well as an Hdac8 inhibitor. Using breakthrough "chemoinformatics" software developed at and exclusively licensed from Duke University called "Inverse Design," TeraDiscoveries systematically discovers, optimizes and develops early stage drugs from target selection through lead discovery and optimization, synthesis, testing and clinical planning. Using our core competency in bioinformatics and drug discovery, we provide an integrated environment for preclinical drug development that dramatically accelerates drug discovery and development. Our business model is to develop a pipeline of early stage drugs, conduct preclinical research, and take them as far as Phase 1 before partnering.

PROPRIETARY TECHNOLOGY

G6, its derivatives and biomarker for Jak2 inhibition for myeloproliferative disorders;
Inverse design - an in silico drug discovery platform.

CORPORATE ALLIANCES

Duke University; University of Florida; Sid Martin Biotechnology Center; NC Biotechnology Center; Microsoft for Azure Platform

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
G6 and derivatives	myelofibrosis, leukemia, polycythemia vera	Optimized Lead	100% remission in mouse studies
vimentin (Jak2 mutation biomarker)	myelofibrosis, leukemia, polycythemia vera	Diagnostics	patent filed
Inverse Design	drug discovery platform	Other	Patent Issued
Hdac8 inhibitor	T cell lymphoma	Research	

SENIOR MANAGEMENT

Edwin R. Addison, Chief Executive Officer • **Lawrence Husick**, Chief Technology Officer • **Shahar Keinan**, Chief Scientific Officer • **Position Filled, not yet announced**, Business Development • **Leslie Pryce**, Business Development • **Jack Young**, Other • **William Shipman**, Other • **Elizabeth Hobbs**, Other • **Karen Addison**, Administrative Assistant • **Peter Sayeski**, Other

BOARD OF DIRECTORS

Edwin R. Addison, TeraDiscoveries • **Lawrence Husick**, Lipton Weinberger & Husick • **Sandy Wienberg**, (pending)

SCIENTIFIC ADVISORY BOARD

Peter Sayeski, University of Florida • **Sandy Weinberg**, Georgia Tech • **Bruce Dawson**, Infinomics • **Shelby Addison, MD**, Medical University of SC

FINANCING HISTORY

Round Date (Amount, US\$) 01/15/2010 (0.50 million) • 09/15/2011 (1.50 million) • 04/15/2012 (7.00 million)

Investors: Edwin R. Addison (27%) • Lawrence A. Husick (18%) • Shahar Kienan (12%)

The Salter Group

Sam Renwick

Managing Director

7000 Sunne Lane #210
Walnut Creek, CA 94597
USA

www.saltergroup.com

1-925-942-0373

Incorporated: 2003

Employees: 20

Ownership: Private

CORPORATE MISSION

Salter Group is a leading financial and strategic advisory firm specializing in providing independent forecasting services, valuations, financial opinions, financial and strategic advisory services and transaction support. Since our formation in 2003, Salter Group has completed over 500 life sciences and health care engagements representing over USD \$10 billion in asset and transaction values.

We offer a unique perspective for the development of forecasts, valuations and advisory services by combining the analytical and modeling rigor of a capital markets constituent with a robust data-intensive primary and secondary research capability that spans 100,000's of thought leaders, care providers, payors and other experts through our partners. We do this in a flexible and cost-efficient manner. Rather than relying on a significant up-front fee regardless of whether a transaction closes (the model for many consulting firms), we have the flexibility to earn our fees in a different fashion, charging less up front but earning a fee if a transaction is successfully completed. The end result is a cost-effective integrated research and model solution that can help your company be better prepared in your discussions with licensing partners, investors, lenders or acquirers.

SENIOR MANAGEMENT

Sam Renwick, Managing Director

Theraclone Sciences, Inc.

BIO Member

Clinical Foci: Infectious Disease, Drug Discovery, Oncology

Steve Gillis, PhD

President

1124 Columbia Street, Suite 300
Seattle, WA 98104
USA

www.theraclone-sciences.com

1-206-805-1600

Incorporated: 2005

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Initiation of P1 clinical trials of TCN-032 for influenza A. TCN-032 was described in a July 2010 publication of PNAS. It is a novel human antibody against a highly conserved epitope on influenza A viruses.

USD \$10.6 million in Series B Extension Financing September, 2011.

In January 2011, Theraclone announced collaboration with Pfizer for the discovery of therapeutic antibodies in oncology and infectious disease indications.

Upcoming

IND filing H1, 2012 for TCN-202, the lead anti-HCMV therapeutic antibody drug candidate.

Additional corporate partnerships in influenza, HCMV, or other indications and for technology platform in 2011-2012

Safety & PK data from P1 clinical trials for TCN-032 1H12.

CORPORATE MISSION

Theraclone Sciences is a discovery and development biotechnology company developing novel therapeutic antibodies for the treatment of indications in infectious disease and cancer. Our proprietary discovery platform allows us to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease. Central to our discovery approach, we identify antibodies produced naturally by human memory B cells in response to disease. This allows us to identify monoclonal antibodies that are likely to be highly effective in combating disease in a broad patient population. The antibodies identified through our discovery process can be further studied as tools for vaccine development. Our most advanced development programs are focused on infectious disease including novel antibodies to fight pandemic and severe seasonal influenza and cytomegalovirus infections. We have also partnered with the International AIDS Vaccine Initiative (IAVI) to identify the most potent and broadly neutralizing anti-HIV antibodies yet discovered, despite more than 10 years of intensive research by investigators worldwide. Theraclone is a venture-funded company founded in 2005. Our investors include ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM, and AREE. We are actively seeking development partners in the US, Europe, and Japan to help us create and commercialize antibody therapeutic products.

PROPRIETARY TECHNOLOGY

I-STAR™ Technology. The human immune system responds to pathogens, like viruses and bacteria, by evolving in real time highly protective proteins called antibodies. The immunological history of these protective responses is archived in human memory B cells, a specialized type of blood cell. The I-STAR platform allows comprehensive interrogation of this memory B cell archive. Theraclone's technology is unique because it enables us to rapidly test the function of tens of thousands of natural human antibodies to find those with exceptional biological activities. The antibodies identified through our discovery process are appropriate for further study as novel therapies to help patients fight existing disease.

CORPORATE ALLIANCES

Funded collaboration agreement with Zenyaku Kogyo for the discovery and development of antibodies for the treatment of pandemic and severe seasonal influenza. Funded collaboration agreement with Pfizer for the discovery of therapeutic antibody candidates for indications in oncology and infectious disease. Funded collaboration agreement with IAVI for the discovery of anti-HIV antibodies.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
TCN-032	Severe seasonal and pandemic influenza	Phase I	Phase I clinical data 1H12.
TCN-202	HCMV infection	Preclinical	IND Filing 1H12.
TCN-350	Asthma, RA	Optimized Lead	

SENIOR MANAGEMENT

Steve Gillis, PhD, President • **Russ Hawkinson**, Chief Financial Officer • **Kristine Swiderek, PhD**, Vice President • **Eleanor Ramos**, Chief Medical Officer

BOARD OF DIRECTORS

Steve Gillis, PhD, President, Theraclone Sciences; Managing Director, ARCH Venture Partners • **Wende Hutton**, Canaan Partners • **Chris Mirabelli, PhD**, HealthCare Ventures • **Bill Greene**, MPM Capital

SCIENTIFIC ADVISORY BOARD

K. Frank Austen, MD, Harvard Medical School • **Laurie Glimcher, MD**, Harvard Medical School • **Robert Schooley, MD**, UCSD • **Robert Lamb, PhD**, Northwestern University

FINANCING HISTORY

Investors: ARCH Venture Partners • Canaan Partners • HealthCare Ventures • MPM Capital • Amgen Ventures (0%)

Tranzyme, Inc.

BIO Member, Presenting Company

Clinical Foci: Gastroenterology, Metabolic Disease, Drug Discovery

Vipin Garg, PhD Chief Executive Officer

4819 Emperor Boulevard
Durham, NC 27703
USA

www.tranzyme.com

1-919-313-4760

Euronext Paris: TZYM

Incorporated: 1998

Employees: 40

Ownership: Public

CORPORATE MISSION

Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. Our two most advanced product candidates, ulimorelin (in Phase 3) and TZP-102 (in Phase 2), are being evaluated for the treatment of predominantly upper GI motility disorders. We believe approximately 20% of adults worldwide are affected by conditions these product candidates are designed to tract. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are currently a limited number of treatment options for patients suffering from these conditions. Ulimorelin and TZP-102 target the ghrelin receptor, a novel mechanism of action, with a highly potent and direct role in the stimulation of GI motility. Current and formerly available drugs targeted the GI function primarily through either the serotonin or dopamine receptors and have had significant safety issues, resulting in product recalls. We believe our product candidates have the potential to offer a safe and effective treatment for GI motility disorders, an area of significant unmet medical need.

PROPRIETARY TECHNOLOGY

Tranzyme's product candidates have been discovered using our proprietary chemistry technology platform, MATCH™ (Macrocyclic Template Chemistry), which enables us to construct synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. MATCH™ compounds mimic the favorable binding characteristics of proteins and peptides such as tight receptor binding for high potency and selectivity, while eliminating the drawbacks associated with these biomolecules — poor metabolic stability, low oral bioavailability, lack of membrane permeability, high manufacturing costs and antigenicity. As part of our business strategy, we continue to leverage our technology platform to discover, develop and commercialize first-in-class products in collaboration with discovery partners.

CORPORATE ALLIANCES

In December, 2009, Tranzyme entered into a strategic collaboration with BMS to discover, develop and commercialize novel compounds discovered using our proprietary chemistry technology platform, against a limited number of targets of interest to BMS. BMS is funding our early lead discovery efforts on these targets and is also responsible for optimizing the identified lead compounds.

In June 2010, Tranzyme entered into a license agreement with Norgine B.V., a leading, GI-focused European specialty pharmaceutical company that provides Norgine with exclusive rights to develop and commercialize ulimorelin in Europe and other select territories. Tranzyme retained rights to ulimorelin in North & South America and Asia. Norgine will share the cost of our development.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Ulimorelin (TZP-101)	Management of postoperative ileus	Phase III	Complete Phase III program
TZP-102	Diabetic gastroparesis	Phase II, IIa, IIb	Initiate Phase IIb
TZP-201	Chemo-induced diarrhea	Preclinical	
TZP-301	Metabolic disease	Lead Series	
Chemistry	Available for collaboration	Research	

SENIOR MANAGEMENT

Vipin Garg, PhD, Chief Executive Officer • **Richard Eisenstadt**, Chief Financial Officer • **Helmut Thomas, PhD**, Senior Vice President • **Gordana Kosutic, MD**, Vice President • **Jennifer Filbey**, Vice President • **Mark Peterson**, Vice President • **David Moore**, Vice President • **Brent Bankoskcy**, Vice President

BOARD OF DIRECTORS

John H. Johnson, Savient Pharmaceuticals, Inc. • **Jean-Paul Castaigne**, Angiochem, Inc. • **Aaron Davidson**, H.I.G. BioVentures • **Brenda D. Gavin**, Quaker BioVentures • **Anne M. VanLent**, AMV Advisors • **Alex Zissoon**, Thomas, Mc Nerney & Partners



Market Data

Current Price	1.09
Currency	Euro
Net Change	-0.91
Volume	17,345
YTD % Change	-0.15
52Wk Range	1.01–2.04
Avg. Daily Volume (thousands).....	73,666

First Call Data

Market Cap (MM)	14.9
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.27
EPS (Last Fiscal Year)	-0.37
Consensus Estimate (Y)	-0.27
Consensus Recommend	--
Price/Sales	3.32

Shareholders

<i>Institution</i>	<i>Holding %</i>
HSBC Global Asset Management (France) SA	0.4%
La Mondiale Groupe	0.0%
<i>Mutual Fund</i>	<i>Holding %</i>
HSBC Global Asset Management (France) SA	0.4%
La Mondiale Groupe	0.0%

Source: Thomson Reuters

Trevena, Inc.

BIO Member, , BIO Board Member, Presenting Company

Clinical Foci: Drug Development, Cardiovascular Disease, CNS

Maxine Gowen

President & CEO

1018 West 8th Avenue
King of Prussia, PA 19406
USA

www.trevenainc.com

1-610-354-8840

Incorporated: 2007

Employees: 33

Ownership: Private

HIGHLIGHTS

Recent

Phase 2a trial for TRV027 was initiated in early 2011 for the development of TRV027 to treat acute heart failure.
IND enabling studies for a novel opioid analgesic, TRV130, were initiated in 3Q11.
Trevena was awarded an NIH grant under the Blueprint Neurotherapeutics Network Program to develop novel agents to treat Major Depressive Disorders.

Upcoming

Phase 2b trial for TRV027 is expected to start in 2H12.
IND for the novel opioid analgesic, TRV130, is expected to be filed in 2Q12.

CORPORATE MISSION

Trevena is a clinical stage drug discovery & development company with a new approach to drugs targeting G-protein coupled receptors (GPCRs) by selective signaling. These are called biased ligands as they activate either G-protein or beta-arrestin signaling through specific GPCRs. Our novel technology has allowed us to develop differentiated drug candidates for both acute heart failure and acute and chronic pain. TRV027 is currently in Phase 2a proof of concept clinical trials for acute heart failure and is a novel iv drug that safely improves the symptoms of heart failure while improving renal function and increasing cardiac contractility. Our second candidate is a novel analgesic with opioid like efficacy but with significantly reduced effects on GI motility and respiratory suppression. This is expected to enter clinical trials in 1H12.

PROPRIETARY TECHNOLOGY

Trevena's proprietary platform enable it to identify pharmacologically distinct biased GPCR ligands which drive beneficial biology without activating responses associated with adverse events. There are at least two major intracellular signaling pathways from nearly all GPCRs which are linked to distinct biologies. When a 'biased ligand' binds to the receptor, it activates one of these pathways while deactivating the other (as opposed to the current industry approach of activating or deactivating all signaling pathways). This enhanced functional specificity enables Trevena to create and characterize agents with increased efficacy and/or decreased adverse effects. Trevena's approach represents the latest development in targeted therapies and will provide the next generation of GPCR drugs.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
TRV027	Acute Heart Failure	Phase II, IIa, IIb	Phase 2 data in 1H12.
TRV130	Post surgical pain	Preclinical	IND file, 2Q12.
Kappa opioid biased ligand	Neuropathic pain	Lead Series	
Delta opioid biased ligand	Depression, pain, Parkinson's Disease	Lead Series	

SENIOR MANAGEMENT

Maxine Gowen, President & CEO • **Art Fratamico**, Chief Business Officer • **Michael Lark**, Chief Scientific Officer • **David Soergel**, Vice President

BOARD OF DIRECTORS

Maxine Gowen, Trevena Inc. • **Terrance G. McGuire**, Polaris Ventures • **Robert Garland**, NEA • **Farah Champs**, Alta Partners • **Christopher K. Mirabelli**, HealthCare Ventures • **Robert R. Ruffolo**, Former President R&D, Wyeth Pharmaceuticals • **Ralph Snyderman**, Duke University

SCIENTIFIC ADVISORY BOARD

Robert J. Lefkowitz, MD, Duke University Medical Center • **Howard A. Rockman, MD**, Duke University Medical Center • **John L. LaMattina, PhD**, Former President, Global Research and Development at Pfizer • **Robert R. Ruffolo, Jr., PhD**, Former President of R&D at Wyeth Pharmaceuticals

FINANCING HISTORY

Round Date (Amount, US\$) 01/01/2008 (25.00 million) • 07/17/2010 (35.00 million)

Investors: Alta Partners (1%) • HealthCare Ventures (1%) • NEA (1%) • Polaris Ventures (1%) • Yasuda (1%)

Trius Therapeutics, Inc.

Presenting Company

Clinical Foci: Infectious Disease, Skin/Dermatological, Pulmonary

Jeff Stein, PhD

Chief Executive Officer

6310 Nancy Ridge Dr, Suite 105
San Diego, CA 92121
USA

www.triusrx.com

1-858-452-0370

NASDAQ: TSRX

Incorporated: 2007

Employees: 68

Ownership: Public

HIGHLIGHTS

Recent

August 5, 2011: Trius Therapeutics Obtains Special Protocol Assessment With FDA for Second Phase 3 Study of Torezolid Phosphate.

July 27, 2011: Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia-Pacific and Emerging Markets.

May 25, 2011: Trius Therapeutics Announces Pricing of USD \$30 million Financing.

Upcoming

Trius complete enrollment of Phase 3 trial of oral dosage form of tedizolid phosphate

Trius initiates enrollment of Phase 3 trial testing IV to oral dosing of tedizolid phosphate

CORPORATE MISSION

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.

We are conducting Phase 3 clinical trials for our lead compound tedizolid (TR-701), an IV and orally administered next generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant *Staphylococcus aureus* (MRSA). With significantly improved potency, safety and compliance, TR-701 is effective against severe skin, lung, blood and bone infections caused by a wide spectrum of bacteria including those resistant to all commonly used drugs. TR-701 is currently the being tested in Phase 3 clinical trials under a Special Protocol Assessment (SPA).

In addition to TR-701, Trius has two ongoing preclinical programs that have emerged from our proprietary discovery platform. Both the GyrB/ParE program and our Marine Natural Products Program are focused on identifying and develop antibiotics to treat infections caused by gram-negative and gram-positive bacteria. These programs are currently funded with USD \$57 million by the U. S. government. Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team collectively has over 90 years of experience in the development and approval of antibiotics.

PROPRIETARY TECHNOLOGY

Trius has developed a proprietary platform called focused antisense screening technology (FAST) which uses antisense technology to identify suitable bacterial drug targets. We have also built state-of-the-art capabilities in structure based drug design (SBDD). These proprietary capabilities enable us to rapidly identify optimal bacterial targets and subsequently design highly potent and selective small molecule inhibitors, which enables us to develop new differentiated antibiotics.

The FAST platform consists of a set of engineered bacterial strains containing antisense DNA fragments whose synthesis can be regulated to inhibit the production of a targeted protein. We have demonstrated that compounds that act on the protein down regulated in the FAST antisense strain require a significantly

CORPORATE ALLIANCES

Trius recently announced a collaboration with Bayer HealthCare to develop and commercialize TR-701 in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East. Under the collaboration agreement Trius retains full development and commercialization rights outside the licensed territory including the United States, Canada and the European Union.

PRODUCTS

Name	Indication	Phase	Milestone
GyrB/ParE	Gram-negative nosocomial infections: cUTI, Intra-abdominal infections, pneumonia	Preclinical	
Marine Natural Products	Gram-negative and gram-positive infections	Preclinical	
TR-701	P3 for acute bacterial skin and skin structure infections (ABSSI). Future: CAP/HAP, osteomyelitis, bacteremia	Phase III	Complete enrollment of oral trial; start enrollment of IV/oral trial

SENIOR MANAGEMENT


Jeff Stein, PhD, Chief Executive Officer • **John Schmid**, Chief Financial Officer • **John Finn**, Chief Scientific Officer • **Craig Thompson**, Marketing • **Karen Shaw**, Senior Vice President • **Karen Potts**, Vice President • **Philippe Prokocimer**, Chief Medical Officer • **Ken Bartizal**, Other • **Neil Abdollahian**, Vice President

BOARD OF DIRECTORS

David Kabakoff, Sofinnova Ventures • **Brian Atwood**, Versant Ventures • **Karin Eastham**, Independent • **Nina Kjellson**, InterWest Partners • **Brendan O'Leary**, Prism Ventures • **Michael Powell**, Sofinnova Ventures • **Theodore Schroeder**, CEO, Cadence Pharmaceuticals • **Risa Stack**, Kleiner Perkins Caufield & Byers • **Paul Truex**, CEO, Anthera Pharmaceuticals • **Jeffrey Stein**, CEO, Trius Therapeutics

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: TSRX



Market Data

Current Price	6.31
Currency	US Dollar
Net Change	4.30
Volume	44,867
YTD % Change	0.70
52Wk Range	2.93–9.00
Avg. Daily Volume (thousands).....	52,729

First Call Data

Market Cap (MM)	180.2
Short Interest Shares	341,512
Short Interest Ratio	9.41
PE (Trailing 12 Months)	-1.30
EPS (Last Fiscal Year)	-2.53
Consensus Estimate (Y)	-1.30
Consensus Recommend	-1.29
Price/Sales	17.94

Shareholders

<i>Institution</i>	<i>Holding %</i>
Wellington Management Co. LLP	4.6%
Sectoral Asset Management, Inc.	3.6%
Redmile Group LLC	2.8%
Great Point Partners LLC	2.6%
Manatuck Hill Partners LLC	2.0%
<i>Mutual Fund</i>	
Wellington Management Co. LLP	4.6%
Sectoral Asset Management, Inc.	3.6%
Redmile Group LLC	2.8%
Great Point Partners LLC	2.6%
Manatuck Hill Partners LLC	2.0%

Source: Thomson Reuters

Zymeworks Inc.

Presenting Company

Clinical Foci: Drug Development

Ali Tehrani

Chief Executive Officer

#540-1385 West 8th Ave
Vancouver, BC V6H 3V9
Canada

www.zymeworks.com

1-604-678-1388

Incorporated: 2004

Employees: 37

Ownership: Private

HIGHLIGHTS

Recent

Zymeworks Inc signed a collaborative research and license agreement with US pharmaceutical giant Merck Sharpe and Dohme Research for up to USD \$1.85 million plus royalties. This will validate Zymeworks asymmetric antibody platform.

CORPORATE MISSION

Zymeworks is focused on developing a pipeline of biobetter candidates through applying its proprietary protein engineering platform to monoclonal antibodies and other classes of protein therapeutics. Zymeworks is also seeking to establish strategic collaborations with leading pharmaceutical and biotechnology companies in the design of novel cross-reactive antibodies and improving antibody dependent cell cytotoxicity (ADCC) response and other effector functions. Zymeworks is a computational biotechnology company with structure-guided technologies for the predictive engineering and optimization of antibodies and protein therapeutics.

PROPRIETARY TECHNOLOGY

Zymeworks has developed a proprietary molecular simulation platform that relates a protein's function and biophysical characteristics to its structure. This insight allows Zymeworks to make knowledge-based modifications to the protein that result in new or improved functional properties leading to more efficacious drugs. In the design of a novel heterodimeric scaffold, novel cross-reactive antibodies and the improvement of ADCC, Zymeworks' platform has the distinctive advantage in the optimization of multiple biophysical properties (affinity, selectivity, stability, effector function) on one protein framework. Zymeworks can design complex mutations (multiple simultaneous changes) and compensating mutations that take into account cooperativity and distal effects using the full-length mAb.

CORPORATE ALLIANCES

Zymeworks has a collaboration with Merck to develop bi-specific antibody therapeutics using Zymeworks' Azymetric™ platform. Under the terms of the agreement Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies generated through use of the Azymetric™ platform toward certain exclusive therapeutic targets. Both companies will collaborate to advance the technology platform, with Merck working to progress the bi-specific therapeutic antibody candidates through clinical development and commercialization.

SENIOR MANAGEMENT

Ali Tehrani, Chief Executive Officer • **Surjit Dixit**, Chief Technology Officer • **Neil Klompas**, Chief Financial Officer • **David Tucker**, Chief Operating Officer

BOARD OF DIRECTORS

Nick Bedford, Former Head of German Equities, UBS Warburg • **Haig Farris**, President, Fractal Capital Corp. • **Kenneth Galbraith**, General Partner, Ventures West Management • **Noel Hall**, Former Co-founder & President of Aspreva Pharmaceuticals • **Patrick McCroskey**, Principal, TPG Biotech • **Ali Tehrani**, President & CEO, Zymeworks Inc. • **Shermaine Tilley**, Partner, CTI Life Sciences Fund • **Don Drakeman**, Venture Partner at Advent Venture Partners

SCIENTIFIC ADVISORY BOARD

Michael J. Gresser, CSO, Oxford BioTherapeutics • **C. Geoffrey Davis**, President & CEO of Angelica Therapeutics • **Richard Lavery**, Head, Department of Molecular Biostructures - Institute de Biologie et Chimie des Proteines • **Mihaly Mezei**, Associate Professor and Director of Molecular Modelling Core, Mt. Sinai School of Medicine • **Bruce Tidor**, Professor, Biological Engineering and Computer Science, MIT